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Welcome
Dear Readers,
Another issue of unmissable articles, abstracts, and interviews awaits inside EMJ Respiratory 8.1 as we 
bring the latest news from the European Respiratory Society (ERS) International Congress, as well as 
our own selection of peer-reviewed articles on the hottest topics in the field, to make sure you keep 
up with the latest in the field of respiratory.
A pandemic will always have the capacity to affect all medical specialties, but the coronavirus disease 
(COVID-19), being a respiratory condition, has put an unprecedented strain on pulmonary healthcare 
professionals. It is therefore imperative that accurate and timely medical research is disseminated at 
the present time, and this is where EMJ come in; this is our promise to you.
 
Our Congress Review of the 30th ERS meeting provides the highlights from the >450 scientific and 
educational sessions, including late-breaking abstract summaries on topics such as personalised 
asthma care, ‘long COVID’ and lung damage, and a novel app that measures night-time coughing to 
predict asthma deterioration. 
Alongside the congress content, EMJ Respiratory 8.1 also offers exclusive interviews with ERS 2020 
Award Winners; our editorial team spoke to Dr Dina Brooks, ERS Assembly Lifetime Achievement 
Award Winner, and Prof Greet Van den Berghe, ERS Gold Medal in ARDS Winner, about their areas of 
expertise and their most valuable learnings from the COVID-19 pandemic so far.
Always open access, always at the forefront; please enjoy the following pages, and I hope that this 
content adds value to your medical practice, whatever your role in the field.
Spencer Gore
Chief Executive Officer, EMG-Health
"It is therefore imperative that accurate and timely 
medical research is disseminated at the present time, and 
this is where EMJ come in; this is our promise to you." 
#############################"
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TYPE 2 INFLAMMATION IS  
HIGHLY HETEROGENEOUS  
AND A PREDICTOR OF RISK 
FOR FUTURE EXACERBATIONS1-4
MAT-GL-2000508
References: 1. Dunican EM, Fahy JV. The role of type 2 inflammation in the pathogenesis of asthma exacerbations. Ann Am Thorac Soc. 2015;12(suppl 2):S144-S149. 2. Rogliani P, Calzetta 
L, Matera MG, et al. Severe asthma and biological therapy: when, which, and for whom [published online ahead of print December 25, 2019]. Pulm Ther. doi:10.1007/s41030-019-00109-
1 3. Fahy JV. Type 2 inflammation in asthma-present in most, absent in many. Nat Rev lmmunol. 2015;15(1):57-65. 4. Peters MC, Mekonnen ZK, Yuan S, Bhakta NR, Woodruff PG, Fahy 
JV. Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. J Allergy Clin Immunol. 2014;133(2):388-394. 5. Global Initiative for Asthma. 
Difficult-to-treat & severe asthma in adolescent and adult patients, 2020. https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf. Accessed April 
14, 2020. 6. Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-
50. 7. Robinson D, Humbert M, Buhl R, et al. Revisiting type 2-high and type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. 
2017;47(2):161-175. 8. Hammad H, Lambrecht BN. Dendritic cells and epithelial cells: linking innate and adaptive immunity in asthma. Nat Rev lmmunol. 2008;8(3):193-204.  
 
Target and treat type 2 inflammation holistically to achieve optimal asthma control1,5
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TO IMPROVE
Lung function
Quality of life
TO REDUCE
Exacerbations
Oral corticosteroids
IDENTIFY TARGET TREAT
Cytokines IL-4, IL-5 and IL-13  
are key drivers of type 2 
inflammation in asthma6-8
IL-4 and IL-13 have distinct and 
overlapping roles with a broad 
impact on asthma symptoms7,8
  PRESENT IN ~50%a TO 70%b OF YOUR ADULT ASTHMA PATIENTS,
Th2 cell differentiation
B-cell class switching  
and IgE production
Eosinophil recruitment  
and trafficking to tissue
Eosinophil differentiation  
in bone marrow
Mucus production and 
goblet cell hyperplasia
Smooth muscle 
hypertrophy and  
tissue remodeling
IL-4 IL-13 IL-5
Type 2 inflammation  
in asthma 
EOS, eosinophils; FeNO, fractional exhaled 
nitric oxide; OCS, oral corticosteroid.
Identifiable by one or more 
of the following criteria5: 
Elevated EOS
Allergen-driven
Elevated FeNO
OCS-dependency
HETEROGENEITY
• Allergen-driven
• Mixed eosinophilic 
   and allergen-driven 
• Eosinophilic 
Encompasses several  
phenotypes2:
SIMPLE IDENTIFICATION
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Foreword
Dear Readers, 
It is a great pleasure for me to welcome you to the new issue of EMJ Respiratory. This year has 
been trying for all healthcare professionals around the world, but perhaps particularly those in the 
field of respiratory. Many have dedicated their lives to fighting the coronavirus disease (COVID-19) 
pandemic on the frontline and progressing research into the disease. One lesson, among many, 
from this year is the importance of collaboration and sharing scientific knowledge, which are both 
fundamental goals of EMJ Respiratory. 
Adapting to the new world we are currently living in, the European Respiratory Society (ERS) 
made the decision to hold their annual congress virtually this year. Furthermore, an additional day 
was added to the scientific programme to disseminate what is known so far about COVID-19. The 
virtual ERS International Congress exemplified the agility of the respiratory field and showcased key 
advancements in respiratory medicine over the last year through live presentations, thousands of 
e-posters, and satellite symposia, a review of which is included in the following pages. 
Complementing the congress review, ERS Award Winners Prof Dina Brooks and Prof Greet Van 
den Berghe provide insight into their respective expertise in pulmonary rehabilitation and intensive 
care medicine. 
Inside this issue there are also articles from respiratory experts discussing topics such as the risk 
factors for severe COVID-19 in the article by Hussain et al., the cellular networks in lung immune 
homeostasis by Borger, and sleep quality during noninvasive and invasive ventilation by Ugurlu et al. 
My Editor’s Pick for this issue is the paper by Chen et al. Asthma, a highly prevalent comorbidity 
during pregnancy, if uncontrolled, can be associated with alterations in placental function and fetal 
growth. The interesting paper by Chen et al. provides the clinical management of asthma during 
pregnancy to prevent adverse outcomes for the fetus, the barriers in the education of health 
professionals, and the importance of self-management skills, especially in this current COVID-19 
pandemic period. 
I hope you all enjoy reading EMJ Respiratory, an issue that I believe to be of interest to you all. 
Dr Antonio Rossi 
Medical Director, Therapeutic Science & Strategy Unit, IQVIA, Milan, Italy 

Location:  ERS International Congress
Date:   6th–9th September 2020
Citation:  EMJ Respir. 2020;8[1]:12-24. Congress Review.
Congress Review
Review of the virtual European Respiratory 
Society (ERS) International Congress 2020
THE 30
th anniversary of the European 
Respiratory Society (ERS) meeting 
was set to be a spectacle in Vienna, 
Austria, but no one could predict what the 
year had in stall for us. In response to the 
ongoing coronavirus disease (COVID-19) 
pandemic, the ERS made the decision to 
hold the 30th ERS International Congress 
virtually. Even with this unexpected turn of 
events, the society put together a platform 
that showcased research and facilitated 
discussion and interaction, which was 
attended by over 33,000 delegates.
In the ‘Welcome to 30th Congress’ section 
of the platform, the ERS President Thierry 
Troosters welcomed attendees to the 
event. Amongst many of his encouraging 
words, Prof Troosters highlighted how 
many professionals in the respiratory 
field had dedicated their lives to fighting 
the COVID-19 pandemic on the frontlines 
or have been involved in researching 
pharmacological and nonpharmacological 
treatments for the many patients affected 
by the disease. He further noted that: “The 
pandemic also showed the pivotal role of 
links to other country and regional societies. 
We exchange knowledge and help each 
other with dissemination of science around 
the pandemic in many of the disease areas 
covered by the society.”
The scientific programme evolved to fit 
with the platform, with some sessions 
being available in multiple languages such 
as English, Spanish, and German. The 
society also added a day dedicated to 
the knowledge that is known so far about 
COVID-19, including COVID-19 prevention, 
management, and the impact on those with 
pre-existing lung conditions. In his welcome 
message, Prof Troosters thanked those who 
contributed to the meeting: “I’m grateful 
to those who have taken time, despite 
overburdened agendas, to contribute to 
the sharing of knowledge and initiation of 
scientific projects, moving the field forward 
at light speed.”
Another new addition to the scientific 
programme this year were ALERT sessions, 
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ERS 2020 REVIEWED
“I’m grateful to those who have taken time, despite 
overburdened agendas, to contribute to the sharing of 
knowledge and initiation of scientific projects, moving 
the field forward at light speed.”
which combined the breaking news from recent, 
unpublished randomised clinical trials in easy-
access sessions. Furthermore, 'Live from the 
Clinic' sessions showed experts performing live 
procedures such as endoscopies, which was only 
possible due to the digital format.
Thousands of e-posters and abstracts were 
presented, which provided insight into the 
latest developments across all aspects of the 
respiratory field. Included in the following 
pages are summaries of a hand-selected 
collection of abstracts, written by the 
presenters themselves.
Prof Troosters acknowledged that we should 
not draw too much attention away from the 
ongoing efforts in preventative health, using 
smoking as an example, which has killed 15 times 
as many people in 2020 as COVID-19, adding 
that air pollution is still a pertinent issue for 
respiratory health. Even though the congress 
was held virtually this year, and thus had a very 
minimal carbon footprint, the society had great 
plans to hold a green face-to-face meeting, 
showcasing their commitment to minimising 
their ecological footprint.
Weighing in on the positives, Prof Troosters 
reminded attendees that: “The coronavirus has 
put some of our projects on hold, but facilitated 
others, for example, the transition towards a 
virtual format for our consultations, rehabilitation 
programmes, or even our congress. We will not 
waste this crisis and continue to build on the 
good things that came out of it.”
We look forward to being able to attend what 
will sure to be another great meeting next 
year in Barcelona, Spain, until then, please 
enjoy the following review of the 30th ERS 
International Congress.
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Personalised Asthma Care: Should we  
Prescribe According to Genetics?
GENETIC differences between children and 
adolescents with asthma may aid treatment 
selection for these patients; this is according to 
a study conducted at the University of Dundee, 
Dundee, UK, the results of which were reported 
at the ERS International Congress 2020 on the 
8th September 2020. 
In total, 241 patients aged between 12 and 
18 years were enrolled in the trial. They were 
all being treated for asthma by their general 
practitioner and were randomly assigned 
to either a group that received treatment 
according to existing guidelines, or to a group 
that utilised personalised medicine techniques, 
in which they received treatment according to 
their genotype. To determine their genotype, the 
participants’ inner cheek cells were tested for 
different versions of the β-2 adrenergic receptor 
ADRB2 gene.
The β-2 adrenergic receptor is a common 
pharmacological target of asthma treatments, 
but previous research has shown that one in 
seven children have one or two copies of the 
altered versions of this gene; this can lead to the 
medication having a negative effect on patients 
symptoms. Therefore, the personalised medicine 
group of this trial were treated with montelukast, 
rather than salmeterol.
Participants were followed for 1 year, during 
which quality of life, the severity of their 
symptoms, and the extent to which asthma 
limited their normal activities were assessed (on 
a scale of 1–7). When comparing the average 
scores for quality of life between the two groups, 
there was only an improvement of 0.16 seen in the 
personalised group. However, when specifically 
looking at those with two copies of the altered 
ADRB2, they found a 0.42 improvement.
Prof Mukhopadhyay, Brighton and Sussex 
Medical School, Brighton, UK, and leader of the 
study team, is hopeful about the implications 
of the results, especially as the genetic test kits 
cost $20 USD: “These results are very promising 
because they show, for the first time, that it 
could be beneficial to test for certain genetic 
differences in children with asthma and select 
medication according to those differences.”
"These results are very promising because they show, for the 
first time, that it could be beneficial to test for certain genetic 
differences in children with asthma and select medication 
according to those differences.”
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'Long COVID': Heart and Lung Damage  
Could Improve with Time
CORONAVIRUS disease (COVID-19) has caused 
long-term heart and lung damage in many 
patients, but this has been shown to improve 
over time, as evidenced by a prospective follow-
up study by researchers from the Tyrolean 
region in Austria. These results were presented 
at the ERS International Congress 2020 on 7th  
September 2020.
Conducted between 29th April and 9th 
June 2020, the study included 86 patients 
hospitalised with COVID-19 who were followed 
up at 6, 12, and 24 weeks, as well as after their 
discharge from the hospital. Clinical examinations, 
laboratory tests, CT scans, and echocardiograms 
were all carried out at every follow-up visit. The 
average age of participants was 61 years, 65% 
were male, 65% were overweight or obese, and 
almost 50% were current or former smokers.
At 6-weeks follow-up, 65% of the patients 
had at least one persistent symptom, the most 
common being breathlessness and coughing 
(47%). Using CT scanning, it was observed that 
88% of patients had lung damage, deemed 
by the presence of ground-glass opacities. 
Echocardiogram analysis also showed that 59% 
of patients had dysfunction of the heart’s left 
ventricle. At 12-weeks follow-up, some recovery 
was seen because lung damage was visible 
in 56% of participants and only 39% reported 
breathlessness. The 24-weeks follow-up has yet 
to be performed.
Dr Sabina Sahanic, The Medical University of 
Innsbruck, Innsbruck, Austria, and one of the 
authors of the study, summarised the findings: 
“The bad news is that people show lung 
impairment from COVID-19 weeks after discharge; 
the good news is that the impairment tends to 
ameliorate over time, which suggests the lungs 
have a mechanism for repairing themselves.”
She concluded: “Knowing how patients have 
been affected long-term by the coronavirus 
might enable symptoms and lung damage to be 
treated much earlier and might have a significant 
impact on further medical recommendations 
and advice.”
“The bad news is that people 
show lung impairment 
from COVID-19 weeks after 
discharge; the good news is 
that the impairment tends to 
ameliorate over time"
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Bronchitis in Early Years as a Prediction Tool  
for Middle-Age Lung Health
LUNG problems in later life can be reliably 
predicted if the patient had bronchitis at 
least once before the age of 7 years; this is 
according to findings from the Tasmanian 
Longitudinal Health Study, which were released 
at the ERS International Congress 2020 on 4th 
September 2020.
Enrolled as children, 8,583 participants who were 
born in Tasmania in 1961 and started school in 
1968 had their lung function initially assessed 
using a spirometer. The researchers took note of 
how much air they could breathe out forcibly in 
1 second and the total volume of air exhaled, as 
well as establishing if they had been diagnosed 
with bronchitis or asthma by the age of 7 years. 
The participants were followed up for an average 
of 46 years. In 2014, a total of 5,729 participants 
responded to a further survey and between 
2012 and 2016, 3,609 participants completed an 
additional survey and 2,629 underwent a clinical 
examination that again used a spirometer to 
access lung function. 
Nonrecurrent, recurrent, or protracted recurrent 
episodes of bronchitis before the age of 7 years 
was associated with a 1.4-fold, 2.0-fold, and 3.2-
fold increased risk of pneumonia, respectively, by 
the time participants reached the average age of 
53; a 1.3-fold, 2.7-fold, and 6.4-fold increased risk 
of ever having asthma, respectively; and a 1.3-fold, 
2.0-fold, and 4.5-fold increased risk of currently 
having asthma, respectively.
Dr Jennifer Perret, a researcher at the University 
of Melbourne, Melbourne, Australia, analysed 
the findings: “The associations with asthma and 
pneumonia strengthened with increasing severity 
of childhood bronchitis.”
However, she did stress that the results should 
be interpreted with caution: “There was no 
statistically significant link between childhood 
bronchitis and chronic bronchitis in middle-age. 
This was an unexpected finding and further study 
would be informative. We are currently exploring 
these associations.”
“The associations with 
asthma and pneumonia 
strengthened with  
increasing severity of 
childhood bronchitis.”
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What is the Cancer Risk 
of ‘Social Smoking’?
MORE smokers are cutting back on their daily 
smoking, but the mortality and cancer risks 
of ‘social smoking’ remain substantially higher 
than for nonsmokers. News from a study by 
Columbia University Irving Medical Center, 
New York City, New York, USA, was presented 
at ERS International Congress 2020 on 1st  
September 2020.
‘Social smokers’, defined as those who smoke 
<10 cigarettes per day, represent an increased 
proportion of smokers in the USA, from 16% 
up to 27%, as many smokers have cut back 
or combined smoking with vaping. However, 
the risks from social smoking have not 
previously been well understood. Researchers 
analysed data from 18,730 people across 
ethnicities as a sample of the general population 
of the USA, to compare risk between social 
smokers, heavier smokers (>20 cigarettes per 
day), and nonsmokers. Participants, with an 
average age of 61 years, were followed for an 
average of 17 years.
The study found that, compared to nonsmokers, 
social smokers were 2.5 times more likely to die 
from respiratory diseases and 8.6 times as likely 
to die from lung cancer, even when controlling 
for age, sex, race, level of education, and body 
weight. Death from respiratory disease or lung 
cancer occurred in 3.3% and 4.7% of social 
smokers, respectively, compared with 10.1% and 
12.9% of heavier smokers, and 1.8% and 0.6% 
of nonsmokers. 
Addressing the value of these findings for 
clinicians at ERS International Congress 2020, 
Prof Jørgen Vestbo, Chair of the European 
Respiratory Advocacy Council and Professor of 
Respiratory Medicine, University of Manchester, 
Manchester, UK, emphasised: “It’s clear that there 
is no safe level of smoking. This large study is 
important because it shows that smoking less 
will probably not have the effect that people 
are hoping for. We need to do all we can to 
support smokers to quit completely using 
evidence-based means.”
"We need to do all we can 
to support smokers to quit 
completely using evidence-
based means.” 
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Flavourings and Solvents Mix to Form New,  
Toxic Chemicals in e-Cigarettes
e-CIGARETTES have propelled into common 
use as a ‘safe’ alternative to tobacco smoking; 
however, recent evidence is questioning the 
real safety of these devices and the associated 
e-liquids. The case for such tobacco alternatives 
being unsafe was further supported by research 
presented at the ERS International Congress 
2020 and reported in a press release dated 
3rd September.
Flavourings are routinely added to e-liquids, 
and, according to manufacturers, are safe 
because they are vaporised by the e-cigarette; 
however, a recent study reported that they 
form new toxic chemicals by combining with 
the solvents, for which there are severe 
safety concerns.
In the toxicological studies, the 
researchers exposed cells that 
line the bronchi to chemicals 
that are commonly used 
as flavourings, for example 
vanillin and cinnamaldehyde, 
and explored the possible 
compounds formed when 
mixed with propylene glycol 
and vegetable glycerine, the 
main solvents used in e-liquids. 
“We consistently observed that the 
new chemicals formed from the flavours 
and e-liquid solvents were more toxic than 
either of their parent compounds,” noted 
author of the study Prof Sven-Eric Jordt, Duke 
University School of Medicine, Durham, North 
Carolina, USA. 
Additionally, TRPV1 and TRPA1, sensory 
irritant receptors in the bronchi responsible 
for numerous inflammatory responses, were 
activated by the new chemicals. Activation of 
these receptors can lead to issues in both the 
cardiovascular system, such as increased heart 
rate and irregular heartbeat in the predisposed, 
and pulmonary system, such as coughing and 
breathing difficulties due to increased secretions 
throughout the airways.
Upon further investigation, the researchers 
found that the newly formed chemicals caused 
the cells lining the bronchi to die, even if the 
chemicals were at low concentrations. Prof 
Jordt commented: “This is the first 
demonstration that these new 
chemicals formed in e-liquids can 
damage and kill lung cells and 
probably do this by damaging 
their metabolism.”
In addition to listing the 
original chemicals, Prof Jordt 
called for manufacturers to 
list the chemicals formed 
when the flavourings are mixed 
with solvents. Furthermore, he 
noted that additional research 
into the toxicological properties 
of these chemical products should be 
conducted, and regulators to be aware of their 
safety profile to assess the level of risk to health 
from e-cigarettes, with the aim for manufacturers 
to reduce the concentration of such chemicals in 
their product.
“We 
consistently 
observed that 
the new chemicals 
formed from the 
flavours and e-liquid 
solvents were more 
toxic than either 
of their parent 
compounds” 
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Heavy Metal Exposure in the Womb  
Associated With Childhood Asthma
CADMIUM is a heavy metal and its use 
is restricted in the European Union (EU) due to 
its known hazards to human health; however, 
exposure to cadmium can occur because it has 
been widely used in batteries and pigments, 
and is present in tobacco. According to new 
research presented at ERS International 
Congress 2020 and in a press release dated the 
3rd September, higher concentrations of cadmium 
in the umbilical cord blood of newborns may 
increase the risk of developing childhood asthma 
and allergies.
In the study, the quantities of cadmium, 
manganese, and lead were measured in 706 
females and their babies at the maternity units 
in Nancy and Poitiers in France. Blood samples 
were taken from the mothers during pregnancy 
and babies from their umbilical cord after 
delivery. During the 8-year follow-up period, 
the researchers noted if any of the children had 
developed asthma, allergic rhinitis, eczema, or 
food allergies, accounting for family medical 
history and smoking status of the parents.
At the time of delivery, the average level of 
cadmium in the mothers was 0.8 µg/L and in the 
cord blood was 0.5 µg/L. For cadmium, higher 
levels in the umbilical cord of babies (>0.7 µg/L) 
were associated with a 24% increased risk of 
developing asthma. Interestingly, lower levels of 
cadmium (<0.3 µg/L) were associated with a 
44% increase in risk of developing a food allergy. 
Manganese levels were linked to risk of eczema, 
a known risk factor for developing asthma: levels 
of >1.1 µg/L in the mother’s blood was associated 
with an increased risk of developing eczema, 
compared with levels <0.5 µg/L.
“Our study doesn’t tell us why this might be the 
case, but it could be that cadmium is interfering 
with babies’ developing immune systems and 
we think this can have an impact on their allergic 
reactions in childhood,” hypothesised the 
research presenter Prof Isabella Annesi-Maesano, 
Institut national de la santé et de la recherche 
médicale (INSERM) and Sorbonne Université, 
Paris, France. 
Prof Daiana Stolz, ERS Education Council Chair, 
University Hospital Basel, Basel, Switzerland, 
commented on the findings: “It’s particularly 
worrying to know that cadmium and other 
metals might be reaching unborn babies via 
the umbilical cord.” She added that this study, 
along with the already known dangers of 
cadmium, supports extremely tight regulations 
of the use and disposal of products containing 
heavy metals.
“It’s particularly worrying 
to know that cadmium 
and other metals might be 
reaching unborn babies via 
the umbilical cord.” 
Creative Commons Attribution-Non Commercial 4.0 November 2020  •  RESPIRATORY 21
“Our results suggest that night-time coughing can be measured 
fairly simply with a smartphone app and that an increase in 
coughing at night is an indicator that asthma  
is deteriorating” 
Novel App Measures Night-Time Coughing  
to Predict Asthma Deterioration
COUGHING at night, measured via a novel 
smartphone app, can indicate the severity of 
asthma progression according to research 
presented at ERS International Congress 2020 
and a press release dated 25th August 2020.
“Smartphones have lots of potential to monitor 
different symptoms and detect changes early,” 
stated research lead Dr Frank Rassouli, Cantonal 
Hospital St Gallen, St Gallen, Switzerland. The 
research group aimed to utilise technology and 
simple interventions to improve the management 
of chronic lung diseases such as asthma. Dr 
Rassouli noted that: “Until now, we haven’t had 
a reliable tool for measuring peoples’ asthma 
symptoms overnight, so we know very little about 
night-time coughing and what it means.”
The study recruited 94 patients with asthma 
being treated at two Swiss clinics. Patients visited 
their clinics at the beginning and end of the 
study, where they were assessed on their usage 
of asthma treatments and symptoms, which 
included shortness of breath and the impact of 
asthma on their daily lives. For 29 days, patients 
slept with a smartphone in their bedroom and the 
app prompted them to report their night-time 
symptoms and measured the noise of their night-
time coughing.
Analysis of the data showed that while there 
was a discrepancy in the amount of night-time 
coughing from patient-to-patient, there was 
a strong correlation between increased night-
time coughing over the course of 1 week and 
subsequent worsening of asthma symptoms. 
“Our results suggest that night-time coughing 
can be measured fairly simply with a smartphone 
app and that an increase in coughing at night 
is an indicator that asthma is deteriorating,” 
Dr Rassouli explained. He further stated that 
monitoring asthma is pivotal because early 
recognition of worsening symptoms would allow 
clinicians to adjust medication accordingly and 
prevent asthma attacks. This study showcases 
a potential new and easily accessible way to 
monitor signs of deteriorating asthma, and with 
this success the researchers are planning to test 
the same technology on patients with chronic 
obstructive pulmonary disease.
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Low Levels of Air Pollution Linked to  
Asthma in Babies and Adults
BABIES raised in areas of higher levels of air 
pollution develop poorer lung function as children 
and teenagers, and adults exposed to low levels 
of air pollution over a prolonged time are more 
likely to develop asthma. These findings from two 
studies were reported at the ERS International 
Congress 2020 and in a press release dated 25th 
August 2020.
In the first study, lead by Dr Qi Zhao, IUF – Leibniz 
Research Institute for Environmental Medicine, 
Düsseldorf, Germany, 915 children from Munich 
and Wesel in Germany were tested for their 
breathing capabilities at the ages of 6, 10, or 15 
years. Forced vital capacity and forced expiratory 
volume in 1 second were measured and compared 
with estimates of the levels of pollution in the 
areas the children lived in their first year of life. 
Factors associated with poorer lung function, 
such as whether the children’s mothers smoked, 
were considered. Results found that the higher 
the babies air pollution exposure was, the worse 
their lung function was when they grew up. Dr 
Zhao concluded that: “Our results suggest that 
babies who grow up breathing polluted air, even 
at levels below European Union (EU) regulations, 
have poorer breathing as they grow into children 
and adults. This is worrying because previous 
research suggests that damage to lungs in the 
first year of life can affect respiratory health 
throughout life.”
A separate study found that adults were also at 
risk. The study, which analysed 23,000 Danish 
nurses, found a correlation between long-term 
exposure to air pollution and the likelihood 
of being diagnosed with asthma. Levels of 
nitrogen dioxide (NO2) and particulate matter 
smaller than 2.5 microns (PM2.5) were compared 
to the levels of road traffic noise where the 
nurses lived, accounting for factors including 
smoking and obesity. While no link was found 
to noise pollution, air pollution increased the 
likelihood of asthma diagnosis. A 29% rise in 
asthma risk was associated to each 6.3 µg/
m3 increase in PM2.5 and a 16% rise in asthma 
risk for each 8.2 µg/m3 increase in NO2. 
Compared to many European cities, the nurses 
were exposed to relatively low levels of air 
pollution; approximately 18.9 µg/m3 and 12.8 µg/
m3 for PM2.5 and NO2, respectively, and current 
European standard for PM2.5 and NO2 are 25.0 
µg/m3 and 40.0 µg/m3, respectively. Researcher 
Dr Shuo Liu, University of Copenhagen, 
Copenhagen, Denmark, asserted: “The fact that 
we found a link with asthma, even at relatively 
low levels of exposure, suggests that there is 
no safe threshold for air pollution. This is strong 
evidence that our regulations on air pollution 
need to be stricter if we want to prevent cases 
of asthma.”
"The fact that we found 
a link with asthma, even 
at relatively low levels of 
exposure, suggests that there 
is no safe threshold for  
air pollution."
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Lung Microbiome Fungal Diversity  
Linked to Disease Severity
FUNGI present in the lung microbiome may 
regulate the inflammatory response in acute 
respiratory distress syndrome (ARDS), with less 
diversity linked to poorer outcomes. A study of 
mechanically ventilated patients was presented 
at ERS International Congress 2020 and in a 
press release dated the 24th August 2020. 
Despite being outnumbered by bacteria as a part 
of the lung microbiome, fungi are known to 
play a role in activating and regulating 
immune responses. Researchers 
at the University of Pittsburgh, 
Pittsburgh, Pennsylvania, USA, 
analysed 202 mechanically 
ventilated patients from October 
2011 to September 2019; 21% 
had a diagnosis of ARDS. Next-
generation sequencing of the 
DNA of the tracheal secretions 
of the patients revealed about 
100 different species of fungi. 
Although species diversity was low in 
all of the samples, for those patients where 
one species dominated the samples, diversity 
was very low. 
ARDS was associated with very low species 
diversity; shock, sepsis, and organ failure were 
associated with lower fungal diversity among 
the patients with ARDS. Reduced diversity was 
found to be associated with more severe lung 
injury, more intensive treatment, and elevated 
levels of the protein pentraxin-3 (an indicator of 
inflammation and disease severity). 
Noel Britton, University of Pittsburgh, an author 
of the abstract, highlighted the value of the 
study: “The association of lower fungal 
diversity with clinical markers of 
disease severity is an important 
finding because it provides 
evidence for a relationship 
between the lung microbiome 
and clinical outcomes in critical 
illness.” Discussing the future 
implications of the findings, Prof 
Tobias Welte, ERS Past President, 
and Hannover University School 
of Medicine, Hannover, Germany, 
said: “The finding from this study, that 
less diversity in the mycobiome is linked 
to worse outcomes for patients with ARDS, is 
fascinating. It’s too early to know what this might 
mean for patients and their doctors, but it has 
the potential to lead to new diagnostic tests and 
better treatments.”
"it 
provides 
evidence for 
a relationship 
between the lung 
microbiome and 
clinical outcomes 
in critical 
illness.” 
Electronic Alerts Improve Asthma Management
ELECTRONIC alerts can improve prescribing and 
asthma management in general practice. A UK 
study presented at ERS International Congress 
2020 revealed the impact of an electronic alert 
system in general practitioner (GP) records.
Excessive prescription and use of short-acting 
reliever inhalers, such as salbutamol, can be 
an indicator of poorly controlled asthma, is a 
risk factor for asthma attacks, and has been 
implicated in asthma-related deaths. These 
short-acting reliever inhalers address asthma 
symptoms but do not improve the underlying 
inflammatory cause. 
The study included 18,244 patients with asthma 
at 132 general practices in north-east London, 
UK, and involved adding an automatic, electronic 
alert that appeared on GP screens when 
accessing the electronic patient records for 
patients who had received three prescriptions for 
short-acting reliever inhalers within a 3-month 
period. The alert recommended an asthma 
review for the patient, to assess symptoms and 
improve asthma control.
This intervention resulted in a 6% reduction in 
excessive prescribing of reliever inhalers in the 12 
months following the first inclusion of the alerts, 
with asthma reviews increasing by 12% in the 3 
months after the alerts. Within 6 months of the 
alerts being introduced, repeat prescribing of 
short-acting β2 agonists reduced by 5% and 
exacerbations requiring oral steroid treatment 
reduced by 8%.
The value of these findings, and the intervention 
approach used, were highlighted by Dr Shauna 
McKibben, Institute of Population Health 
Sciences, Queen Mary University of London, 
London, UK, and clinical nurse specialist in 
asthma and allergy at Imperial College Healthcare 
NHS Trust, London, UK: “Excessive short-
acting β2 agonists use is only one indicator for 
poor asthma control but the risks are not well 
understood by patients and are often overlooked 
by healthcare professionals. Further research 
into the development and robust evaluation 
of tools to support primary care staff in 
the management of people with asthma is 
essential to improve asthma control and reduce 
hospital admissions.”
"Within 6 months of the alerts being introduced, repeat prescribing 
of short-acting β2 agonists reduced by 5% and exacerbations 
requiring oral steroid treatment reduced by 8%."
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  Well tolerated2 and the highest purity4,#
  Shortest infusion time (~ 15 min) with 
 lowest volume3,5,6,#
  Innovative MyAlpha1™ self-administration 
programme empowers HCPs and patients***
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The Treatment of Severe Respiratory  
Disorders in Challenging Times
This industry symposium took place on 7th September 2020,  
as part of the virtual European Respiratory Society  
(ERS) International Congress 2020
Chairpeople: Tobias Welte,1 Marco Idzko,2 Timm Greulich3
Speakers: Michael Larbig,4 Maria Sucena,5 Felix Herth,⁶ Robert Sandhaus,⁷  
Alice Turner,⁸ Dave Singh,⁹ James Chalmers10
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Meeting Summary
Prof Welte opened the symposium by describing the key roles of hypercoagulation and inflammation 
in the course of severe coronavirus disease (COVID-19). This was complemented by Dr Larbig’s talk 
that introduced CSL312, a new human monoclonal antibody targeting coagulation factor XIIa, which 
aims to target both hypercoagulation and inflammation. Prof Idzko followed with a discussion about 
the challenges of treating respiratory conditions such as alpha-1 antitrypsin deficiency (AATD) during 
the COVID-19 pandemic. Dr Sucena explained that many patients had been unable or unwilling to 
attend health centres to receive alpha-1 antitrypsin (AAT) therapy, putting them at risk of increased 
morbidity. In response, Prof Herth discussed the use of self-administered AAT to ensure that patients 
receive regular therapy. Prof Greulich described the difficulties in providing robust evidence for the 
positive impact of AAT therapy on mortality, and Prof Sandhaus introduced a recent observational study 
that overcomes some of these problems, with findings that suggest AAT therapy results in improved 
survival rates and a slower decline in quality of life (QoL). Finally, Profs Idzko, Singh, and Chalmers 
emphasised that better treatments are needed for other respiratory conditions, and introduced drugs 
that are currently under development to address this need; these include a new antibody intended 
to treat a broad range of the severe asthma population (CSL311; CSL Behring, King of Prussia, 
Pennsylvania, USA) and nebulised IgG to treat non-cystic fibrosis bronchiectasis (NCFB) (CSL787; 
CSL Behring). Overall, advances continue to be made in the treatment of severe respiratory conditions, 
despite the difficulties posed by the current COVID-19 pandemic.
Challenges of Treating Lung 
Disease Caused by COVID-19
Professor Tobias Welte and 
Doctor Michael Larbig
Prof Welte described COVID-19, caused by the 
new coronavirus strain severe acute respiratory 
syndrome coronavirus-2 (SARS-CoV-2), as a 
disease that primarily affects the respiratory 
epithelium. The virus enters the bloodstream at 
an early stage and the course of COVID-19 is then 
dictated by damage to the vascular endothelium 
and vascular leakage.1 This means that unlike 
classic acute respiratory distress syndrome, 
severe COVID-19 is more likely in patients with 
endothelial dysfunction, such as those with 
diabetes, obesity, or arterial hypertension, 
compared with patients with respiratory diseases 
in general.1 
Repair mechanisms in the vascular endothelium 
can lead to hypercoagulation that may cause 
thrombosis, leading to pulmonary emboli and 
affecting gas exchange. Recent research has 
shown that capillary thrombosis is a major 
pathomechanism of severe COVID-19 disease at 
the microvascular level.2,3
Drugs currently under investigation for COVID-19 
treatment fall into three groups:
 > Antivirals, such as remdesivir, aim to reduce 
the viral load, which may drive the early stage 
of COVID-19.
 > Anti-inflammatories aim to reduce the 
hyperinflammatory burden, which is a 
consequence of the host immune response to 
endothelial damage.4 This immune response 
is driven by lymphocytes but also involves 
mediators such as cytokines.3-6 Patients with 
severe disease have been shown to have very 
high concentrations of cytokines, suggestive 
of a cytokine storm.
 > Anticoagulants, such as heparin, aim to 
counteract the coagulation recently shown to 
be involved in COVID-19 disease.6-8 It remains 
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to be seen whether anticoagulants with more 
specific targets than heparin could be used to 
reduce right–left shunting on the pulmonary 
level, which would reduce hypoxaemia and 
the need for mechanical ventilation in severe 
COVID-19.9 For example, CSL312 is a new drug 
that targets factor XIIa and is currently being 
tested in a Phase II clinical trial.10
 
Targeting Factor XII in COVID-19 
Disease
Dr Larbig explained that factor XII becomes 
activated upon contact with damaged tissues, 
and in turn activates factor XIIa, which initiates 
the kallikrein–kinin system.11 This results in 
inflammation, vasodilation, and capillary leakage, 
which can cause fluid accumulation in lung tissue.11 
Factor XIIa also triggers the complement system 
and the intrinsic coagulation cascade, which 
can lead to thrombosis (Figure 1).10,11 In addition, 
ex vivo human lung tissue models have shown 
that factor XIIa has proinflammatory properties.12
Growing evidence suggests that 
vascular leakage, pathological thrombosis, 
proinflammation, and complement activation 
may play a role in COVID-19,3,13,14 making factor 
XIIa a viable target for this disease. Human 
monoclonal antibody CSL312 has the potential 
to block the pathology triggered by activated 
factor XIIa, but to investigate whether it can 
influence disease progression in patients with 
severe COVID-19 disease, high-quality scientific 
data are needed. Despite the difficulties of 
conducting a controlled, randomised clinical trial 
during the current pandemic, investigators in 
many countries have shown that it is possible, and 
a placebo-controlled trial of CSL312 is currently 
underway in patients with COVID-19.10 
Figure 1: Mechanisms of action of factor XIIa on the immune system. 
FXI: factor XI; FXII: factor XII; FXIIa: factor XIIa; HK: high molecular weight kininogen; PK: prekallikrein.
Adapted with permission from Weidmann et al.11
FXII
FXI
Thrombin
Fibrin
PK
HK
Bradykinin
Kallikrein–kinin system: 
inflammation, vasodilation, 
and capillary leakage
Intrinsic coagulation pathway:
thrombosis
FXIIa
 
Creative Commons Attribution-Non Commercial 4.0 November 2020  •  RESPIRATORY 29
Questions and Answers
Q: When do you expect to see 
preliminary results from the CSL312 trial 
targeting COVID-19 patients with severe 
pneumonia?
Prof Welte explained that many studies are 
currently underway to investigate potential 
treatments for COVID-19, but that few drugs 
have been found to be effective. He believes 
that addressing the coagulation pathway is one 
of the most promising ways to treat COVID-19 
and emphasised that preliminary data from the 
CSL312 trial should be available in early 2021.
Q: What is the biggest challenge in 
treating COVID-19 patients with severe 
pneumonia?
Prof Welte replied that these patients have 
hypoxaemia and most require mechanical 
ventilation. Unlike other respiratory infections, 
patients with a severe course of COVID-19 need 
ventilation for weeks rather than days, and this 
increases the risk for cardiovascular and renal 
complications as well as secondary infections.
Q: Do you have any recommendations for 
protecting medical staff from COVID-19?
Prof Welte explained that in his hospital, double-
masking was introduced from the beginning 
of the pandemic, preventing hospital-acquired 
infections. He recommends that in outpatient 
situations, social distancing, the use of face masks, 
and regular disinfection of the hands should be 
used to minimise transmission of the virus, as for 
any infectious disease.
Treatment of Alpha-1 Antitrypsin 
Deficiency in Times of COVID-19
Professor Marco Idzko,  
Professor Timm Greulich,  
Doctor Maria Sucena, and 
Professor Felix Herth
Prof Idzko highlighted that the treatment of 
severe respiratory diseases, such as AATD, is 
challenging during the COVID-19 pandemic. 
While there is a need to protect medical 
staff by introducing additional safety 
measures for diagnostic procedures, such as the 
lung function test,15 it is crucial to continue 
treating patients.
AATD is a genetic disease that results in 
reduced circulating levels of AAT (also known 
as α-1 protease inhibitor), a protein that protects 
lung tissue against the inflammatory enzyme 
neutrophil elastase.16 Patients with AATD are 
more susceptible to infection and structural 
damage of the lung, as well as liver disease 
caused by hepatocyte inclusions formed from 
misfolded AAT.16 Treatment options include 
regular AAT therapy to restore circulating levels 
of the protein.
Prof Greulich explained that although the risk of 
severe COVID-19 disease has not been assessed 
in patients with AATD, the fact that they are 
already severely ill means that they are more likely 
to have a poor outcome from COVID-19 than 
healthy patients. This makes it difficult to treat 
patients in many European countries because 
treatment is performed in health centres and 
attending these appointments will increase the 
risk of contracting SARS-CoV-2. In addition, the 
COVID-19 pandemic may restrict the resources 
available in these centres. If AAT therapy is 
interrupted, patients with AATD are at increased 
risk of lung infections, loss of lung density, and 
liver damage.16
Alpha-1 Antitrypsin Deficiency 
Treatment in Portugal During the 
COVID-19 Pandemic
Dr Sucena explained that the first case of SARS-
CoV-2 infection in Portugal was confirmed on 
2nd March 2020, and within a very short time 
frame, Portugal had to reorganise its national 
health service (Serviço Nacional de Saúde [SNS]) 
to focus on managing the COVID-19 pandemic. 
This meant that patients without COVID-19 had 
restricted access to hospitals and other health 
facilities: personal appointments were replaced 
with phone calls, day hospitals were closed or 
had their activities reduced, and bronchoscopies 
were only performed in urgent situations.
Although there were very few confirmed 
COVID-19 cases in patients with AATD in Portugal, 
Dr Sucena emphasised that the pandemic had 
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a major impact on patients across the country 
because AAT treatment is only available in public 
day hospitals. During the first few weeks of the 
COVID-19 pandemic, AAT therapy was often 
cancelled, or patients were referred to alternative 
centres. Where treatment was still available, some 
patients chose not to attend because of the 
perceived risk of infection. 
Health facilities in Portugal began to reopen to 
patients without COVID-19 in early May 2020, 
but as SARS-CoV-2 still exists in the general 
population, the SNS must evolve to manage 
COVID-19 while also caring for other patients. The 
course of the COVID-19 pandemic over the next 
few months will dictate the availability of AAT 
therapy to patients with AATD. 
Prof Greulich highlighted that other countries 
are likely to face similar problems. The cancellation 
of appointments for patients with AATD will 
have left healthcare professionals unsure of the 
best way to care for their patients. Although 
some face-to-face appointments can be replaced 
by virtual appointments, other approaches are 
needed for treatment.
Alpha-1 Antitrypsin Deficiency  
Self-Administration in Germany and 
Austria During the COVID-19 Pandemic
A proportion of patients with chronic diseases 
have always been unwilling to attend 
appointments in health centres because of 
infection risk anxieties, and this problem has 
been exacerbated by the COVID-19 pandemic. 
However, for patients with AATD who are 
unable or unwilling to attend health centre 
appointments, a human AAT therapy (Respreeza®, 
CSL Behring) is licensed in Europe for at-home 
self-administration.17
Prof Herth emphasised the importance of 
selecting the right patients for self-administration 
of AAT therapy. Patients need to be physically and 
mentally fit, without significant comorbidities, 
and they should have the necessary motivation 
to learn how to self-administer their treatment. 
Prof Herth explained that in his preselected 
population, self-administration is suitable for 
30–50% of patients with AATD. Many of these 
patients have been receiving intravenous AAT 
therapy for several years and are already familiar 
with the procedure. Training suitable patients is 
the next step, and guidance and support is offered 
for this process, including guidelines to help 
patients learn the required techniques (Figure 2).
Prof Herth explained that the use of self-
administered therapy by his patients guaranteed 
that they would receive their treatment on time 
every week, which has been extremely helpful 
during the COVID-19 pandemic.
Questions and Answers
Q: What is the legal situation for AAT 
therapy self-administration?
Prof Herth advised healthcare professionals to 
conduct well-documented, thorough training to 
protect staff legally.
Q: How many training sessions do you  
think are required for AAT therapy  
self-administration?
Prof Herth explained that this varied depending 
on the patient; for some, one training session 
might be enough, but generally about three 
sessions are required. If patients are still uncertain 
about the techniques, they can perform their initial 
infusions under the supervision of a healthcare 
practitioner in a medical centre. 
Q: What, if any, adverse events might 
occur during AAT infusion?
AAT therapy has been used for many years, and 
for this reason, Prof Herth explained, physicians 
know that adverse events are unusual. Provided 
that patients have undergone adequate 
training, self-administration at home is as safe 
as administration in a health centre. Should an 
adverse event occur at home, the patient can 
stop the infusion. 
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The Impact of Alpha-1 Antitrypsin 
Deficiency Therapy on Mortality
Professor Timm Greulich, 
Professor Robert Sandhaus,  
Doctor Alice Turner, and  
Professor Tobias Welte
With many patients with AATD going untreated 
during the current pandemic, it is important to 
consider the impact that AAT therapy has on 
their overall mortality. Prof Greulich explained 
that an early study of AATD mortality using the 
National Heart, Lung, and Blood Institute (NHLBI) 
registry in the USA indicated that patients 
(N=1,129) who received intravenous AAT therapy 
had a lower risk of mortality compared with 
those who did not receive therapy (risk ratio: 0.64; 
95% confidence interval: 0.43–0.94; p=0.02).18 
More recently, an international, double-blind, 
randomised, placebo-controlled trial (RAPID) 
was conducted in 2015 to compare lung density 
in patients with AATD (N=180) who received AAT 
therapy with those treated with placebo.19 Over 
the 2-year study period, only four deaths were 
reported: one in the AAT group and three in the 
placebo group. The small number of patients in 
this study makes it difficult to derive important 
findings regarding mortality; a comparative 
study of mortality in patients with chronic 
obstructive pulmonary disease (COPD), for 
example, included >6,000 patients.20 To overcome 
this problem, more recent studies have used 
retrospective national registry data from around 
the world to investigate outcomes in patients 
receiving AAT therapy. 
A Comparison of Outcomes Between 
AAT-Naïve and AAT-Treated Patients 
with AATD-Related Lung Disease  
Using Retrospective Data
Prof Sandhaus introduced a recent 
observational study that compared mortality, 
lung transplantation, and QoL data between 
matched patients with AATD-related lung 
disease in UK and USA national registries.21 
Patients in the UK registry were treated with 
standard of care (control cohort), while those in 
the USA received standard of care plus plasma-
derived intravenous AAT therapy (AAT cohort).21
Figure 2: Part of a step-by-step training guide for self-administration of alpha-1 antitrypsin therapy.
Key points:
• Work under aseptic conditions 
• Reconstitute the concentrate
• Infuse the drug appropriately 
• Take care of the infusion site and veins 
• Document the infusion
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Dr Turner explained that inclusion criteria 
included evidence of lung disease, PiZZ genotype 
(a homozygous substitution of lysine for glutamic 
acid at position 342) or worse AATD genotype, 
and age >18 years.21 Patients were matched by 
age, sex, baseline year, and smoking status.21 
After matching, each cohort consisted of 655 
patients, with a mean age of 52 years and a male 
predominance of approximately 60% in each 
group.21 Median follow-up time was 7 years in the 
control group, and 9 years in the AAT group.21 
Approximately 6% of patients in each cohort 
received a lung transplant during the study 
period, and 193 of the control group died versus 
167 of the AAT group (p=0.122).21 
Kaplan–Meier analysis showed a statistically 
significant difference in overall survival between 
the two cohorts, with a 10-year survival probability 
of 68.5% in the control group and 80.0% in the 
AAT group (p<0.001).21 Among patients who 
received a lung transplant during the study 
period, those in the control group were likely 
to undergo surgery sooner, with a median time 
to lung transplant of 5 years, compared with 13 
years in the AAT group (p<0.001).21 Because lung 
transplant is an important life event, Dr Turner 
stressed that delaying the need for surgery is a 
potential indicator of delayed disease progression. 
Observational data has inherent limitations, such 
as confounding comorbidity and immortal time 
bias. For example, patients could have started 
AAT therapy many years before the AATD registry 
existed, and this treatment period would not be 
represented in the data. Respective analyses are 
being conducted on the data gathered for this 
study to address some of these issues.
One post hoc analysis that has already been 
performed is the assessment of QoL. Prof 
Sandhaus explained that any truly disease-
modifying therapy might influence this outcome. 
By looking at QoL measured by the St. George's 
Respiratory Questionnaire (SGRQ) over a 
specific time frame, immortal time bias can 
be eliminated, and to a large extent, one can 
control for the impact of factors like baseline 
forced expiratory volume in 1 second (FEV1) and 
comorbidities on this outcome. Upcoming data 
from this analysis indicate that QoL in patients 
who received AAT therapy declined more slowly 
than in controls.
Despite this study not fulfilling the criteria of a 
randomised clinical trial, it provides encouraging 
data on the positive impact of AAT therapy 
in patients with AATD. When the findings 
are translated to median life-years gained, an 
outcome commonly measured in clinical trials, 
patients receiving AAT therapy were found to 
gain around 6 life-years compared with controls. 
This is similar to data from a post hoc analysis of 
the RAPID trial, which indicate that AAT therapy 
may result in a gain of about 5.5 life-years, 
as measured by time to terminal respiratory 
failure estimated from the average group lung 
tissue atrophy.19
Questions and Answers
Q: What other investigations are planned 
to further investigate the impact of AATD 
treatment on mortality in the real world?
Prof Greulich described the European Alpha-1 
Research Collaboration (EARCO),22,23 a new 
European Respiratory Society (ERS) Clinical 
Research Collaboration, which aims to collect 
international data from approximately 3,000 
patients with AATD over the next few years. He 
explained that baseline data should be available 
in the near future, and longitudinal data will 
be available after 3–5 years, depending on 
funding. EARCO will provide the opportunity for 
researchers to match patients using a variety of 
baseline characteristics to minimise bias.
Development of Specialised 
Treatments for Severe Respiratory 
Conditions
Professor Marco Idzko,  
Professor Dave Singh, and 
Professor James Chalmers
While AAT therapy is effective at treating 
lung disease in patients with AATD, Prof Idzko 
emphasised that there remains an unmet need 
in other respiratory conditions, such as severe 
asthma and NCFB. 
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Targeting the Different Immunological 
Phenotypes of Severe Asthma
In the vast majority of patients with asthma, 
symptoms can be controlled with combination 
therapy of inhaled steroids and either long-
acting muscarinic antagonists or long-acting 
β agonists.24 However, around 5–10% of patients 
have a severe form of asthma that cannot be 
controlled without maximal inhalation therapy.24 
These patients experience considerable morbidity 
and account for approximately 50% of the total 
healthcare cost associated with asthma.25
Prof Idzko explained that progress has been 
made in identifying the immunological 
phenotypes of severe asthma over the past 
year. It is now possible to discriminate between 
allergic/nonallergic Th2 cell high (Th2-high) 
eosinophilic asthma, which is characterised 
by increased levels of eosinophils in the blood 
and sputum, but normal neutrophil counts, and 
Th2-low neutrophilic asthma, which is 
characterised by elevated levels of neutrophils.26
The improved understanding of immunological 
phenotypes has led to the development of 
new, targeted therapies for both allergic and 
nonallergic Th2-high eosinophilic asthma, with 
a particular focus on IL-5 pathways.26 However, 
Prof Idzko highlighted that these therapies are 
not always effective, and treatments for patients 
with Th2-low neutrophilic asthma have yet to 
be developed.
Prof Singh highlighted that granulocyte-
macrophage colony-stimulating factor (GM-
CSF), IL-3, and IL-5 all play an important role in 
the maturation of a broad range of inflammatory 
cells, including eosinophils and neutrophils.27 
All three cytokines are expressed at higher 
levels in the lungs of patients with asthma 
compared with controls. The fully human 
IgG4-κ monoclonal antibody (CSL311) is currently 
in drug development, which specifically targets 
the β common chain in the receptors for GM-CSF, 
IL-3, and IL-5, and could result in a broad range 
of anti-inflammatory activity.27,28 Compared with 
treatments currently used in clinical practice, 
CSL311 may be better placed to treat the broader 
severe asthma population, and a Phase I trial 
of CSL311 in patients with mild asthma is now 
underway, with results expected in 2021.28,29
Questions and Answers
Q: If we develop drugs that act on the 
broad range of severe asthma, will we still 
need to phenotype our patients? 
Prof Idzko emphasised that although CSL311 
could be effective in a broad severe asthma 
population, it is still important to look for 
phenotypic biomarkers such as eosinophils, IgE 
levels, and exhaled nitric oxide levels. Asthma 
therapy, both now and in the future, should 
always be personalised to the characteristics and 
phenotype of each patient.
Q: Some patients with severe asthma 
experience considerable limitations in 
their daily life. Could new treatments 
such as CSL311 improve QoL as well as 
exacerbation rates?
Prof Idzko explained that any treatment that 
reduces asthma exacerbations would be 
expected to improve QoL. However, measuring 
this outcome in clinical trial conditions will require 
long study periods with detailed questionnaires.
Reducing the Frequency of 
Exacerbations in Non-cystic Fibrosis 
Bronchiectasis
Prof Idzko highlighted that NCFB is another 
respiratory disorder that is challenging to treat. 
NCFB is defined as the irreversible, pathological 
dilation of the bronchi, and is characterised by 
recurrent infection, inflammation, persistent 
cough, and sputum production.30 
Prof Chalmers explained that the therapeutic 
goal in NCFB is to prevent exacerbations, or to 
treat them early when they do occur to prevent 
further lung damage. Exacerbations are driven 
by bacterial infection, which also promotes 
neutrophilic inflammation that can lead to 
structural lung damage.30,31
In patients who experience frequent 
exacerbations, the ERS guidelines provide a 
conditional recommendation for the long-term 
use of antibiotics.32 However, there is limited 
evidence to support this approach,32 and the 
development of antibiotic resistance is a major 
problem. Prof Chalmers emphasised that there 
is a need for additional therapies, and one 
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drug under investigation for NCFB is nebulised 
IgG (CSL787).
The proposed primary mode of action for 
CSL787 is prevention of exacerbations by 
reducing bacterial burden in the lungs. CSL787 
may also enhance local immunity, with the 
potential to protect the lung from infection. 
Phase I studies are now being prepared to 
investigate the use of nebulised IgG to prevent 
chronic respiratory tract infection and the 
progression of lung disease.
Summary
Despite the challenges of providing routine 
healthcare and conducting clinical trials during 
the current COVID-19 pandemic, advances 
continue to be made in the development of 
drugs to treat severe respiratory conditions.
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Meeting Summary
Currently, there are many different inhaler options for the treatment of airway diseases. While 
having options can be of benefit, it also presents a challenge for physicians and other healthcare 
providers (HCP). Selecting the correct drug and dose is only one-half of their role; they also need to 
be sufficiently familiar with each device to be able to select the best option for each patient, as well 
as correctly advising patients on their use, as errors with inhaler use adversely affect the success 
of treatment. Understanding the key principles in device technology will help clinicians to navigate 
this field.
In the first presentation, Prof Rabe considered the selection of treatment in patients with chronic 
obstructive pulmonary disease (COPD) and discussed which patients are most likely to benefit 
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Why Do Some Patients with 
Chronic Obstructive Pulmonary 
Disease Benefit from Inhaled 
Corticosteroid Treatment?
Professor Klaus Rabe
Prof Rabe first showed the current Global 
Initiative for Chronic Obstructive Lung Disease 
(GOLD) initial treatment guidelines and explained 
the reasoning behind the recommendation to 
consider ICS treatment for patients with a blood 
eosinophil count >300 cells/µL. An analysis by 
Harries et al.1 summarised the effect of ICS on 
COPD in 12 clinical studies. While the overall 
effect size was positive, there were a few outliers. 
It transpired that the higher the eosinophil 
threshold selected in each trial, the larger the 
effect size; this explained the difference between 
the studies. The conclusion was also supported 
by clinical trials on triple combinations, in which 
patients with a blood eosinophil count of >300 
cells/µL were most likely to benefit from the 
addition of ICS.2-6 Prof Rabe concluded that ICS 
treatment must be personalised and based on 
clinical and biological markers. Markers strongly 
supporting inclusion of ICS in treatment are two or 
more hospitalisations for exacerbations per year 
despite appropriate long-acting bronchodilator 
therapy, a blood eosinophil count >300 cells/µL, 
and history or current diagnosis of asthma. ICS 
treatment may also be considered in patients 
with only one moderate exacerbation per year 
and a blood eosinophil count of 100–200 cells/
µL. However, it should be avoided in patients 
experiencing repeated pneumonia events, those 
with a blood eosinophil count <100 cells/µL, and 
those with a history of mycobacterial infections.7
Key Features of Inhaler Device 
Technology
Professor Lauri Lehtimäki
Prof Lehtimäki then led the discussion on the 
relevance of inhaler technology for patients. 
Particle size and inhalation flow are the two 
factors that affect particle deposition within 
the respiratory system. Smaller particles are 
more likely to travel deeper into the lungs as 
they more easily follow the streamlines of the 
inhalation flow. However, particles that are too 
small are ineffective as they are not deposited 
within the time of inhalation and are exhaled. 
With fixed particle size, a higher flow rate 
leads to more central deposition than lower 
flow rates.8 In real life, all device-formulation 
from the use of inhaled corticosteroid (ICS). He noted that the largest effect size in exacerbation 
reduction was achieved in patients with higher levels of blood eosinophilic component and/or a past 
history of asthma.
Prof Lehtimäki then provided an overview of inhaler device technology, environmental factors relating 
to their manufacture and disposal, and the application of digital technology to improve inhaler use 
and patient adherence. Because of the high greenhouse gas potential of propellants in pressurised 
metered-dose inhalers (pMDI), their carbon footprint is estimated to be 10–37 times higher than that 
of dry powder inhalers (DPI). Digital solutions will help to assess patient adherence and inhalation 
quality in the future.
Next, Dr Usmani discussed inhaler device handling errors and how to avoid them. During the last 
40 years, handling errors have not decreased, and many HCP are thought to be overwhelmed by 
the plethora of devices and drugs on offer. Education in the correct use of devices for both trainers 
and users is paramount to the success of inhalation therapy. Important advice includes avoiding the 
prescription of different devices to the same patient, and to favour combination products to avoid 
multiple inhalers. 
Finally, Prof Bateman reviewed the rationale and evidence for maintenance and reliever therapy, and 
in particular the value of the anti-inflammatory effect of ICS doses taken when symptoms occur. This 
approach, when compared with similar or even higher maintenance doses of ICS with a short-acting 
β-agonist (SABA) reliever, has been consistently associated with lower exacerbations rates.
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combinations are optimised for specific 
inhalation manoeuvres and patients should 
follow the manufacturer’s instructions.
There are three main types of portable inhaler 
devices. DPI come in prefilled and capsule-based 
variants and rely on the patient’s inspiratory 
effort to disaggregate the drug particles from 
large lactose carriers. In general, the higher the 
resistance of the inhaler’s flow channel, the lower 
the required inhalation flow is. With the medium-
high and high-resistance inhalers, the required 
inhalation flow is generally only 30 L/min.9 The 
benefit of using inhalation flow for drug dispersion 
is that the patient can prepare the inhaler for 
actuation and then inhale when they are ready, 
without the need to co-ordinate these events. In 
pMDI, propellant gas is utilised to aerosolise the 
drug solution or suspension. They require the 
patient to co-ordinate the actuation and inhalation 
for successful drug delivery. Spacers are often 
needed for optimal dosing, but different brands 
have been shown to affect dosing differently.10 
There are also some models that are breath 
actuated. Soft mist inhalers create small droplets 
from solution via a mechanical apparatus rather 
than pressurised gas. There are many factors to 
consider when designing an inhaler, but the ideal 
inhaler device should be:
 > effective
 > efficient
 > engaging
 > error-tolerant
 > easy-to-teach
 > easy-to-switch-to
 > environmentally friendly.
 
Prof Lehtimäki provided some practical tips on 
how to choose inhaled medication for the patient. 
The first was to define the pharmacological 
interventions required and to choose the drug 
class accordingly. Next was to discuss, try, and 
confirm with the patients the inhaler they are 
able to use and most comfortable with. Using 
more than one different type of inhaler increases 
the risk of inhaler errors;11,12 therefore, it is best to 
select a device type that can offer as many of 
the drugs needed as possible. It is paramount to 
always teach and check inhaler technique. 
Novel devices with digital integration or add-ons 
are now entering the market. In the future, they will 
help clinicians to assess whether poor treatment 
results are attributable to poor adherence or lack 
of efficacy, as well as help the patient to play a 
more active role in their own treatment. The 
ideal digital aide should remind the patient to 
take their medication, monitor inhalations, and 
check the patient’s inhalation technique. As an 
example, Figure 1 shows the components of 
the Easyhaler® (Orion Pharma, Espoo, Finland) 
DPI connected to the Propeller sensor and 
platform. The sensor attaches to all Easyhaler 
products and pairs with the Propeller mobile app. 
Figure 1: Schematic presentation of digital aide integration to mobile platform.
EASYHALER + SNAP-ON SENSOR PATIENT (MOBILE APP) PLATFORM
 Attaches with the inhaler 
 Pairs with smartphone and web apps
 Collects data
 Automatically tracks medication use
 Transmits data
 Reminds and alerts
 Provides insight on triggers
 Gives personalised feedback and 
education
 Analyses and presents visualised data
 Provides ability to share data and 
progress with healthcare providers
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The platform provides the patients and 
caregivers with an opportunity to monitor 
adherence and to receive reminders when it is 
time to take a dose. The platform also provides 
personalised feedback and insight on triggers. 
Finally, HCP can access a portal to view patient 
data and ultimately make better informed 
therapeutic decisions. The use of such digital 
platforms has been shown to improve both 
patient adherence and asthma control.13,14
Patients, prescribers, and manufacturers are 
increasingly aware of the environmental impact 
of inhalation therapies. There are large variations 
between different inhaler devices in this respect. 
According to Montreal Protocol Medical and 
Chemicals Technical Options Committee 
(MCTOC) 2018 Assessment Report,15 pMDI have 
a 10–37 times higher carbon footprint compared 
to DPI. This conclusion was supported by an 
analysis by Janson et al.16 for selected marketed 
inhalers.15 Changing from a pMDI to DPI has 
almost the same impact on personal carbon 
footprint as changing to a plant-based diet 
or switching from gasoline to a hybrid car. As 
an example, breakdown of carbon footprint 
of Easyhaler DPI is provided in Figure 2.17 The 
difference between DPI and pMDI arises largely 
from the propellants used in pMDI devices. While 
original ozone-depleting chlorofluorocarbons 
have been phased out, modern hydrofluoroalkane 
propellants are still extremely powerful 
greenhouse gases.8 The patient’s ability to use 
the inhaler, their preferences, and efficacy of the 
medication are the most important factors in 
selecting inhaled medication, but environmental 
aspects of the device are emerging as a factor in 
treatment selection. 
Figure 2: Breakdown of Easyhaler® (Orion Pharma, Espoo, Finland) carbon footprint according to raw materials, 
manufacture, distribution, and disposal.  
Total cradle-to-grave life cycle emissions for one Easyhaler (average) is 0.588 kg CO2e.
Average of the four Easyhaler products (salbutamol, formoterol, salmeterol-fluticasone, and budesonide-formoterol 
Easyhaler). For each, the most used strength and number of doses per product was used for this analysis. Analyses 
were performed in accordance with ISO 14040 and ISO 14044 and verified by external carbon footprinting company 
(Carbon Footprint Ltd., Basingstoke, UK).
API: active pharmaceutical ingredient.
Adapted from Orion.17
TOTAL CRADLE-TO-GRAVE LIFE CYCLE EMISSIONS 
FOR ONE EASYHALER (AVERAGE) 0.588KG CO e2
COMPONENTS NEEDED FOR MANUFACTURE OF API AND CARRIER
0.1% 
RAW MATERIALS TRANSPORT
1.9% 
INHALER COMPONENTS, 
PACKAGING, PATIENT LEAFLET
24.2%
API AND CARRIER
40.5%
ASSEMBLY OF THE FINAL PRODUCT; 
INHALER AND FORMULATION 
(API AND CARRIER)
AND PACKAGING
 13.0%
INHALER COMPONENTS,
 PACKAGING, PATIENT LEAFLET
 6.5%
PRODUCT DISTRIBUTION
1.4%
DISPOSAL
12.3%
RAW MATERIALS
MANUFACTURE
DISTRIBUTION
DISPOSAL
*Average of the four Easyhaler® products (salbutamol, formoterol, salmeterol-fluticasone, and budesonide-formoterol 
Easyhaler®). For each, the most commonly used strength and number of doses per product was used for this analysis. 
Analyses were performed in accordance with ISO 14040 and ISO 14044 and verified by external carbon foot printing 
company. Carbon Footprint Ltd. API = Active pharmaceutical ingredient. 1. Carbon life cycle assessment report for 
Orion Corporation. Orion Pharma. Executive summary. Carbon Footprint Ltd 2020.
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Trainers and Trainees: How to 
Ensure Successful Inhalation 
Treatment for Patients?
Doctor Omar Usmani
Dr Usmani began his talk with an overview on 
inhaler development. However, the technological 
advances have not translated to more proficient 
use. A systematic review by Sanchis et al.18 showed 
that despite the advances in technology, the 
correct inhaler technique by the patient has been 
stagnated at approximately 30% for the past 40 
years. However, the lack of inhaler knowledge 
is not only limited to the patients, but is also 
evident in HCP.19 Plaza et al.20 studied the inhaler 
technique of physicians, respiratory therapists, 
and pharmacists and found the success rate of 
HCP to be only 12%. Even though the inhaler 
device is essential to the treatment of pulmonary 
patients, respiratory doctors get very little 
or no training in the devices. Still, both the 
Global Initiative for Asthma (GINA) and GOLD 
treatment guidelines stress the importance 
of inhaler technique and adherence in the 
assessment of the patient.21,22 While it is generally 
agreed that inhaler errors are a problem, there 
is no consensus on the definition, which has 
been illustrated in a systematic review by 
Usmani et al.23 that found 299 descriptions of 
inhaler errors. 
Different types of inhalers vary in how challenging 
the required inhalation manoeuvre is. Figure 
3 shows results of a study conducted in the 
UK on patients with asthma in a primary care 
setting.24 Over 90% of the patients were able 
to achieve sufficient flow rates even for high-
resistance inhalers, but >30% of the patients 
who used a pMDI were inhaling too forcefully. In 
conclusion, almost everyone was able to use a 
high-resistance DPI, but a significant portion of 
the patients using pMDI were not able to use 
their inhaler correctly, even after teaching and 
coaching by HCP.24
British inhaler treatment guidelines promote the 
‘ACT’-method for device selection.25 Firstly, when 
prescribing inhaled medications, the HCP should 
Assess whether the patient is able to inhale 
quickly, deeply, and forcefully (DPI) or slowly 
and steadily (pMDI, soft mist inhalers, or breath-
actuated inhaler). The inhaler type that is better 
suited for the patient is then Chosen. Inhalers 
have considerable environmental impact and 
when it does not compromise the treatment, it 
should be considered when choosing the device 
for the patient. Lastly, the patient should be 
Trained to use their device with placebo inhalers 
and materials should be given so the patient can 
revise the technique. It is also essential to check 
and correct the patient’s inhalation technique at 
every opportunity. 
A patient's inhalation technique can be estimated 
using seven steps:
1. Preparation
 > Check dose counter
 > Shake inhaler if instructed
 
2. Priming
 > Prime the device ready for use
 
3. Exhaling
 > Exhale gently away from the mouthpiece
 
4. Mouth
 > Place the mouthpiece in mouth, tilt the chin, 
and close lips tightly around the mouthpiece
 
5. Inhalation
 > DPI: quick and deep
 > pMDI: slow and steady
 
6. Breath holding
 > Remove inhaler from mouth and hold breath 
for up to 5 seconds
 
7. Closing and repeating
 > Close the inhaler/cap
 > Repeat if necessary
 
Finally, Dr Usmani gave some practical tips for 
the clinicians. Firstly, the inhaler device should 
not be changed without talking to the patient. 
Doyle et al.26 showed that switching without 
consent may diminish self-control, which is 
associated with better asthma management. 
Secondly, inhaler devices should not be mixed. 
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For patients with asthma or COPD it has been 
shown that the disease control worsens and 
exacerbations are more common in patients 
with inhalers needing different inhalation 
techniques.11,12 At least, the inhaler selection should 
be stratified to the same type of device. Thirdly, 
patients' inhaler technique should be checked 
at every opportunity and fourthly, HCP need to 
train themselves. The most expensive inhaler is 
the one not used, or taught, correctly.
Figure 3: Measured inspiratory flows with pressurised metered dose inhalers and high dry powder inhaler 
resistances.
MED: medium; PIF: peak inspiratory flow; pMDI: pressurised metred dose inhalers.
Adapted from Haughney et al.24
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Changing Perceptions and 
Improving Asthma Outcomes: 
Spotlight on Maintenance and 
Reliever Therapy
Professor Eric Bateman
Prof Bateman described patient factors that 
influence adherence to ICS treatment in asthma.27 
Paramount among these were the patient’s 
beliefs about the necessity for treatment and 
concerns about the safety of the treatment. 
Acceptance of the necessity for treatment 
with low concern about safety was associated 
with the highest adherence rates, whereas 
indifference or scepticism with or without 
concerns about safety led to low adherence. 
Additional factors for some patients are perceived 
social stigma or embarrassment about inhaler 
use, and fear of addiction.28 In a large European 
survey of patient attitudes to asthma treatment, 
fewer than one-half of the patients reported 
taking their inhaler every day, and most reported 
taking it on some days and not on others, or 
only when symptoms occurred.29 The problem of 
nonadherence with controller treatment results in 
many patients relying entirely on SABA taken as-
needed, living with high levels of symptoms, and 
at risk of asthma attacks.30 In addition, regular 
(four times daily) SABA use has been shown to 
increase airway hyperresponsiveness and worsen 
eosinophilic inflammation compared to regimens 
that include an ICS.31 In national surveys, the 
prescription of three or more canisters of SABA 
per year has been associated with increased risk 
of exacerbations and even of asthma deaths.32 
This is explained in part by reliance and escalating 
use of SABA and an associated delay in seeking 
medical care.33 Remote detection of excessive 
SABA use as a trigger to timely medical 
interventions is a potential application for novel 
digital platforms currently under development.
An alternative approach to reliever use, now 
recommended as the preferred option in the 
2019 and 2020 GINA guide, is the use of an 
ICS/formoterol combination inhaler. The basis 
for this is that increasing symptoms in asthma 
usually reflects worsening airway inflammation, 
indicated, for example, by an increased level of 
exhaled nitric oxide.34 In experimental rhinovirus 
infection in patients with moderate asthma, 
symptoms of the common cold peak at Day 5, 
and asthma symptoms at Day 7.35 The latter are 
associated with large increases in cytokines, 
reflecting Type 2 inflammation: IL-4, IL-5, and IL-13. 
The prompt administration of the ICS-containing 
reliever (effectively an ‘anti-inflammatory 
reliever’) ensures that both symptoms and the 
cause of symptoms are addressed, as well as 
preventing severe exacerbations.36 This effect 
is evident in analyses of exacerbation risk in 
the days following reliever use: high symptom-
prompted reliever use is an indicator of high 
exacerbation risk. This is considerably reduced if 
the reliever contains an ICS.37 The level of day-to-
day asthma symptom control with this regimen 
is similar to that of the fixed maintenance dose 
plus SABA regimens.37 On the basis of four 
recent clinical trials on the use of as-needed ICS/
formoterol without daily controller, this treatment 
is now recommended by GINA as the preferred 
approach in mild asthma. In the ‘real-life’ NOVEL 
START study, patients using an anti-inflammatory 
reliever required fewer courses of oral 
glucocorticoids, and had a lesser need of urgent 
medical care than both those taking SABA as-
needed alone, and patients who received low-
dose maintenance budesonide plus SABA as-
needed.36 Prof Bateman concluded with the 
reminder that exacerbations occur in all severities 
of asthma and that maintenance and reliever 
treatment leverages normal patient behaviour 
when faced with symptoms. Use of an anti-
inflammatory reliever titrated in this way provides 
a safer option, a ‘safety net’, preventing a large 
proportion of severe attacks across the range of 
asthma treatment steps.
Summary
Professor Eric Bateman
Many factors should affect the selection of 
inhaler devices. The patient’s mastery of the 
device and preference must be taken into 
account, but prescribers should consider 
selecting devices that have the lowest impact 
on the environment. By selecting devices with a 
high resistance, inspiratory flow is rarely a limiting 
factor because a low flow is sufficient for optimal 
results. There is an urgent need to formalise, and 
make mandatory, training in the use of inhaler 
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devices for HCP. Proficiency of both HCP and 
patients is essential for successful therapy. 
Finally, maintenance and reliever therapy, which 
simplifies treatment by requiring a single inhaler 
for both maintenance and relief of symptoms, 
and leverages patients’ normal tendency to self-
medicate when symptomatic, has been shown to 
improve ICS coverage, especially in patients who 
have faltering adherence. 
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Meeting Summary
Breath sounds, such as wheeze, may be one of the oldest clinical signs described in the medical 
dictionary, but their definition and interpretation among clinicians varies widely. Efforts to classify 
breath sounds have often created further confusion over what does and does not constitute wheeze, 
a breath sound that can be indicative of asthma, bronchiolitis, and various other air trapping 
lung diseases in preschool children. There is also a disconnect between parental and physician 
understanding of wheeze, with high levels of disagreement between the two groups. The result is 
a failure to recognise or to hyperdiagnose wheeze. This can lead to inappropriate medication use, 
including over- and underuse, and children undergoing unnecessary testing and procedures, as well 
as increased levels of anxiety for parents and carers. Crucially, failing to recognise wheeze can delay 
the detection of asthmatic disorders, blocking access to preventative treatments, and make 
exacerbation more likely. 
During this symposium, Assoc Prof Priftis, Prof Karadag, and Prof van Aalderen discussed the 
definition of wheeze, what it might mean in preschool children, and the implications of not recognising 
it. They also talked about the importance of a patient-centred approach to diagnosis, how to ‘close 
the gap’ between patient and physician understanding, and suggested that new technologies, such as 
artificial intelligence (AI), may play a role in detecting wheeze.
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What Is a Wheeze and Why Is 
It Important to Confirm It Is a 
Wheezing Sound?
Associate Professor  
Doctor Kostas Priftis
In 1819, René Laënnec, inventor of the 
stethoscope, said that breath sounds were “much 
more difficult to describe than to distinguish.” 
Just over 200 years later, the same is still true, 
said Assoc Prof Priftis.
“Noisy breathing is a very well-known clinical sign 
used by all physicians, especially paediatricians,” 
he said. Yet, despite its wide and long-term 
usage as a clinical sign, interpreting the 
meaning behind noisy breathing is far from 
straightforward. Various papers have attempted 
to assist by classifying and defining breathing 
sounds in recent years, but there remains 
much confusion and little standardisation 
among physicians, Assoc Prof Priftis told the 
symposium attendees. 
Classifications 
Bohadana et al.’s1 ‘Fundamentals of Lung 
Auscultation’, published in 2014, attempted 
to define and classify breathing sounds in a 
bid to help clinicians better recognise signs of 
respiratory disease. It grouped tracheal sound, 
lung or vesicular sounds, and bronchial breathing 
together as normal respiratory sounds. The 
abnormal respiratory sounds were split into 
subcategories: musical (m), nonmusical (nm), and 
mixed. Stridor, wheeze, and rhonchus fell into the 
‘m’ group, whereas fine crackle, coarse crackle, 
and pleural friction rub were considered ‘nm’. The 
authors classified squawk as mixed.
Two years later, Assoc Prof Priftis explained, a 
European Respiratory Society (ERS) taskforce 
published a statement that classed a wheeze as 
an adventitious sound, originating from the chest 
wall, trachea, or mouth. The authors described it 
as a continuous, high-pitched respiratory sound. 
Rhonchus was also defined as being continuous, 
but low-pitched.2 
“A wheeze […] can be heard with or without a 
stethoscope, especially during expiration, and 
is produced by the obstruction of airflow within 
intrathoracic airways,” said Assoc Prof Priftis. 
“In this way, we can detect asthma, as it is an 
asthma sign, but it can also be produced by other 
causes such as bronchiolitis, bronchomalacia, or 
a foreign body.”
Clinical Importance 
Recognising breath sounds is essential to the 
early diagnosis and appropriate treatment of 
respiratory health conditions. 
However, a 2016 study by ERS taskforce 
members on lung sounds found that even the 
experts were unable to agree on the correct 
classification of prerecorded respiratory noises.3 
When the study participants were asked to 
choose between 10 predefined breath sounds 
according to the recommended English 
language nomenclature, there was little 
agreement between them. When the field was 
reduced to four breathing sounds, namely 
expiratory crackle, inspiratory crackle, expiratory 
wheeze, and inspiratory wheeze, the specialists 
were slightly more in agreement. However, it was 
only when the experts were asked to classify the 
sounds as simply either a crackle or a wheeze 
that they achieved a ‘good’ or ‘excellent’ level of 
agreement. Simplifying the description of lung 
sounds would, Assoc Prof Priftis argued, help 
to increase agreement on their use. “It seems 
the essence of our clinical practice is to confirm 
a breath sound as a crackle or a wheeze,” said 
Assoc Prof Priftis, highlighting a 1979 paper 
that described just two types of breath sounds, 
discontinuous and continuous, with wheeze 
falling into the latter.4 
The ERS taskforce also sought to understand 
if there were common terms for the different 
breathing sounds. They found huge variation 
across countries and, in some cases, within 
countries regarding the word they used to 
describe ‘wheezing’.3 “Again, it was a mess, 
because even in the same country we had 
different names for the same sound,” said Assoc 
Prof Priftis. If doctors have difficulty naming 
and recognising breath sounds, how could they 
explain how to interpret them to patients and 
their parents, he questioned. 
Objective Recognition and Description 
An objective description of wheeze would 
inform more universal recognition of the breath 
sound that can be indicative of health conditions 
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such as asthma and bronchiolitis, both of which 
benefit from early detection and treatment, 
considered Assoc Prof Priftis. Crackles and 
wheezes, he argued, are well recognised and 
routinely used in daily practice, meaning that 
no further classification is required. Further 
descriptions would serve to introduce confusion 
and nonstandardisation. “Enough is enough, 
we need no more,” he said.
Assoc Prof Priftis concluded: “After 200 years 
of stethoscope usage, it is still more difficult to 
describe than to distinguish breath sounds.” 
The Struggle of  
Paediatricians and Parents  
with a Wheezing Child
Professor Doctor Bülent Karadag
For all the reasons highlighted by Assoc Prof 
Priftis, said Prof Karadag, recognising wheezing 
in a child can be challenging. In addition, this 
is often compounded by a lack of agreement 
between healthcare professionals and families 
on whether the symptom is present and, if it is, 
what it means. It is important to remember that 
not every wheeze a parent reports will match 
the clinical description, and that not every 
confirmed wheeze is caused by asthma, clarified 
Prof Karadag.
Prof Karadag started his presentation with a list 
of reasons why it was important to recognise 
wheeze. “Now we are moving into autumn 
and winter, our emergency rooms will be full 
of wheezing children with bronchiolitis and 
asthma,” he said, explaining that wheeze was the 
“most important tool” for diagnosing asthma. 
“In order to get appropriate medical treatment, 
you should diagnose wheezing. Otherwise, you 
will not be giving inhaled steroids or leukotriene 
receptor antagonists to treat and to control 
asthma,” he warned. Recognising wheeze and 
its causes, he explained, also helps clinicians to 
avoid inappropriate antibiotics and unnecessary 
laboratory testing.
Crucially, recognising wheeze is an integral part 
of patient-centred care, he continued. Clinicians 
can decrease children’s and parents’ anxiety 
levels by identifying and explaining the 
breathing sound, he said. To demonstrate his 
point, Prof Karadag highlighted a UK study of 
parents of preschool children with recurrent 
wheeze. It found a mix of positive and negative 
feelings about healthcare services among those 
whose wheezing toddlers were being cared 
for in primary care, emergency departments, 
paediatric wards, and paediatric specialist clinics. 
Following discharge, however, parents only 
reported feelings of stress, fear, or anger relating 
to their child’s care.5 Prof Karadag explained: 
“When they are at home there are no happy 
moments because there is uncertainty. Is it 
wheeze? Is there any severe disease? Should I 
take my child to the emergency room? But even 
in the emergency room and paediatric ward, if 
the diagnosis is not clear, if the physician cannot 
say it is wheezing, this fear and anger continues.”
Discrepancy in Understanding 
Prof Karadag said that there was a significant 
discrepancy between parental and physician 
understanding of wheeze. 
One of the first papers to demonstrate this was 
published 20 years ago and showed that parents 
and doctors only agreed in 45% of cases.6 In 
39% of cases, doctors defined a child’s breathing 
sound as wheezing, though it had not been 
described as such by the parents. Additionally, in 
14% of cases the parents said it was a wheeze, 
but the doctor disagreed. A key point here is the 
differing terminology for wheeze, as outlined 
by Assoc Prof Priftis, Prof Karadag said. When 
parents were asked to describe their child’s 
breathing sound, they used a multitude of words, 
including hissing, squeaking, whistle, and rasp.6 
“Doctors do not know what to label it, but from 
the patient/parent side, it is terrible. In Turkey, 
I can never be sure of what they will call it, so 
I always ask them to mimic the sound, but it is 
not accurate.”
Another study, from 1996, showed that the easier 
it is to hear the wheezing, the higher the level of 
agreement between parent and doctor.7 “When 
you look at the peak expiratory flow rates, if you 
hear the wheezing easily, flow rate is something 
around 55%, and if there is no sound, it is about 
90%. So, if the parents are hearing wheezing at 
home easily, you should ask them to rush directly 
to the emergency room because there may be a 
risk of hypoxia.”
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Other factors that might affect parental 
understanding, interpretation, and terminology 
surrounding wheeze are ethnicity and 
socioeconomic background. A UK study of 
4,000 patients showed that parents from a South 
Asian background and those who did not speak 
English as a first language were less likely to 
correctly define wheeze compared to Caucasian, 
native speakers, for example.8 
Agreement matters because there is a link 
between parent-reported wheezing and 
general practitioner-recorded asthma diagnosis, 
according to a 2018 study from Wales, UK.9 “If 
the parents report true wheeze, true positive 
wheeze, asthma prevalence is nearly 20%. But if 
there is a false positive wheeze it is 4%.10 So, if 
there is an agreement between the physician and 
the parents, you can say that the risk of asthma 
is much higher than in the normal population,” 
stated Prof Karadag.
Summarising the problem, he said: “Identifying 
wheezing is challenging for parents. Children may 
not be able to, and of course we don’t expect them 
to, articulate their breathing trouble.” Wheeze 
does not always sound the same, and it can be 
confused with noisy breathing, congestion, a 
blocked nose, or even a throat infection.
Not Every Wheeze Is Asthma
Recognising wheeze is the first step on a 
diagnostic journey, but the destination is not 
always asthma. Clinicians need to ask if the 
sound is a wheeze or a rattle, and consider any 
additional findings, including whether the noise 
is localised. They should also be aware of the risk 
of bronchial disease, said Prof Karadag. “There 
are two parts to this: is it really wheezing and 
is there any underlying disease?” he asked. In 
acute bronchiolitis, which is more common than 
asthma, clinicians will hear polyphonic wheeze 
and inspiratory crackles. Children with acute 
bronchitis may present with an audible rattle, 
caused by secretions, which it is also a symptom 
of acute viral bronchiolitis. Detecting asthma, 
therefore, is not as straightforward as recognising 
wheeze. Wheeze at rest and nocturnal cough 
are indicators of asthma, said Prof Karadag. 
He continued: “In conclusion, many cultures do 
not have a word for wheeze, and nearly half of 
parents struggle to identify wheezing sounds. 
Doctors fear patients will be undertreated due 
to the lack of awareness around wheezing. The 
‘wait-and-see’ approach may cause delayed 
interventions to prevent attacks, and if physicians 
hesitate, they will miss any underlying diagnosis, 
mainly pneumonia. My take-home message is 
that it is important to clarify the sound heard 
by the parents, and even the sound heard by 
doctors. We need to standardise it and AI may 
help us to overcome this barrier.”
New Tool to Help  
Parents Confirm Wheeze
Professor Doctor Wim van 
Aalderen
AI may play a role in helping parents and 
physicians detect wheeze in children. Devices 
such as the OMRON WheezeScan (HWZ-1000T-E; 
OMRON Healthcare, Kyoto, Japan), which has 
been recently been launched as an aid for 
parents in the UK and Germany, use a validated 
algorithm to listen to auscultation and return 
a ‘wheeze’ or ‘no wheeze’ result. The value of 
such tools, which currently allow parents to 
confirm their suspicions of wheeze in children 
aged between 4 months and 7 years old, lies in 
their potential to assist in the early diagnosis of 
asthma and other respiratory conditions, said 
Prof van Aalderen, highlighting that preschool 
wheeze costs the UK £53 million a year, or 0.15% 
of country’s overall health budget.11
Prevalence and Interpretation 
Discussing the impact of wheeze, he said that 
one in three children experience it before their 3rd 
birthday, adding that the cumulative prevalence 
is 50% by the age of 6 years. A well-known study 
from 1995 found that 40% of those who had a 
wheezing episode before the age of 3 years, and 
most of those who persistently wheezed before 
turning 6 years of age, went on to be diagnosed 
with asthma.12 “This is a very important study, but 
[…] it doesn’t help you if you are in your office 
with a wheezing child in front of you. It doesn’t 
give a clue about the future of the wheeze of this 
child,” remarked Prof van Aalderen.
Of course, asthma is not the only cause of 
wheeze. Recurrent viral upper airway infections 
and cigarette smoke exposure can cause the 
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breathing sound, and postviral wheeze is 
common in young children, especially in those 
recovering from respiratory syncytial virus. 
Prof van Aalderen also listed several rare 
diseases as possible differential diagnoses of 
preschool wheezing. These included cystic 
fibrosis, congenital heart disease, and anatomic 
malformation, such as tracheomalacia.
He reiterated the point made by both Assoc 
Prof Priftis and Prof Karadag, that wheeze can 
be interpreted differently between parent/carer 
and healthcare provider and is dependent upon 
whether it is reported retrospectively or in real 
time. “For us, what is important is the agreement 
between parents and healthcare providers,” he 
said, pointing to a 2000 study showing these 
two groups disagreed on their assessment of 
wheezing in 55% of cases.6 The importance of 
this was highlighted in a paper published in 2004, 
which found the lung function in children with 
physician-confirmed wheeze was significantly 
lower than that in children with parental-only 
reported wheeze.13
Predictors of Asthma 
Detecting wheeze is an important first step in 
the diagnostic journey, but it is not the only 
predictor of asthma. Clinicians with a confirmed 
incidence of wheeze will carry out a physical 
examination and take a thorough history, paying 
particular attention to any family history of 
asthma or allergies. Noninvasive measurements 
such as exhaled nitric oxide and serum markers, 
especially IgE if there is a history of allergic 
disease, may also be useful, explained Prof van 
Aalderen. “History, a positive family history for 
allergic disease in the first-line, and a positive 
specific IgE all increase the chance of developing 
asthma, but there is overlap between groups 
and there is no diagnostic available for daily 
practice,” he said.
Artificially Detecting Wheeze
New technologies may help parents to identify 
wheeze, and lead to greater agreement between 
them and physicians. WheezeScan, for example, 
connects to an app that allows parents to share 
information with doctors. They do not, however, 
change the role of the clinician: “If a parent 
reports to you that their child has wheeze, you 
still have to do a full follow-up in your own office. 
It helps with diagnosis, but your job as a doctor 
remains the same as it was yesterday,” explained 
Prof van Aalderen.
Questions and Answers
Following the presentations, the panel answered 
questions from delegates and from each other. 
Q: Should We Teach Parents  
What Wheeze Is?
Assoc Prof Priftis said parents would simply 
need to know if a child were wheezing or not so 
they could relay that information to their doctor. 
It is then the clinician’s role to differentiate 
what the wheeze means through the history 
and examination. 
Q: How Can We Close the Gap Between 
Parent and Physician Understanding  
of Wheeze?  
Prof Karadag said we were “at the start of a new 
era in terms of closing the gap.” This is being 
driven in part by new technologies, such as AI, 
but also by a new emphasis on personalised 
care. “Being a good physician and making the 
right decisions depends on the time you are 
spending with your patient,” he said. Factors 
such as the parent’s education and occupation, 
whether the child is their first, and how old they 
were when they became a parent, for example, 
all have a bearing on their interpretation of a 
wheeze and its severity, he observed. “I think 
giving enough time to each patient and taking 
a detailed history will help physicians to close 
this gap.”
The essential point, said Assoc Prof Priftis, 
is to educate doctors so they can educate 
their patients. 
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Meeting Summary
Dupilumab (Dupixent®) is a fully human monoclonal antibody1 that inhibits IL signalling of both 
IL-4 and IL-13, which are drivers of type 2 inflammation in multiple atopic diseases, including 
asthma.2 Dupilumab has been developed as an add-on maintenance treatment for asthma in adult 
and adolescent patients. There are some differences in specific indications of disease severity and 
clinical characteristics on the USA and European Union (EU) labels,3,4 and in the EU the approved 
indication for dupilumab in asthma is specifically for patients exhibiting type 2 inflammation, 
characterised by elevated blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO).4 
The clinical development programme for dupilumab in asthma (LIBERTY ASTHMA) includes the 
pivotal Phase III trials QUEST5,6 and VENTURE,7,8 and an open-label extension study (OLE), TRAVERSE,9 
which recruited patients from QUEST, VENTURE, and two Phase II studies.
Dr Wechsler presented the first long-term efficacy and safety data to emerge from TRAVERSE at 
the European Respiratory Society (ERS) International Congress 2020. He showed that the long-term 
safety profile of dupilumab was consistent with that observed in the parent studies and that efficacy 
was maintained, including a persistently low exacerbation rate and improvements in lung function 
sustained for up to 96 weeks. Dr Hanania presented a poster reporting a post hoc analysis of QUEST, 
which explored exacerbation rates in patient subgroups defined according to degree of lung function 
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Dupilumab Long-Term Safety and 
Efficacy in Patients with Asthma:  
LIBERTY ASTHMA TRAVERSE
Doctor Michael E. Wechsler
LIBERTY ASTHMA TRAVERSE,9 the first long-
term study of the safety and efficacy of dupilumab 
in asthma, was an OLE study in patients with 
asthma who had participated in any of four 
Phase II or III clinical trials of dupilumab: a Phase 
IIa proof-of-concept study (EXPEDITION),10 a 
Phase IIb dose-ranging investigation,11 and the 
Phase III QUEST6 and VENTURE8 studies. Patients 
entering TRAVERSE received open-label 
treatment with dupilumab 300 mg every 2 
weeks (q2w) for 48–96 weeks. The study 
population comprised 2,282 adult and adolescent 
patients (aged ≥12 years) with moderate-to-
severe asthma, including some patients with 
OCS-dependent asthma.
Dr Wechsler presented the headline safety and 
efficacy results from TRAVERSE. The safety 
profile was consistent with that seen in the parent 
studies, and no new safety signals were observed. 
Treatment-emergent adverse events were 
experienced by 76–88% of patients at any time 
during TRAVERSE, across study groups based on 
parent study and randomised treatment group in 
the parent study. The most common treatment-
emergent adverse events were nasopharyngitis 
and injection site erythema. The rate of serious 
adverse events was 9–13%.
Efficacy results were presented for the non-OCS-
dependent patient population, which included 
patients recruited from the Phase IIb study and 
the Phase III QUEST study (n=2,062). The primary 
efficacy endpoint was annualised exacerbation 
rate (AER). Low exacerbation rates observed in 
the parent studies were sustained in the OLE and 
ranged from 0.31 to 0.35 across study groups in 
the overall exposed population (Figure 1). This 
compares with baseline AER of 1.85–2.37 across 
treatment groups at the start of the Phase IIb and 
QUEST studies. A subgroup of patients with type 
2 asthma phenotype (defined as eosinophils ≥150 
cells/µl or FeNO ≥25 parts per billion at parent 
study baseline; n=1,679) had similar results, with 
AER during the TRAVERSE study ranging from 
0.29 to 0.33 (Figure 1). 
An analysis of lung function based on forced 
expiratory volume in 1 second (FEV1) showed that 
for patients who were randomised to dupilumab 
in the parent studies (Phase IIb or QUEST), 
improvements in FEV1 were sustained throughout 
the OLE, while patients who received placebo 
in the parent studies had rapid improvements in 
FEV1 on commencing dupilumab in the OLE. 
Baseline FEV1 was 1.75–1.86 L across treatment 
groups at baseline in the Phase IIb and QUEST 
parent studies, increasing to 2.02–2.12 L by 
Week 96 of TRAVERSE, representing a 13–
22% improvement in the non-OCS-dependent 
population. Similar improvements in lung 
function, by 13–25%, were seen in the subgroup of 
patients with type 2 phenotype asthma.
Transient increases in eosinophils have been 
observed in dupilumab clinical studies, including 
parent studies feeding into TRAVERSE, and 
are consistent with the mechanism of action 
of dupilumab.5,7,12 In the parent studies, mean 
eosinophil counts returned to baseline or close to 
baseline by the end of the study.5,7,12 Monitoring 
of eosinophil counts continued in the OLE for 
patients in the non-OCS-dependent population 
(patients recruited from the Phase IIb and QUEST 
studies). Transient increases were observed 
during the first few weeks of TRAVERSE in 
patients who had received placebo in QUEST 
and commenced dupilumab treatment on 
entering TRAVERSE, and in patients entering 
TRAVERSE from the Phase IIb study, who had a 
16-week treatment-free follow-up period between 
completing the double-blind treatment period 
in the parent study and entering the OLE; these 
increases resolved by Weeks 12–24. Longer-term 
follow up showed that, by Week 96 of the OLE, 
mean eosinophil counts had decreased to below 
parent study baseline levels.
improvement. Dr Maspero presented a similar post hoc analysis of VENTURE, which was a study 
in patients who were glucocorticoid-dependent, exploring relationships between oral corticosteroid 
(OCS) use and lung function improvement. Both analyses showed that dupilumab improved outcomes 
(exacerbation rates and OCS use, respectively) across patient subgroups with varying degrees of 
improvement in lung function.
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Eosinophils are a key marker of type 2 asthma. 
Serum IgE is an additional marker, specifically of 
allergic asthma, which is characterised by IgE-
mediated type 2 inflammation.13 Serum IgE has 
been measured as an exploratory biomarker in 
dupilumab asthma studies. Data on serum IgE 
were available for patients who participated in 
the Phase IIb study, and serum IgE measurements 
were repeated in these patients (n=532) during 
the OLE. At the start of the OLE, mean serum 
IgE was lower in patients from the dupilumab 
treatment group compared with those from the 
placebo group in the Phase IIb feeder study. By 
Week 96 of the OLE, mean IgE levels dropped 
markedly in both groups, decreasing by 82% 
from parent study baseline in the overall Phase IIb 
study population.
Dr Wechsler concluded that long-term treatment 
with dupilumab was generally well tolerated, 
and that the clinical efficacy observed in the 
parent studies was maintained, including a 
persistently low exacerbation rate and sustained 
improvements in lung function. Markers of type 
2 inflammation also decreased during long-term 
dupilumab treatment.
Effect of Dupilumab on  
Severe Exacerbations in Asthma 
Patients With and Without Lung 
Function Improvements
Doctor Nicola A. Hanania 
LIBERTY ASTHMA QUEST study is the largest 
randomised controlled trial of dupilumab in 
patients with asthma, contributing >50% of the 
patients who enrolled in the TRAVERSE study 
described above. In the QUEST study, a total 
of 1,902 adult or adolescent patients (aged ≥12 
years) with uncontrolled moderate-to-severe 
asthma were randomised to treatment with 
dupilumab 200 mg or 300 mg q2w, or matched 
placebo, for 52 weeks. The primary endpoints 
were annualised rate of severe exacerbations 
over 52 weeks and change from baseline to 
Week 12 in prebronchodilator FEV1.
5 Significantly 
lower annualised rates of severe exacerbations 
were recorded in both dupilumab groups 
compared with matched placebo (46–48% 
relative reductions), while mean increases in 
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Figure 1: Annualised exacerbation rate in the non-oral-corticosteroid-dependent population in LIBERTY ASTHMA 
TRAVERSE.
AER was assessed in the exposed population (observed cases). 
*The total number of events that occurred during the treatment period divided by the total number of patient years 
in the treatment period.
AER: annualised exacerbation rate; eos: eosinophils; FeNO: fractional exhaled nitric oxide; ppb: parts per billion.
Creative Commons Attribution-Non Commercial 4.0 November 2020  •  RESPIRATORY 53
FEV1 were significantly greater in dupilumab 
groups (320–340 mL) compared with placebo 
(180–210 mL).5 
Dr Hanania presented a post hoc analysis 
exploring the relationship between these two 
outcomes. The objective of the analysis was to 
assess the efficacy of dupilumab in reducing 
severe exacerbations in subgroups of patients 
who did and did not achieve clinically meaningful 
improvements in lung function. This is of 
interest because poor lung function (low FEV1) 
is associated with difficult-to-treat disease and 
worse outcomes.14 
Two definitions of clinically meaningful 
improvement in lung function were applied, with 
thresholds of ≥100 mL or ≥200 mL increase in 
pre-bronchodilator FEV1 from baseline to Week 
12 constituting a clinically meaningful 
improvement. Using the 100 mL threshold, 62% 
of patients in dupilumab groups (combined 
dose groups) and 49% of patients in combined 
matched placebo groups achieved clinically 
meaningful improvement. In total, 49% and 
37% of patients, respectively, achieved clinically 
meaningful improvement using the more 
stringent definition of ≥200 mL increase in 
prebronchodilator FEV1. Annualised rates 
of severe exacerbations were lower among 
patients with clinically meaningful improvements 
in lung function (either definition) than 
among their counterparts without clinically 
meaningful improvements, both in dupilumab 
treatment groups and in placebo groups 
(Figure 2). Significant treatment effects of 
dupilumab on reducing annualised severe 
exacerbation rates were apparent in all patient 
subgroups, with and without clinically meaningful 
improvements in lung function based on either 
definition (Figure 2). There was a trend for 
a greater magnitude of reduction in severe 
exacerbations, with dupilumab versus placebo, in 
the patient subgroups with clinically meaningful 
improvements in lung function. There was a 37–
54% reduction among patients with improved 
lung function (either definition) compared with 
35–38% reduction in patients without clinically 
meaningful improvements in lung function 
(Figure 2), but the interactions between 
treatment effect and subgroups were not 
statistically significant. 
In the primary efficacy analyses in QUEST, 
treatment effects on severe exacerbation rates 
were greater in patients with elevated type 
2 biomarkers than in the overall intent-to-
treat population.5 This post hoc analysis was 
repeated in the subgroup of patients with blood 
eosinophils ≥150 cells/µL and/or FeNO ≥25 
parts per billion (which represented most of 
the overall analysis population: 1,469 of 1,841 
patients included in the analysis). Results 
were similar to the analysis in the overall study 
population, with significant effects of dupilumab 
on annualised rates of severe exacerbations 
seen both in patients with and without clinically 
meaningful improvements in lung function.
In conclusion, this post hoc analysis showed that 
higher proportions of patients achieved clinically 
meaningful improvements in lung function 
when treated with dupilumab compared with 
placebo, but the effect of dupilumab on reducing 
annualised severe exacerbation rate was not 
dependent on achieving improvement in 
lung function.
Effect of Dupilumab on Oral 
Corticosteroid Use in Severe 
Asthma Patients With Improving 
Lung Function
Doctor Jorge F. Maspero
Dr Maspero presented a post hoc analysis of 
the VENTURE trial, exploring the impact of 
dupilumab on the need for OCS in patients 
with differing degrees of response in terms of 
improvement in lung function. Inclusion criteria 
for VENTURE included regular use of systemic 
(oral) glucocorticoids (5–35 mg/day prednisone, 
prednisolone, or equivalent) in the 6 months 
prior to enrolment, and the study population 
was therefore a glucocorticoid-dependent 
population with severe asthma (n=210).7 Patients 
aged ≥12 years were randomised to receive 
dupilumab 300 mg q2w or placebo, as add-on 
treatment to their existing treatment regimen 
(including bronchodilators, inhaled corticosteroids, 
and OCS), for 24 weeks. During the study period, 
patients’ OCS doses were reviewed every 4 
weeks and reduced in accordance with a 
predetermined schedule, dependent on the 
patient’s optimised baseline OCS dose, until 
the patient met prespecified criteria indicating 
that further dose reduction was not acceptable. 
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The primary study endpoint was percentage 
reduction in OCS dose from baseline to Week 
24; key secondary endpoints were proportion 
of patients with at least 50% reduction in OCS 
dose at Week 24, and proportion of patients with 
reduction in OCS dose to <5 mg/day.7 
In the overall study population, OCS doses 
decreased by 70% (least-squares mean 
percentage change) from baseline to Week 24 
in the dupilumab group, compared with a 42% 
reduction in the placebo group (p<0.001). 
In addition, significantly higher proportions 
of patients in the dupilumab group compared 
with the placebo group met the secondary 
endpoints of ≥50% reduction in OCS dose 
(80% versus 50%, respectively) and reduction 
in OCS dose to <5 mg/day (69% versus 33%, 
respectively). Despite greater reductions in 
OCS use in the dupilumab group, the rate of 
severe exacerbations was significantly lower 
and there was a greater increase in mean 
prebronchodilator FEV1 in the dupilumab group 
compared with the placebo group.7
In the post hoc analysis that Dr Maspero 
presented, similar to the analysis of QUEST 
presented by Dr Hanania and described above, 
patients were stratified according to their degree 
of lung function improvement, using thresholds 
of </≥100 mL and </≥200 mL increases in 
prebronchodilator FEV1 from baseline to 
Week 24.
Figure 2: Annualised rate of severe exacerbations during the 52-week treatment period in QUEST in patients 
with/without clinically meaningful improvements of ≥100 mL and ≥200 mL increases in prebronchodilator forced 
expiratory volume in 1 second at Week 12 (overall intent-to-treat population).
**p<0.01 versus matched placebo. 
***p<0.001 versus matched placebo.
CI: confidence interval; pre-BD FEV1: pre-bronchodilator forced expiratory volume in 1 second; q2w: every 2 weeks.
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Among patients with ≥100 mL or ≥200 mL 
increase in FEV1, those in the dupilumab group 
had 68–70% reductions in OCS dose (similar 
magnitude of reduction regardless of which FEV1 
threshold was used), while patients in the placebo 
group reduced their OCS doses by only 29–30% 
(p<0.001 for dupilumab versus placebo; Figure 3). 
Among patients with lesser degrees of lung 
function improvement (<100 mL or <200 mL), 
reductions in OCS dose in the dupilumab group 
were similar to those in the improved lung function 
subgroups (63–64%), but did not reach statistical 
significance versus placebo.
Similar patterns were observed for other 
measures of OCS use. In patient subgroups with 
≥100 mL or ≥200 mL increase in FEV1, 85–88% 
of patients in the dupilumab group achieved 
≥50% reduction in OCS dose, compared with 
49–53% in the placebo group; 79–82% and 
40–43% of patients, respectively, reduced 
their OCS dose to <5 mg/day; and 57–59% and 
31–33%, respectively, achieved the maximum 
OCS dose reduction possible according to 
their individual dose-reduction schedules (all 
p<0.05 for dupilumab versus placebo). In the 
patient subgroups with lower degrees of lung 
function improvement (<100 mL and <200 mL 
increase in FEV1), the magnitudes of effect of 
dupilumab on each of these endpoints were 
broadly similar, but did not reach statistical 
significance versus placebo in most cases. This 
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Figure 3: Oral corticosteroid dose reduction (%) from baseline at Week 24 in patients with improvement from 
baseline in prebronchodilator forced expiratory volume in 1 second of <100, <200, ≥100, or ≥200 mL at Week 24.  
***p<0.001 versus matched placebo.
LS: least squares; OCS: oral corticosteroid; q2w: every 2 weeks; SE: standard error.
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may reflect factors such as different sizes of 
subgroups (subgroups of patients with <100 mL 
and <200 mL increase in FEV1 were relatively small 
compared to the corresponding subgroups with 
≥100 mL and ≥200 mL increases in FEV1) because 
there was no statistically significant interaction 
between treatment effect and subgroup.
Dr Maspero noted that the findings may be 
limited by the post hoc nature of the analysis 
and the low sample sizes in some subgroups. 
Nonetheless, this analysis indicated that OCS-
dependent severe asthma patients, with various 
levels of improvement in lung function, were 
able to reduce OCS use during treatment with 
dupilumab to a greater extent than patients 
receiving placebo, based on multiple measures of 
OCS use.
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Meeting Summary
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent, chronic inflammatory condition of 
the nasal passages and paranasal sinuses.1 Patients with CRSwNP experience a range of symptoms, 
including smell impairment, nasal obstruction, nasal congestion, headaches, and postnasal drip.2 
The high symptom burden experienced by patients with CRSwNP negatively impacts their health-
related quality of life (HRQoL).1-3 Most patients with CRSwNP have a type 2 pattern of inflammation 
characterised by elevated levels of IL-4, IL-5, and IL-13 and tissue infiltration by eosinophils, 
lymphocytes, basophils, and mast cells.4-6 First-line management options are limited and endoscopic 
sinus surgery is used when pharmacological interventions are unsuccessful; however, a considerable 
proportion of patients experience symptom recurrence following surgery.3,6-9 Dupilumab is a human 
monoclonal antibody that binds to the IL-4 receptor α subunit and inhibits signalling of IL-4 and 
IL-13, both of which act as key drivers of type 2 inflammation.10-13 Dupilumab has been approved in 
the USA and the European Union (EU) as an add-on maintenance treatment in adult patients with 
inadequately-controlled CRSwNP.14,15
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Dupilumab Efficacy in Patients 
with Chronic Rhinosinusitis with 
Nasal Polyps by History of Prior 
Sinonasal Surgery: Pooled Results 
From the SINUS-24 and SINUS-52 
Phase III Studies
Professor Claire Hopkins
Patients with serious CRSwNP or who 
experience disease relapse following 
pharmacological interventions may undergo 
endoscopic sinus surgery. However, symptom 
reappearance following surgery is common, 
occurring in 50−80% of patients within 3−5 
years.3,6-9,16-18 Moreover, patients may not 
experience an improvement in smell following 
multiple surgeries. This study investigated 
dupilumab efficacy by quantifying prior sinonasal 
surgeries and the time since last surgery in 
patients with severe CRSwNP refractory to the 
standard of care. Pooled efficacy and safety 
datasets up to Week 24 from the Phase III 
SINUS-24 and SINUS-52 studies were used for 
the analysis. SINUS-24 and SINUS-52 evaluated 
dupilumab on a background of mometasone 
furoate nasal spray compared with mometasone 
furoate nasal spray alone (placebo).19 Participants 
enrolled in SINUS-24 were randomly assigned (1:1) 
to receive either subcutaneous dupilumab 300 
mg (n=143) or placebo (n=133) every 2 weeks 
(q2w) for 24 weeks.19 Patients in SINUS-52 were 
randomly assigned (1:1:1) to dupilumab 300 mg 
q2w for 52 weeks (n=150), dupilumab q2w for 24 
weeks and then every 4 weeks for the remaining 
28 weeks (n=145), or placebo q2w for 52 weeks 
(n=153). Rescue treatment with either systemic 
corticosteroids and/or surgery was permitted for 
study participants.19 Patients were categorised 
according to the number of prior surgeries and 
time since last surgery. At baseline, the proportion 
of patients in these categories was well balanced 
between the study arms. Efficacy was measured 
using several scores:20 nasal polyp score (NPS), 
scale: 0−4 in each nostril, 0: no nasal polyps, 8: 
large nasal polyps causing complete obstruction 
of the inferior nasal cavity; nasal congestion 
(NC) score, scale: 0−3, 0: no symptoms, 3: severe 
symptoms that are hard to tolerate and cause 
interference with daily activities; Lund–Mackay 
(LMK) score, scale: 0−24 (0−12 for each nostril), 
0: healthy, 2: total opacification; loss of smell 
symptom score, scale: 0–3, 0: no symptoms, 3: 
severe symptoms; University of Pennsylvania 
Smell Identification Test (UPSIT), scale: 0–40, <19: 
anosmia; the 22-item Sino-Nasal Outcome Test 
(SNOT-22), range: 0–110, item score: 0–5, 0: no 
problem, 5: problem as bad as it can be.
NPS NC score
Subgroup Dupilumab better Placebo better Dupilumab better Placebo better
Number of surgeries
No surgery 
1 surgery 
2 surgeries 
>3 surgeries
Time since most recent 
surgery
<3 years  
>3 and <5 years 
>5 and <10 years 
>10 years 
LS mean difference (95% CI) LS mean difference (95% CI)
-4     -3    -2    -1     0      1      2     3      4  -2             -1            0             1              2    
**
**
*
Figure 1: Efficacy outcomes using multiple measures assessing chronic rhinosinusitis with nasal polyp disease 
severity at Week 24 in patients receiving either dupilumab or placebo. 
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A total of 458 individuals were included in this 
study. Baseline sinus disease, measured by NPS 
(p=0.0047), NC score (p=0.0151), and LMK score 
(p<0.0001), was significantly worse for those 
patients who had not received surgery compared 
with individuals who had undergone surgery. 
This was also true for olfactory dysfunction 
measured by the UPSIT and loss of smell scores 
(both p<0.0001). At baseline, patients who had 
surgery <3 years previously were younger (mean 
age: 46.4 years), had a higher LMK score (19.96), 
and lower mean bilateral endoscopic NPS (5.41; 
LMK score UPSIT score
Subgroup Dupilumab better Placebo better Dupilumab better Placebo better
Number of surgeries
No surgery 
1 surgery 
2 surgeries 
>3 surgeries
Time since most recent 
surgery
<3 years  
>3 and <5 years 
>5 and <10 years 
>10 years 
LS mean difference (95% CI) LS mean difference (95% CI)
-10          -5            0             5             10  18            9             0            -9           -18  
*
***
Loss of smell score SNOT-22 score
Subgroup Dupilumab better Placebo better Dupilumab better Placebo better
Number of surgeries
No surgery 
1 surgery 
2 surgeries 
>3 surgeries
Time since most recent 
surgery
<3 years  
>3 and <5 years 
>5 and <10 years 
>10 years 
LS mean difference (95% CI) LS mean difference (95% CI)
-2           -1             0              1             2 -36  -27   -18    -9    0      9     18    27   36
Figure 1 continued. 
Subgroup-by-treatment interaction (comparing number of surgeries versus no surgery and time since more recent 
surgery versus <3 years).
*p<0.05 
**p<0.01 
***p<0.001
CI: confidence interval; LMK: Lund-Mackay; LS: least squares; NC: nasal congestion; NPS: nasal polyp score; SNOT-22: 
22-item Sino-Nasal Outcome Test; UPSIT: University of Pennsylvania Smell Identification Test.
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all p<0.0001) compared with participants in the 
≥3 to <5 years, ≥5 to 10 years, and ≥10 year groups. 
The study found that dupilumab improved all 
outcome measures irrespective of the number 
of prior surgeries or time since last surgery 
(Figure 1). Significantly greater improvements in 
the NPS were observed in patients who had a 
shorter time since last surgery (time since more 
recent surgery versus <3 years; p<0.05). Patients 
who received dupilumab with ≥3 surgeries had 
significantly higher NC scores compared with 
those individuals who did not have prior surgery 
(p<0.01; Figure 1). Dupilumab was also associated 
with greater improvements in both the LMK and 
UPSIT scores compared with placebo regardless 
of the time since last surgery or the number of prior 
surgeries (Figure 1). Significant improvements in 
LMK scores were seen in patients with a shorter 
time since last surgery compared to those with 
longer time since last surgery (<3 years versus 
>5 and <10 years; p<0.05, <3 years versus ≥10 
years; p<0.001). Dupilumab also resulted in 
improvements in smell and SNOT-22 scores 
compared with placebo regardless of number of 
prior surgeries and time since last surgery. 
The efficacy of dupilumab was demonstrated 
over 24 weeks with a shorter time (<3 years) 
since last surgery associated with improved NPS 
and LMK scores, which may be indicative of high 
type 2 inflammation burden in these patients. 
Dupilumab reduced the need for rescue treatment 
with systemic corticosteroid and/or NP surgeries 
versus placebo, regardless of the number of prior 
surgeries or the time since last surgery within 
10 years (Figure 2). Dupilumab had a favourable 
tolerability profile in individuals with and without 
prior surgery. The most common treatment 
emergent adverse events occurring in ≥5% of 
patients were nasopharyngitis (dupilumab 12.5% 
versus placebo 14.5%), nasal polyps (dupilumab 
2.7% versus placebo 11.7%), and injection-site 
erythema (dupilumab 6.3% versus placebo 
7.8%). This study demonstrated that over 24 
weeks dupilumab consistently improved multiple 
measures of CRSwNP disease severity regardless 
of the number of prior sinonasal surgeries or time 
to last surgery. 
Dupilumab Improved Smell 
Outcomes in Patients Irrespective 
of Years Since Chronic 
Rhinosinusitis with Nasal Polyps 
Diagnosis: Pooled Results From 
the SINUS-24 and SINUS-52 
Phase III Studies
Professor Joaquim Mullol
Of all the symptoms experienced by patients 
with CRSwNP, the loss of smell is particularly 
troublesome and refractory to existing 
therapies.21,22 Loss of smell can be correlated with 
disease severity and has a considerable negative 
impact on an individual’s HRQoL.21-23
The objective of this study was to evaluate the 
effect of dupilumab on the individuals’ sense 
of smell in patients with severe CRSwNP using 
pooled data from SINUS-24 and SINUS-52 and 
to categorise these data according to the time 
since CRSwNP diagnosis. The study design of 
SINUS-24 and SINUS-52 was described in a 
previous review. Pooled data from SINUS-24 and 
SINUS-52 were analysed post hoc and the time 
since first diagnosis of CRSwNP was categorised 
into four groups: <5 years, 5 to <10 years, 10 to 
<15 years, and ≥15 years. Sense of smell outcomes 
at 24 weeks were determined by the loss of smell 
symptom score, UPSIT, and the smell/taste item 
of the SNOT-22 test.
Pooled data for each study arm and the time 
from diagnosis groups were analysed by the least 
square mean difference and 95% confidence 
interval (CI) of the change from baseline to Week 
24. Furthermore, the odds ratio (95% CI) and 
risk difference (95% CI) were calculated for the 
absence of anosmia (UPSIT ≥19) for dupilumab 
versus placebo at Week 24. Findings from 
different subgroups were compared using the 
treatment-by-subgroup interaction p value.
A total of 719 patients were included in this 
analysis: <5 years, n=236; 5 to <10 years, n=157; 10 
to <15 years, n=118; ≥15 years, n=208. 
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Figure 2: Probability of the need for rescue treatment and/or surgery according to A) number of prior surgeries 
and B) time since surgery in patients receiving either dupilumab or placebo. 
p values derived from Cox proportional hazard models with the event of first systemic corticosteroid use and/or 
nasal polyp surgery (actual or planned, whichever is earlier) as the response variable, and study identifier, treatment, 
asthma/nonsteroidal anti-inflammatory drugs-exacerbated respiratory disease status, prior surgery history, and 
region (pooled countries) as covariates. No significant subgroup-by-treatment interaction. 
NS: not significant; SCS: systemic corticosteroid; q2w: every 2 weeks. 
≥
≥ ≥ ≥
2
A
B
Most study participants were male (n=435; 
60.5%) and at baseline there were significantly 
more patients in the ≥15 years subgroup who 
had ≥1 prior surgery (n=187; 89.9%; p<0.0001) 
compared with other time from diagnosis 
groups. Baseline data found that in severe, 
inadequately-controlled CRSwNP, a longer 
duration of CRSwNP was associated with 
greater impairment in the sense of smell.
This study found that in multiple measures of 
smell loss, dupilumab improved the sense of 
smell compared with placebo irrespective of 
the time from diagnosis (Figure 3). Significant 
differences were reported for all time from 
diagnosis groups (p<0.0001) except the <5 years 
subgroup. Furthermore, the investigation found 
that the proportion of patients in each subgroup 
without anosmia at Week 24 was significantly 
higher in all time from diagnosis groups for those 
receiving dupilumab than patients receiving 
placebo (nominal p<0.0001 derived using a 
linear probability model with treatment group, 
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Figure 3: Outcomes in measures of sense of smell from baseline to Week 24 according to years since chronic 
rhinosinusitis with nasal polyp diagnosis.
Absence of anosmia: UPSIT ≥19. In each subgroup, each of the imputed complete data was analysed by fitting an 
ANCOVA model for quantitative parameters with the corresponding baseline value, treatment group, asthma/
nonsteroidal anti-inflammatory drugs-exacerbated respiratory disease status, prior surgery history, and regions as 
covariates. The interaction p value was computed by fitting a similar ANCOVA model plus the time since diagnosis 
and the time since diagnosis-by-treatment interaction, using the <5 years subgroup as a reference. There was no 
significant difference versus the <5 years subgroup (p<0.05). 
ANCOVA: analysis of covariance; CI: confidence interval; LS: least squares; SNOT-22: 22-item Sino-Nasal Outcomes 
Test; UPSIT: University of Pennsylvania Smell Identification Test.
3
≥
≥
study, asthma/nonsteroidal anti-inflammatory 
drugs-exacerbated respiratory disease status, 
prior surgery history, and region as covariates). 
The study concluded that dupilumab improved 
smell outcomes from baseline to Week 24 in all 
patient subgroups regardless of the time from 
diagnosis. These results highlight the sense of 
smell improvements associated with dupilumab 
for patients with severe CRSwNP who otherwise 
have few therapeutic options and poor HRQoL.21-23
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BACKGROUND AND AIM
Since their introduction to the European and 
USA markets in 2006–2007, electronic cigarettes 
(e-cigarettes) have become popular nicotine-
Abstract Reviews
The following abstract review articles provide unique 
insights from posters presented at ERS International 
Congress 2020, written by the poster authors 
themselves.
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delivery devices.1 They have been rapidly adopted 
by millions of users worldwide and are steadily 
spreading among younger people, especially 
in high-income and urban populations.2 As 
the number of e-cigarette users is increasing, 
so is exposure to passive vape. Passive vape 
exposure remains a concern as previous studies 
have demonstrated that vape from e-cigarettes 
can contain toxic chemicals that are harmful to 
health.3 A World Health Organization (WHO)-
commissioned review found that while there are 
a limited number of studies in this area, it can be 
concluded that e-cigarette vapour is a new air 
contamination source for particulate matter (PM), 
which includes fine and ultrafine particles, as well 
as 1,2-propanediol, volatile organic compounds, 
heavy metals, and nicotine.4 More research is 
needed to better understand potential health 
effects to passive bystanders, especially among 
vulnerable populations, including individuals 
with existing respiratory disease, known to be 
frail to environmental exposure.5
The aim of this study was to investigate acute 
local and systemic effects of short-term passive 
exposure to vape from e-cigarettes among 
individuals with mild or moderate chronic 
obstructive pulmonary disease (COPD).
MATERIALS AND METHODS
The study was conducted at the Climate 
Chamber facilities at the Department of Public 
Health, Aarhus University, Aarhus, Denmark. 
Exposure sessions took place under controlled 
conditions in a 79 m3 climate chamber made of 
welded stainless steel, while exposure generation 
took place in a similar 29 m3 adjacent chamber. In 
a double-blinded crossover study, non-smoking 
patients with COPD were randomly exposed 
for 4 hours to passive vape (median PM2.5: 18 
μg/m3; range: 8–333) and clean air (PM2.5<6 
μg/m3) separated by 14 days. In order to blind 
the exposure, e-cigarette users in an adjacent 
chamber were either vaping or chewing gum, 
and the (vape-polluted) air was passed to the 
exposure chamber. Particles were measured 
using an ultrafine particle counter (P-TRAK®, 
TSI Incorporated, Shoreview, Minnesota, USA) 
and a scanning mobility particle sizer. Health 
effects, including surfactant protein-A (SP-A) 
and albumin in exhaled air, spirometry, fractional 
exhaled nitric oxide, and plasma proteins, were 
evaluated before, right after, and 24 hours after 
exposure. Participants reported symptoms every 
30 minutes throughout exposure sessions. Data 
were analysed using mixed models.
RESULTS
Sixteen patients (six female, 10 male) with 
moderately severe COPD and a mean age of 
67.6 years participated. The primary outcome, 
SP-A in exhaled air, was affected by time and 
exposure to vape, indicating a negative effect of 
passive vape on SP-A the morning after exposure 
(-1.78 [-3.35 to -0.20]; p=0.03). Furthermore, 
several plasma proteins increased significantly, 
indicating inflammation caused by vape 
exposure. Throat irritation was more pronounced 
during passive vape exposure, while forced 
vital capacity and forced expiratory volume in 
1 second decreased. However, estimates were 
only borderline significant (forced vital capacity: 
-0.07 [-0.15 to 0.00]; p=0.07) (forced expiratory 
volume in 1 second: -0.05 [-0.10 to 0.00]; 
p=0.07). No effect on fractional exhaled nitric 
oxide was observed among the 16 patients with 
COPD exposed to passive vape.
CONCLUSION
This study shows that passive vaping is capable 
of exerting acute inflammatory responses in 
lungs and blood as well as throat irritation among 
patients with COPD. Although more research is 
required, it is clear that e-cigarette emissions are 
not merely harmless vapour. In the future, more 
studies on passive vape exposure in sensitive 
subgroups are recommended, as such studies 
are virtually nonexistent.
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BACKGROUND AND AIMS
Chronic obstructive pulmonary disease (COPD) 
is a chronic inflammatory lung disease that 
affects nearly 10% of people over the age of 40 
years.1 COPD is a disease of accelerated ageing,2 
associated with accumulation of senescent 
cells in the lung.3,4 Senescent cells are in cell-
cycle arrest and therefore do not proliferate. 
However, they remain metabolically active and 
secrete a milieu of proinflammatory mediators, 
known as the senescence-associated secretory 
phenotype,5 which is the same inflammatory 
profile seen in the lungs of COPD patients.6 
These cells may, therefore, play a role in COPD 
pathogenesis through the loss of lung repair 
mechanisms and release of inflammatory 
mediators. Altered iron metabolism is important 
in the pathogenesis of COPD, with iron chelation 
therapy being shown to be protective at early 
time points in vivo.7 Elevated levels of iron are 
found within bronchoalveolar lavage fluid of 
COPD patients,8 but the consequences of this 
are not fully elucidated. Recently, data have 
suggested elevated levels of intracellular iron 
are found in senescent cells, with this potentially 
driving cellular senescence.9 However, this has not 
been studied in the context of COPD. The aim of 
this study was to assess the relationship between 
excess intracellular iron and cellular senescence 
in COPD small airway epithelial cells (SAEC). 
METHODS
Total intracellular iron was detected in SAEC from 
non-smokers (NS) and COPD patients by graphite 
furnace atomic absorbance spectrometry. 
SAEC were treated with ammonia iron (Fe3+) 
citrate (FAC), the iron chelator deferoxamine, 
or doxorubicin to induce senescence. Iron and 
senescence markers were detected by Western 
blot and quantitative reverse transcription PCR in 
lung homogenate samples and SAEC.  
RESULTS
Both intracellular and haem iron were significantly 
increased in COPD SAEC compared to NS. 
Treatment of NS and COPD SAEC with FAC 
caused a significant increase in total iron, with 
COPD SAEC taking up significantly more iron than 
NS cells. Chelation of iron significantly reduced 
intracellular iron levels in COPD SAEC, but not 
NS. Significant increases in the gene expression 
of senescence markers p21Cip1 and BCL-2 were 
detected in lung homogenate samples of COPD 
patients compared to NS, with significantly 
increased expression of the transferrin receptor 
and decreased expression of ferroportin also 
observed. Elevated protein levels of the transferrin 
heavy chain and transferrin receptor were 
detected in COPD SAEC compared to NS, and 
these correlated with changes in the expression 
of p21 and the anti-ageing molecules sirtuin-1 
and -6. Induction of cellular senescence using 
doxorubicin led to elevated gene expression of 
both p21 and the transferrin receptor, suggesting 
a link between senescence and elevated 
iron uptake. 
CONCLUSIONS
Elevated levels of intracellular iron were observed 
in COPD SAEC compared to NS. COPD SAEC 
had increased capacity to uptake extracellular 
iron, which could be chelated. COPD SAEC 
and lung homogenate samples had increased 
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senescence markers, as well as altered iron 
metabolism proteins. Senescence induction led 
to increased expression of the iron import protein, 
the transferrin receptor. Overall, these data 
suggest both elevated intracellular iron levels 
and senescence in COPD SAEC. Further work is 
needed to elucidate how these two processes 
are linked.
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BACKGROUND AND AIMS
Community-acquired pneumonia (CAP) is a 
common cause of antibiotic prescription, hospital 
admission, and mortality.1 Treatment according 
to guidelines has shown to be beneficial in CAP.2 
However, adherence to the recommendations 
given in guidelines is highly variable.3 The authors 
have previously conducted a quality improvement 
project to increase guideline adherence;4 the 
project itself was a success, but the impact on key 
outcomes had not yet been assessed.
The aim of this study was to estimate the 
impact of a stewardship programme on patient 
management and outcomes in patients admitted 
with CAP.
MATERIALS AND METHODS
The authors conducted a before-after study 
comparing the odds for key outcomes in CAP 
before and after the implementation of an 
8-month stewardship programme at three 
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Danish hospitals. Comparisons were made 
using logistic regression models. The outcomes 
considered were antibiotics for ≤7 days, 
intravenous antibiotics for ≤3 days, antibiotics 
according to the guideline, length of stay ≤5 days, 
in-hospital mortality, and 30-day mortality. As 
stability within 72 hours of admission is a strong 
confounder, all analyses were performed on the 
overall cohort as well as a subset of patients 
stable within 72 hours. Univariable and 
multivariable analyses were performed, as well 
as a sensitivity analysis on a propensity score-
matched cohort. The variables used for adjustment 
and matching were age, sex, comorbidities, 
pneumonia severity, antibiotics before admission, 
multilobular infiltrates, low oxygen saturation at 
admission, and a positive smoking history.
RESULTS
In total, 771 patients were eligible for participation 
in the present study. Of these, 423 were admitted 
in the baseline period and 348 in the follow-
up period. The study cohort was a classic CAP 
cohort; the mean age was 72 years, and the sex 
ratio was balanced. Severe CAP with a CURB-
65 score of 3–5 was observed in 17% of cases. 
Median durations of intravenous antibiotic 
treatment, total antibiotic treatment, and length 
of hospital stay were 2.6, 10.0, and 4.0 days at 
baseline, respectively.
The adjusted odds ratios (OR; 95% confidence 
interval [CI]) for antibiotics for ≤7 days were 1.85 
(1.34–2.55) for the overall cohort and 2.14 (1.43–
3.22) for the stable subgroup. The adjusted OR 
(95% CI) for correct empiric antibiotics were 1.94 
(1.42–2.65) in the overall cohort and 1.78 (1.19–
2.66) in stable patients. For all other outcomes, 
the effect sizes indicated no significant changes. 
Results for the propensity score-matched 
cohort were comparable to the results from the 
multivariable analyses.
CONCLUSION
The stewardship programme led to an increase 
in patients treated with the correct antibiotics 
according to the guideline, as well as a higher 
number of patients treated for 7 days or less. 
Significant changes were not observed for 
intravenous antibiotic treatment for 3 days or 
less, nor length of hospital stay of 5 days or less. 
However, the median durations of intravenous 
antibiotics and hospital stay were already 
satisfactory at baseline and noticeably better 
than reported in previously conducted studies. 
Hence, the improvement potential was not great. 
Significant changes regarding in-hospital or 
30-day mortality were not detected. This was 
unsurprising, as the study was not powered to 
detect significant changes in mortality.
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BACKGROUND AND AIMS
Despite technical advances in investigations 
and treatment, the 5-year survival for lung 
cancer (LC) remains poor. Studies suggest 
that continued smoking after a diagnosis of 
LC independently worsens quality of life and 
shortens life expectancy; however, these were 
small, retrospective cohorts where smoking was 
usually only self-reported and only recorded at 
baseline. The authors have recently shown that 
quitting smoking following a diagnosis of non-
small cell lung cancer (NSCLC) may lead to a 
reduction in mortality by 17% at 1 year.1
Smoking can adversely affect outcome by 
causing and accelerating other illnesses in 
people with LC. Smokers are more likely to be 
diagnosed with chronic obstructive pulmonary 
disease, heart disease, cerebrovascular disease, 
high blood pressure, diabetes, thrombosis, and 
many other conditions.2,3 Continued smoking 
worsens any comorbid condition, which can lead 
to increased risk of infections, resulting in delays 
or interruptions to LC treatment. 
In patients with head and neck cancer, those 
who stopped smoking following diagnosis 
survived twice as long as those who continued 
to smoke. Those who continued to smoke had a 
four-times greater rate of recurrence.4 In patients 
with breast cancer, recurrence in smokers was 
15% higher (p=0.039) compared to those who 
quit.5 This is further replicated in patients with 
prostate cancer.6 
The aim of the study was to determine if 
quitting smoking after a diagnosis of LC 
reduces complication rates, including treatment 
interruptions and hospital admission.
MATERIALS AND METHODS
As part of a UK multicentre, prospective, 
observational cohort study of 1,134 patients with 
newly diagnosed NSCLC, the authors recorded 
self-reported smoking status, validated with 
exhaled carbon monoxide readings, at baseline 
and each follow-up visit until death for up to 
2 years. Treatment complications were noted 
by free text if reported by the patient (e.g., 
diarrhoea, vomiting), or by the clinical team (e.g., 
post-operative wound infection, chemotherapy-
induced neutropenia, radiation pneumonitis). 
They were reviewed by a study clinician blinded 
to smoking status but were not graded according 
to severity.
Smoking cessation treatments were offered 
according to local services. Data were recorded 
on study case report forms and confirmed from 
hospital records and cancer databases; data were 
analysed with Stata.
RESULTS
Of the 1,134 patients recruited, 290 (25.6%) were 
smokers at baseline and 84 (29%) of these quit 
within 3 months of diagnosis. Continued smokers 
(66.5 years; standard deviation: 9.4) were of 
similar age to quitters (66.1 years; standard 
deviation: 9.6; p=0.232), but 34.7% of quitters 
had Stage I and II NSCLC, compared to 19.2% of 
smokers (p<0.001). 28.6% underwent surgery 
compared to 8.1% in those who continued to 
smoke (p<0.001). At 12 months, 55.6% of quitters 
were deceased compared to 68.1% of continued 
smokers (p<0.01).
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At 1 month, quitters had fewer treatment 
complications than those who continued to 
smoke (p=0.03). At 6 months (p=0.76) and 
12 months (p=1.00), there were no differences 
in complication rates between quitters and 
continued smokers (Figure 1).
CONCLUSION
Quitting smoking after a diagnosis of NSCLC is 
associated with fewer treatment complications 
at Month 1. This may be due to the confounding 
effects of increased Stage I and II tumours and 
higher number of surgical resections in quitters. 
The authors have continued to follow outcomes 
with larger numbers, grouping treatment-related 
complications into ‘mild’, ‘moderate’, or ‘severe’ 
according to standard definitions, as well as 
noting whether these complications necessitated 
treatment delays or treatment changes.
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BACKGROUND AND AIMS 
In recent years, there has been a revolution 
in genomic profiling and molecular typing of 
lung cancer. EGFR is a key oncogene, and a 
gold standard for determining EGFR mutation 
status is a histological specimen taken by a 
bronchoscopic method or surgical material, but it 
is often difficult to obtain enough tumour tissue 
for morphological and molecular verification. 
Isolation of free circulating peripheral blood 
tumour DNA (ctDNA), known as ‘liquid biopsy’, 
is a noninvasive alternative method to tissue 
biopsy for performing molecular screening in 
patients suitable for targeted therapy. This study 
aimed to compare the prevalence of EGFR 
mutation status in bronchoalveolar lavage (BAL) 
and peripheral blood according to the gold 
standard tissue biopsy in patients with primary 
lung adenocarcinoma.
MATERIALS AND METHODS
All patients scheduled for bronchoscopy in 
the authors’ hospital between October 2018 
and August 2019 were assessed. The exclusion 
criteria did not differ to those for standard 
contraindications for a bronchoscopy. Flexible 
bronchoscopy was performed in all patients 
under local anaesthesia. The biopsy techniques 
were forceps biopsy, transbronchial biopsy with 
or without fluorographic control (based on 
preliminary CT data), and BAL.
RESULTS
In the period of the study, 140 bronchoscopies 
were performed. In 112 patients (80%), a tumour 
was verified. Adenocarcinoma was present in 
23.2% (26/112) of the patients with lung cancer, 
which was verified with immunohistochemistry. 
The groups did not differ regarding age and 
tumour maximum diameter. However, there 
were significantly more females with EGFR 
mutation (77%; 10/13) as opposed to males 
(23%; 3/13; p=0.017). 
Thirteen patients had wild-type EGFR and the 
other 13 had EGFR mutation. EGFR mutation 
from a peripheral blood sample was identified 
in 38.5% (5/13) of patients, whereas EGFR 
mutation obtained from BAL was identified in 
92.3% (12/13) (Table 1). In one case, in both liquid 
biopsy samples (BAL and plasma) additional 
T790M mutation along with deletion in exon 19 
were found, which was not established in the 
corresponding formalin-fixed paraffin-embedded 
tissue sample (Patient 8). Neither BAL nor 
blood sample confirmed EGFR mutation in one 
patient, which was defined as positive only in the 
tissue sample.
CONCLUSION
The current standard for detection of mutation 
in patients with unknown status after negative 
tissue sampling is rebiopsy. Unfortunately, 
rebiopsy is not always feasible due to many 
reasons. In this context, liquid biopsy could be an 
effective solution. 
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However, results from individual studies are 
variable,1-3 with many indicating that detection 
of EGFR mutations in ctDNA is more difficult in 
plasma samples than in tumour tissue, with an 
average sensitivity of 65–70%. On the other hand, 
establishing EGFR status from BAL is a viable and 
safe procedure, especially in impaired patients with 
promising results.
In this study, the authors demonstrated the 
superiority of BAL to venous blood liquid biopsy 
in establishing an EGFR mutation. This could 
facilitate a diagnosis with a minimally invasive 
method and lower risk for the patient with 
comparable results to formalin-fixed paraffin-
embedded tissue.
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BAL: bronchoalveolar lavage.
Table 1: Confirmation of EGFR mutation in bronchoalveolar lavage and blood samples.
Confirmed EGFR mutation
BAL sample 12 (92.3%)
Blood sample 5 (38.5%)
Total patients 13 (100.0%)
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BACKGROUND AND AIMS
Perinatal medicine has improved considerably 
since the 1980s, with the arrival of innovative 
treatments such as antenatal steroids, exogenous 
surfactant, and better ventilatory techniques. 
This has improved survival rates for infants 
born extremely preterm (EP), particularly 
among the most immature and vulnerable 
infants.1 Conceivably, these trends might have 
influenced long-term health outcomes for this 
group of individuals in opposite directions, with 
the overall development difficult to predict. 
Bronchopulmonary dysplasia (BPD), a chronic 
lung-disease of prematurity, is one of the most 
common complications of preterm birth,2 
leading to varying degrees of compromised 
lung function in early adulthood.3 The aim 
of this study was to assess pulmonary 
outcome at 18 years of age in EP-born 
and matched term-born control cohorts, 
born in three different decades and characterised 
by improvements in neonatal care. 
METHODS
Three population-based birth-cohorts of subjects 
born at gestational age ≤28 weeks or with birth 
weight ≤1,000 g in 1982–1985 (82–85 cohort), 
1991–1992 (91–92 cohort), and 1999–2000 (99–
00 cohort) and individually matched term-
born control subjects performed spirometry 
at approximately 18 years of age. Independent 
sample t-tests were used to compare 'within-
decade’ differences between the EP and term-
born groups, whereas one-way ANOVA analyses 
were performed to compare lung function 
deficits for the EP-born over three decades. 
Figure 1: Forced expiratory volume in 1 second (FEV1) Z-score group means with 95% confidence intervals. 
BPD: bronchopulmonary dysplasia; EP: extremely preterm.
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RESULTS
In total, 118 EP and 111 term-born participants 
(68% and 80% of eligible subjects, respectively) 
performed spirometry at approximately 18 
years of age. Forced expiratory volume in 1 
second (FEV1) Z-scores were lower in EP-born 
compared to term-born in all three cohorts, 
deficits being -1.23, -0.68, -0.45 for the 82–85, 
91–92, and 99–00 cohorts, respectively (p<0.01; 
p<0.01; p=0.04). Mean FEV1 Z-scores improved 
significantly from the 82–85 to the 99–00 EP-
born cohort, but not for the corresponding term-
born controls (mean differences: 0.67 [p=0.02] 
and 0.11 [p=1.0], respectively). When splitting the 
EP-born by BPD, mean FEV1 Z-scores improved 
significantly from the 82–85 to the 99–00 
cohort for subjects with BPD, but not for those 
without BPD (mean differences: 1.12 [p=0.02] 
and 0.46 [p=0.59], respectively; Figure 1).
CONCLUSION
At 18 years of age, survivors of EP birth from 
all three cohorts had lower lung function than 
their term-born peers. Pulmonary outcome 
had improved over the three decades, mainly 
explained by those with BPD. 
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BACKGROUND AND AIM
Asthma UK has a well-established, free asthma 
telephone helpline, for which people with 
asthma can receive individual advice on 
managing their condition from a nurse during 
the working day (weekdays 9 am–5 pm [BST]). 
However, not all people with asthma are 
receiving the care they need. The Asthma UK 
2018 Annual Asthma Survey found that only 
33% of people aged 18–29 received three 
elements of basic care: an annual review, an 
inhaler technique check, and a written asthma 
action plan.1 Provision of a telephone helpline 
requires significant investment of manpower 
and the supply and demand is often difficult 
to predict and manage. Additionally, given 
that people with asthma looking for help are 
often adolescents and young adults, of whom 
most extensively use a mobile phone on a daily 
basis, a telephone service is increasingly not 
the medium they would choose and may 
indeed put them off seeking help. The team at 
Asthma UK developed a WhatsApp service that 
aimed to help capitalise on this groups’ high level 
of digital literacy and engagement, and address 
this unmet care need. The service allows people 
with asthma to message a nurse directly and 
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receive advice via a text message, a useful link, 
infographic,  or video.
METHOD
Early popularity of the service necessitated a 
plan to scale it up. To understand the feasibility of 
this, user research was conducted via a post-chat 
survey and in-depth interviews were conducted 
with users. Key objectives of this research were 
to find out if the service helped improve a user’s 
management of their asthma; how to improve the 
user experience; enable a better understanding of 
service users; and to develop a service taxonomy 
to tag and analyse the conversations. This created 
improved service intelligence, which helped 
to scale up the service. To scale it up, a rapid 
procurement process was necessary in order to 
cope with an expected peak in use during winter, 
and an off-the-shelf platform best met these 
requirements. Staff were trained on how to use 
the new platform, and Asthma UK and the British 
Lung Foundation partnership (AUK–BLF) worked 
with the company procured to ensure a smooth 
launch of the expanded platform.
RESULTS
This service proved popular with service users, 
with 91.5% 'very satisfied' with the service. The 
content was apparently pitched at the correct 
health literacy level, with 98.4% finding the advice 
easy to understand. The survey results indicated 
that 63.5% of service users felt more confident 
in managing their asthma. Those aged 18–33 
comprised 37.6% of the survey respondents, 
suggesting success in attracting a younger 
demographic to use this service.
CONCLUSIONS
This research has positive implications for future 
models of care. It shows that remote health 
advice can be delivered in a manner tailored to 
new audiences and can help people manage 
their asthma with more confidence and be 
better informed about their condition. The 
future challenge will be to ensure that these 
improvements are sustained, and to scale up this 
project to help more people with asthma, and 
potentially other conditions.
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BACKGROUND AND AIM
Occupational exposure to vapours, gases, dusts, 
and fumes (VGDF) has been associated with 
lower lung function1 and a higher risk of chronic 
obstructive pulmonary disease (COPD).2 The 
proportion of COPD attributable to occupational 
exposures has been estimated at 14%.3 
A proposed mechanism underlying the effect 
of VGDF on COPD is through oxidative stress. 
A reduced antioxidant capacity has been found 
in COPD patients4 and higher levels of oxidative 
stress biomarkers have been associated with 
exposure to VGDF.5 The effect of VGDF on 
the lung might be apparent (or might be 
substantial) only in the presence of genetic 
variation (e.g., single nucleotide polymorphisms 
[SNP]) in antioxidant genes, indicating a gene–
environment interaction. The study aimed to 
identify interactions between variants in well-
known antioxidant genes and VGDF exposure on 
COPD risk.
METHODS
To assess antioxidant gene–VGDF interactions, 
the authors included 199,607 working individuals 
from the large UK Biobank (UKB; aged 39–
71; 49% male; 44% never-smoker). Of these, 
16,389 individuals had COPD spirometrically 
defined as forced expiratory volume in 1 second 
(FEV1)/forced vital capacity (FVC)< lower limit 
of normal (GLI-2012) and 34% were exposed 
to VGDF estimated using the airborne chemical 
(ACE) job exposure matrix.6 All independent 
SNP within 15 antioxidant genes selected based 
on a recent review were analysed.7 Gene–VGDF 
interactions were invested using a case-only 
approach using BOLT-LMM adjusted for sex, 
age, height, smoking status, genotyping batch, 
and centre, and accounting for population 
stratification/relatedness. Analyses were stratified 
according to smoking status. For significant 
interacting SNP, the authors assessed effects 
on gene-expression and DNA methylation levels 
using the online tool PhenoScanner.8
RESULTS
Overall, subjects exposed to VGDF had a 7% 
increased risk of COPD (Table 1a). However, this 
increase in risk was only seen in ever-smokers 
and was significantly different to never-smokers 
(interaction p=8.79x10-5). 
In the SNP–VGDF interaction analyses, the 
authors identified nine nominally significant 
interactions (p<0.05) for the antioxidant genes 
CAT (two SNP), GC (two SNP), GSTP1, GSTT1, 
NOS1, SOD1, and SOD2. Except for a SNP in GC, 
none of the SNP had a marginal effect on COPD 
and would therefore not be found if ignoring the 
effect modification by VGDF. Of the nine SNP, 
only two rare SNP with minor allele frequencies 
<3% in GSTP1 (rs8191445) and NOS1 (rs145671209) 
survived correction for multiple testing (false 
discovery rate <5%). Subjects exposed to VGDF 
and carrying a copy of the minor allele of the 
GSTP1 and NOS1 SNP had a respective 19% and 
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30% higher risk of COPD compared to subject 
not exposed to VGDF and not carrying a copy 
of the minor allele (Table 1b). Although the 
interactions were only significant in never-
smokers, the three-way SNP–VGDF–smoking 
interactions were not significant (p=0.338 for 
GSTP1 and p=0.460 for NOS1). The GSTP1 SNP 
was associated with expression of two nearby 
genes (DOC2GP/NDUFS8) in whole blood. No 
association was found with DNA methylation for 
either SNP. 
CONCLUSION
These results suggest that VGDF exposure is 
associated with a higher risk of COPD, but that 
this risk may be confined to smokers. Those with 
rare variations in the antioxidant genes GSTP1 
and NOS1 may be more susceptible to the effects 
of VGDF on COPD, and this effect might be 
more apparent in never-smokers. Further work is 
needed to replicate these results in independent 
samples and to investigate the possibility 
of three-way SNP–VGDF–smoking interactions. 
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Significant results are presented in bold.
CI: confidence interval; COPD: chronic obstructive pulmonary disease; OR: odds ratio; SNP: single nucleotide 
polymorphism; VGDF: vapours, gases, dusts, and fumes.
Table 1: Results of the association analysis of A) VGDF with COPD (marginal effect of VGDF); and B) of the SNP-
VGDF interaction analyses for both the GSTP1 and the NOS1 SNP, stratified by smoking.
All 
(N=199,607)
Never-smokers 
(n=112,476)
Ever-smokers 
(n=87,180)
OR 95% CI p value OR 95% CI p value OR 95% CI p value
a)     Marginal effect of VGDF
VGDF 1.07 1.03–1.11 2.59x10-4 1.01 0.95–1.06 0.851 1.12 1.07–1.18 1.45x10-6
b)     Results from the interaction analysis
VGDF 1.06 1.02–1.10 3.20x10-3 0.99 0.94–1.04 0.695 1.12 1.06–1.17 1.32x10-5
GSTP1 
(rs8191445)
0.90 0.82–0.98 0.020 0.90 0.79–1.03 0.121 0.89 0.78–1.01 0.074
VGDF*GSTP1 1.19 1.03–1.37 0.019 1.27 1.03–1.57 0.024 1.13 0.93–1.38 0.212
VGDF 1.06 1.02–1.10 1.44x10-3 0.99 0.94–1.05 0.846 1.12 1.07–1.17 5.73x10-6
NOS1 
(rs145671209)
0.89 0.78–1.01 0.069 0.86 0.71–1.03 0.094 0.93 0.77–1.11 0.408
VGDF*NOS1 1.30 1.07–1.59 0.010 1.42 1.05–1.91 0.021 1.21 0.92–1.60 0.171
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BACKGROUND 
Bronchiectasis is a chronic respiratory condition 
that has a significant impact on morbidity, 
quality of life, mortality, and healthcare services.1 
The current aims of therapeutic management 
are preservation of lung function, reduction of 
exacerbations, minimising complications, and 
improving quality of life.2,3 The British Thoracic 
Society (BTS) guidelines suggest a five-step plan 
to treat patients with bronchiectasis, ranging 
from Step 1, which includes all patients, to Step 5, 
which is specific to those with worse symptoms.3 
Therapeutic strategies and interventions 
common to most international guidelines include 
antibiotics, airway clearance techniques, and 
pulmonary rehabilitation.2,3 The aim is to break the 
vicious recurrent cycle of infection, inflammation, 
impaired mucociliary clearance, and structural 
lung damage. Self-management (SM) has 
been recommended in clinical guidelines as an 
important intervention that could potentially 
empower patients to manage their condition, 
reduce exacerbations and therefore disease 
burden, and improve quality of life.3 Yet, to 
date, there is very little evidence to support SM 
programmes for patients with bronchiectasis, 
despite being a recommendation in Step 1 of the 
BTS guidelines. A previous Cochrane systematic 
review found insufficient evidence to determine 
whether SM interventions benefit patients with 
bronchiectasis,4 which has since been confirmed 
by a broader review.5 
METHODS 
Three focus groups of 17 adults with 
bronchiectasis were conducted at three 
National Health Service (NHS) sites in North 
West England, UK. Additionally, semi-structured 
interviews were undertaken with 11 healthcare 
professionals (HCP), including doctors, nurses, 
and physiotherapists. Thematic analysis 
identified key findings which were verified by 
independent audit. This study was approved by 
NHS London Harrow Research Ethics committee 
(ref 18/LO/1671).
RESULTS
Four key and common themes were identified 
from both HCP and patients: what is SM?; 
influencers of SM; benefits of SM; and barriers 
to SM (Table 1). When considering what SM is, 
both groups recognised similar components of 
SM. Sub-themes varied among the groups, with 
patients highlighting that SM was about learning 
what works for you, and how it can be used to 
moderate behaviour. HCP focussed on delivery 
and structure of SM and resources. Influencers 
for engaging in SM were recognised by HCP as 
individual patient attributes in addition to the 
knowledge and skills of HCP. Both groups saw 
distinct benefits to SM, namely treating and 
preventing exacerbations and controlling anxiety, 
and, from the patients’ perspective, as a proxy 
for HCP; HCP focussed on clinical outcomes, 
empowering patients and improving economic 
benefits to healthcare delivery. Patients and 
HCP recognised common barriers, but only 
patients referred to SM as time-consuming. Both 
groups recognised the importance of access (or 
lack of) to resources including HCP’s knowledge of 
the condition. 
Patients did not refer to distinct traits in 
themselves that may influence engagement in 
SM, but demographics gave insight into activity 
levels relating to SM.
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Patients valued peer learning whilst HCP 
acknowledged individuals’ need for different 
approaches and it’s not one size fits all.
SUMMARY 
Both patients and HCP had common insights 
about SM for patients with bronchiectasis. All 
participants were positive about SM, but barriers 
were identified that provided a vital insight 
necessary to the design of future programmes. 
Findings from this study suggest that patients’ 
psychosocial and socioeconomic circumstances 
may affect adoption and activation of 
SM behaviours.
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HCP: healthcare professionals.
Table 1: Key themes and subthemes for patients and healthcare professionals. 
What is self-management?
Patients HCP
Components
Learning what 
works for you
Moderating 
behaviour
Components
Delivery and 
structure
Resources
Influencers on self-management
Patients HCP
Peer, carer, and 
social support
HCP knowledge Easy access The patient The HCP
Benefits of self-management
Patients HCP
Treat and prevent 
exacerbations
Proxy for HCP Control anxiety
Empowering 
patients
Clinical outcomes
Economic 
benefits
Barriers to self-management
Patients HCP
Time-consuming
Lack of access to 
HCP
Outlook on life Patient factors Lack of tools/resources resentment
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BACKGROUND AND AIMS
In 2014, the European Union (EU) H2020 
CONNECARE project was initiated in the 
Netherlands, Spain, Italy, Germany, Israel, and 
the UK. In this project, clinicians, information 
technology (IT) professionals, IT companies, and 
researchers work together to develop an online 
integrated care platform for complex chronic 
patients. The European population is ageing and 
thereby the proportion of people with one or more 
chronic diseases is increasing. At this moment, 
many healthcare systems are fragmented 
into medical specialisations, whereas a large 
proportion of chronic patients have more than 
one chronic illness. The aim of the CONNECARE 
platform is to develop an integrated care system 
that facilitates co-operation between healthcare 
professionals and supporting patients in self-
management thereby enhancing personalised 
healthcare. The aim of this study was to evaluate 
the feasibility and usability of the CONNECARE 
platform by patients and case managers.
METHODS
The first prototype consists of a dashboard for 
case managers and a self-management app for 
patients, a chat function, symptom questionnaires, 
and the integration of an activity tracker. The 
system was evaluated for 6 months in Dutch 
patients with chronic obstructive pulmonary 
disease (COPD). A group of COPD patients were 
randomly assigned to the app with or without 
weekly messages regarding physical activity. The 
feasibility was evaluated via questionnaires and 
focus groups with COPD patients, tracking of 
step counts, and a comparison between patients 
who received weekly messages. These messages 
contained information about the benefits of 
physical activity, for example “Making a phone 
call? Good moment for a little walk.” Usability 
was evaluated by using the system usability scale 
(SUS), a logbook for technical issues, and an 
evaluation of case managers’ opinions. 
RESULTS
Of the 46 patients with COPD who participated 
in the study (mean age: 60±13 years; range: 
31–82 years; 52% male; 30% had asthma; 65% 
had COPD; 4% had asthma–COPD overlap), 21 
received the weekly messages. The authors found 
no statistically significant difference in step count 
between the groups. Patients were able to use the 
app and to communicate with the case manager 
via the messaging function in the app. Regular 
evaluations with patients and stakeholders led 
to constant optimisation of the application. 
However, three patients felt uncomfortable 
when using the activity tracker: “Others can see 
my data if I use Bluetooth.” The SUS in patients 
after 3 months was 81% (‘excellent’; n=30) and 
dropped to 74% after 6 months (‘good’). There 
was no difference in SUS between patients with 
low or high social economic status. The chat 
function was considered to be easy to use.
CONCLUSION
The initial version of the CONNECARE system 
was easy to use by patients and feasible to 
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implement even in this COPD population. 
The ongoing evaluation in patients and case 
managers and regular communication with IT 
specialist led to constant optimisation of the 
system and the communication between all 
different stakeholders appeared to be essential 
in the development of this system. There are 
no significant effects of messages on the effort 
step count, possibly because of the low number 
of participants. Future studies should look into 
the effect of regular stimulating messages on 
physical activity in a larger group possibly also 
including individualised messages. The next step 
for the CONNECARE system is to prepare it for 
the technical and process integration in existing 
healthcare systems.
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BACKGROUND AND AIM
Lung cancer immunotherapy has improved 
the survival for patients with advanced non-
small cell lung cancer (NSCLC). Immunotherapy 
could improve the prognosis for lung cancer by 
activation of tumour-infiltrating lymphocytes, 
which are silenced by the expression of T-cell 
receptor inhibitor molecules such as programmed 
cell death protein 1. Immunotherapy, such as 
antiprogrammed death-ligand 1 antibody therapy, 
results in the activation of tumour-infiltrating 
lymphocytes into cytotoxic CD4+ and CD8+ T cells 
in the tumour microenvironment and suppression 
of immune-repressing regulatory T cells (Treg).1 
The authors previously demonstrated that the 
recognition and elimination of lung tumour cells 
by T lymphocytes requires the presence of T-box-
expressed in T cells (T-bet), a transcriptional 
regulator that induces Th1 differentiation, 
which promotes cytolytic CD8+ T cells, natural 
killer, and natural killer T cells and inhibits Treg 
cells.2 Moreover, recent studies showed that 
IL-2 in the tumour microenvironment supports 
acquisition of cytotoxic activity by Th cells 
orchestrated by the transcriptional repressor 
B lymphocytes-induced maturation protein-1 
(Blimp-1).3 As Blimp-1 also affects the homeostasis 
and function of CD4 and CD8+ T cells as well as 
Treg cells, the authors hypothesised that this 
transcription factor might play an important role 
in lung cancer. 
METHODS
The authors have recently described their 
biobank obtained from a cohort of patients 
with NSCLC.6 Specifically, after lung resection, 
the authors immediately transported on ice the 
lung samples in cell culture medium to their 
department and froze samples immediately 
for further analysis. Next, proteins from these 
lung sections were extracted and the Blimp-1 
protein expression was analysed by Western blot 
analysis using proteins isolated from the different 
region of the lung of a cohort of patients that 
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underwent surgery because of NSCLC and 
subsequent histological classification as lung 
adenocarcinoma (ADC). 
RESULTS
The authors found that patients with lung ADC 
had a significant induction of Blimp-1 protein 
expression in the tumoural region of ADC (solid 
tumour) as compared control lung region 
(tumour-free control area). The expression of 
T-bet in these patients was further analysed 
and it was found that T-bet, as opposed to 
Blimp-1, was mainly expressed in the control 
region of the lung of these patients and 
downregulated in the tumoral region. Next, 
the localisation of Blimp1 positive cells in the 
tumour microenvironment was analysed by 
immunostaining lung sections from the cohort of 
patients using anti-Blimp 1 antibodies followed 
by DAPI staining. Here, the accumulation of 
Blimp1-positive cells surrounding the tumour was 
observed, as compared to the control region. 
CONCLUSION
In conclusion, these data suggest that Blimp-1 
might represent an additional new marker to be 
considered in the absence of T-bet as regulator 
of antitumour immune responses in lung cancer.
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What led you to pursue a career in 
cardiopulmonary rehabilitation?
When I was doing my physiotherapy degree, 
I had a very inspiring instructor who taught 
cardiopulmonary physiotherapy. Her passion was 
contagious. In addition, I loved being in acute 
care and I enjoyed the hospital environment. 
I felt that we could make such a difference to 
people’s lives. I then enrolled in a MSc degree in 
respiratory physiology and very much enjoyed the 
scientific enquiry.  
This year, you received the ERS Assembly 
Lifetime Achievement Award. Which 
contributions to respiratory medicine are 
you most proud of?
I am most proud of the studies we have done 
to figure out how to maintain the effects of 
pulmonary rehabilitation longer. We have created 
different models of follow-up after completion of 
rehabilitation. One example is to use community 
centres and fitness instructors in maintenance 
programmes. I do not think we have the perfect 
answer yet, but we know that some contact with 
a healthcare professional is important. We also 
know that we can create safe community-based 
follow-up programmes. One study where we used 
dance to keep people with chronic obstructive 
pulmonary disease active after pulmonary 
rehabilitation showed us that the activities need 
to be enjoyable for the individuals. 
Could you please tell us about your 
current research and the outcomes you 
hope for? 
My most challenging study at this time is 
an international randomised controlled trial 
Dr Dina Brooks
ERS Assembly Lifetime Achievement Award Winner
School of Rehabilitation Sciences, McMaster University,  
Hamilton, Canada
Congress Interviews
We spoke with two European Respiratory  
Society (ERS) 2020 Award Winners about their  
area of expertise and the coronavirus disease  
(COVID-19) pandemic.
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examining the effect of balance training on falls 
in individuals with chronic obstructive pulmonary 
disease. We have partners in Australia, Europe, 
and Canada and we are trying to recruit over 300 
patients. Managing such a large trial has been 
challenging but exciting. 
What impact is the COVID-19 pandemic 
having on pulmonary rehabilitation, and 
how do you think it will shape the future 
of the field?
Pulmonary rehabilitation has had to pivot to 
be virtual to some degree or another. Virtual 
pulmonary rehabilitation is a challenge as it is 
difficult to assess physical function and prescribe 
specific exercises. However, there are many 
advantages as it minimises the barriers related 
to access. The virtual rehabilitation will be great 
long-term, especially for those who live far from 
pulmonary rehabilitation centres. 
What is the biggest challenge facing 
cardiopulmonary rehabilitation currently?
The biggest challenge is the stigma against 
people with lung disease. The stigma impacts 
funding and services that people with pulmonary 
disease can access.
Which ongoing developments in 
cardiopulmonary rehabilitation do you 
consider to be promising and exciting?
Exciting developments include the role of non-
traditional approaches in rehabilitation. For 
example, I am excited about the potential of 
dance as a way to maintain physical activity.  
Mobile and digital health are being 
utilised in many areas of medicine. What 
is your opinion on their potential in 
cardiopulmonary rehabilitation?
It is an area that we are studying. We are 
interested in the perspectives of patients and 
healthcare professional. Mobile and digital health 
will resonate with some patients but not others. 
The key is how to choose wisely which patients 
would benefit from mobile and digital health.  
"The virtual  
rehabilitation will be great 
long-term, especially for those 
who live far from pulmonary 
rehabilitation centres."
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Prof Greet Van den Berghe
ERS Gold Medal in ARDS Winner  
Chair Intensive Care Medicine, UZ Leuven, and Head Laboratory of 
Intensive Care Medicine, KU Leuven, Leuven, Belgium
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What attracted you to specialise in the 
endocrinology of critical illness?
When I was a junior attending physician in the 
intensive care unit (ICU), quite some time ago, I 
noticed that long-stay ICU patients, adults and 
children alike, quickly started to look much older 
than their chronological age and at the same time 
showed endocrine and metabolic abnormalities 
that mimicked certain alterations characteristic 
of ‘ageing’. I hypothesised that maybe this 
‘accelerated ageing’ phenotype of ICU patients 
could in part be iatrogenic and, if so, could 
perhaps be preventable. These thoughts were 
the trigger for my PhD research, in which I could 
show that the infusion of dopamine, a drug at 
that time used in virtually every ICU patient, was 
causing a suppression of the anterior pituitary, 
which could be reversed by omitting its use. In 
my postdoctoral research, we went a step further 
and identified the biphasic neuroendocrine and 
metabolic responses to acute and prolonged 
critical illness both in patients and in animal 
models. This research clarified many earlier 
apparent paradoxes and provided the basis for 
the subsequent large scale randomised controlled 
trials (RCT) that we have performed with 
our team. 
One of your main research areas regards 
parenteral nutrition in the critically ill. 
What have been your most  
interesting results?
As ICU patients cannot eat normally by mouth 
and often do not tolerate gastric tube feeding, a 
finding that was associated with poor outcome, 
for decades ICU physicians advocated the 
early use of supplemental parenteral nutrition, 
which was assumed to prevent the loss of lean 
body mass in critically ill patients and hereby to 
improve outcome. However, the causality of this 
association was never tested by well-designed 
RCT. After we had shown that hyperglycaemia, 
which is substantially aggravated by the infusion 
of parenteral nutrition, was causally related to 
poor outcome, we started to have doubts about 
the assumed benefit of the early use of parenteral 
nutrition for ICU patients. In fact, we hypothesised 
that fasting responses during severe illnesses 
may have evolutionary conserved benefits by 
helping the body to clear cellular damage, which 
is essential for recovery from critical illness. After 
further consolidation of this hypothesis through 
research in our animal models, we performed two 
large, multicentre RCT comparing the use of early 
parenteral nutrition with not using it and instead 
accepting virtual fasting up to 1 week in the ICU. 
The results were striking. Omitting the use of 
early parenteral nutrition and hereby allowing 
the fasting responses, such as the activation of 
autophagy, to play their cellular housekeeping 
roles during the first week of critical illness, 
accelerated recovery from critical illness both 
in adults and even more so in young children. 
We also could show that this simple metabolic 
intervention, the omission of the early use of 
parenteral nutrition, also had long-term benefits, 
years after critical illness and treatment in the 
ICU. In particular in critically ill children, this long-
term benefit meant prevention of neurocognitive 
impairment of which the importance cannot be 
neglected. Very recently, we could show that 
epigenetic alterations, more specifically aberrant 
alterations in DNA methylation, provided a 
biological basis for this long-term harm induced 
by the early use of parenteral nutrition during 
critical illness. 
This year, you were awarded the ERS Gold 
Medal in ARDS. Please could you tell about 
the key research that contributed to this?
I have no idea, as the nomination really came 
as a total surprise to me. I can only speculate 
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on what exactly contributed to being awarded 
this prestigious Gold Medal. Perhaps because 
my translational research - from the bed to the 
bench and back - spans from basic research on 
pathophysiology and on the discovery of novel 
preventive and therapeutic targets all the way 
to clinical research with large RCT with patient-
centred hard clinical endpoints, including long-
term physical and neurocognitive outcomes. 
Over the years that you have been 
practising in intensive care, how 
have you seen the field change 
in terms of advancements 
to the technology or 
approaches used?
Intensive care medicine is 
a rather young discipline 
which took a start in the 1950s 
with the polio epidemic and 
the introduction of mechanical 
ventilation. Since then, there has 
been a truly revolutionising phase 
with new technologies being developed and 
introduced in the clinic, which allowed to prevent 
death from previously lethal conditions. Those 
early years were characterised by progressively 
introducing more and more treatments that were 
assumed to improve outcome, or if not were 
probably harmless, although solid evidence from 
good quality research was often lacking. The 
recent years have been characterised by a shift 
towards critically questioning and investigating 
a lot of what we were used to do in the ICU 
and the main lesson, in my view, is that also in 
intensive care medicine, “less may be more”. The 
assumption “if not beneficial, likely harmless” has 
proven wrong more often than occasionally. I am a 
strong advocate of further prioritising excellence 
in basic and clinical research in intensive care, and 
of not rushing into conclusions based on results 
from too small or poorly designed studies, in 
order to improve patient outcomes. No less so in 
the context of the COVID-19 pandemic. 
In your opinion, what do you believe to be 
a particularly promising area in the field of 
intensive care medicine?
I can only answer this question from my own 
focus and research interests, which inevitably is 
biased, I am afraid. Currently, my group 
is focussing on three large areas. 
First, we are performing exciting 
research on how metabolic 
interventions, such as blood 
glucose control or feeding 
strategies, affect the epigenome 
as a potential mediator of ICU-
acquired weakness and its 
long-term legacy. Second, the 
team is investigating whether 
the evolutionary conserved 
catabolic pathways, such as lipolysis 
and ketogenesis, can be exploited in the 
search for prevention of brain dysfunction and 
of ICU-acquired weakness in critically ill patients. 
In that context, the team is also exploring the 
role of fasting-mimicking diets in the ICU. A third 
large programme is on further understanding the 
hypothalamic–pituitary–adrenal stress responses 
to acute and prolonged critical illness. The latter 
is also one of the main research questions that 
are being addressed by the team in relation to 
COVID-19-induced respiratory and multiple organ 
failure. I hope that all three programmes will reveal 
insights that will be important to pave the way 
towards improved outcome for critically ill adults 
and children. More generally in intensive care 
medicine, I think that the fascinating link between 
metabolism, coagulation, and immunology is one 
to further explore in detail.  
Q4 "I 
hope 
that all three 
programmes will 
reveal insights that 
will be important to 
pave the way towards 
improved outcome 
for critically ill 
adults and 
children."
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"Everybody now understands 
the importance of our medical 
discipline and hopefully this 
will result in the allocation of 
more governmental budgets 
to clinical intensive care and to 
research in the field."
What impact is the COVID-19 pandemic 
having on intensive care medicine, and how 
do you think it will shape the future of  
the field?
The COVID-19 pandemic has already had an 
enormous impact on intensive care medicine and 
on the medical and paramedical staff all around 
the globe. It has been a very stressful time for all 
of us and some have paid a too high price while 
helping patients and trying to cope. Again, I can 
only speculate about the future, but one good 
thing that may result from the COVID-19 disaster 
is that intensive care medicine now no longer is 
something obscure and unknown to the lay public 
and to policy makers. Everybody now understands 
the importance of our medical discipline and 
hopefully this will result in the allocation of more 
governmental budgets to clinical intensive care 
and to research in the field. 
In intensive care medicine, what have been 
the most important learnings from the 
COVID-19 pandemic so far?
If you are referring to the most important new 
insights about the disease pathophysiology and 
possible treatments, I think it is too early to know 
for sure. As I said earlier, we should not rush 
into conclusions. We should continue to focus 
on high-quality research so that we understand 
better before we introduce treatments that may 
not only be beneficial but could also carry risk 
of harm. 
While being cautious and advising not to 
overinterpret any of the available data, I think 
that the severe form of COVID-19 respiratory 
failure and acute respiratory distress syndrome, 
that we have seen in our ICU worldwide, is 
quite different from the typical bacterial sepsis-
induced acute respiratory distress syndrome. 
There is reason to believe that severe COVID-19 
may start as a local ‘endotheliitis’ in the lungs 
rather than as a particularly destructive form 
of ‘alveolitis’ and that the early activation of 
coagulation may be a key trigger upstream in the 
cascade of inflammation and organ failure. In my 
personal opinion, protecting the endothelium, 
by omitting early use of parenteral nutrition and 
preventing hyperglycaemia and by a cautious use 
of corticosteroids for selected patients, to name 
but a few strategies that may work, while putting 
a brake on the coagulation cascade very early on 
in the disease course could be quite important 
in preventing poor outcome. This has been the 
strategy that we have followed during the first 
COVID-19 wave in our centre, where the very low 
mortality rate may have been a consequence 
hereof. But again, high-quality research via RCT is 
the only way to investigate properly whether that 
statement is true or false. 
Nebuliser therapy during
times of Corona: 
safe and effective
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about nebuliser therapy during 
the coronavirus pandemic:
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If you are interested in submitting your 
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Sore Throat Treatment Guidelines are Fanning the 
Flames of Antimicrobial Resistance
Interview Summary
Sore throat represents a significant yet under-recognised battle in the war against 
antimicrobial resistance (AMR). It is one of the most common reasons people visit a doctor 
and approximately 60% walk away with a prescription for antibiotics.1 However, studies have 
indicated that 70–95% of all cases are viral2 and most patients would be better served with 
symptom relief. 
A systematic review of global sore throat management guidelines by members of the 
Global Respiratory Infection Partnership (GRIP) suggested the problem could be rooted 
in a focus on serious, yet increasingly rare, conditions, such as quinsy and acute rheumatic 
fever (ARF). While ARF can be a dangerous complication of Group A streptococci (GAS), 
which are identified in 15–30% of sore throat cases, the incidence of ARF is exceedingly 
rare in most parts of the world.3 All but one of the 36 identified guideline documents 
discussed antibiotic therapy and less than two-thirds advocated the use of laboratory tests 
to confirm GAS. Just 50% gave advice on symptom relief, which evidence suggests is the 
most appropriate approach in most cases.4
Dr Martin Duerden, lecturer in therapeutics and prescribing at Cardiff University, Cardiff, 
UK, member of the GRIP, recently retired general practitioner, and co-author of the review, 
believes countries should re-evaluate their guidelines. 
In this interview, Dr Duerden talks about the role of fit-for-purpose sore throat guidelines 
in antimicrobial stewardship, the importance of appropriate symptom relief, and how 
coronavirus disease (COVID-19)  could represent an opportunity for change.
Interviewees: Martin Duerden
University of Cardiff, Cardiff, UK
Disclosure: Dr Duerden is a member of the Global Respiratory Infection Partnership (GRIP), 
which receives an educational grant from Reckitt Benckiser (RB).
Support: The publication of this article was funded by Reckitt Benckiser (RB) Group.
Acknowledgements: Medical writing assistance was provided by Amanda Barrell, Brighton, UK.
Disclaimer: The opinions expressed in this article belong solely to the named interviewee.
Citation: EMJ Respir. 2020;DOI/10.33590/emjrespir/200914.
ANTIMICROBIAL STEWARDSHIP AND 
SORE THROATS
More than one-half of the people who visit a 
healthcare professional with sore throat, one of 
the most common health complaints globally, 
are prescribed antibiotics.1 Historically this 
approach was employed, among other reasons, 
to avoid ARF, which was much more common 
in the 1950s and 1960s. This is a complication of 
GAS infection that can lead to rheumatic heart 
disease, mortality, and morbidity. While it is still 
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seen in some low-to-middle-income countries in 
Africa, Southeast Asia, and the Western Pacific, 
ARF is actually exceedingly rare elsewhere.4 
The overwhelming majority of sore throats 
are viral in origin, said Dr Duerden, adding that 
antibiotics are often not even required in the 
15–30% of cases in which GAS is identified. The 
over-prescription of antibiotics for sore throat, 
which is better treated with symptom relief such 
as paracetamol, nonsteroidal anti-inflammatory 
drugs (NSAID), lozenges, and sprays, is “really 
quite concerning,” commented Dr Duerden. 
“We are seeing increasing resistance to 
antibiotics and are finding severe infections, such 
as septicaemia, difficult to treat. We now know 
there’s really a large number of deaths associated 
with resistant bacteria that don’t respond to 
standard therapy.”5 Continuing, Dr Duerden 
emphasised that: “We have not had a new class 
of antibiotics for about 40 years and we are 
running out of them, the use of antibiotics for 
sore throat is actually stoking up the problem.” 
GUIDELINE REVIEW
To check the consistency of diagnostic and 
treatment criteria for sore throat, Coutinho 
et al.3 carried out a multilingual, multi-region, 
systematic literature search that identified 
36 treatment guidelines for sore throat from 
26 countries.3 All but one provided criteria 
for starting antibiotic therapy as a first-line 
treatment, but fewer than two-thirds advocated 
the use of laboratory tests to diagnose GAS 
prior to initiating therapy. Importantly, only 
one-half discussed symptom relief, which Dr 
Duerden described as the mainstay of treatment 
in most cases.3
Combined with the right diagnostic tests, 
antibiotics may be an important part of ARF 
containment strategies in high-risk areas. 
However, the approach is irrelevant in the many 
countries where ARF is exceedingly rare, Dr 
Duerden explained.
The study also highlighted worrying 
regional differences between the guidelines. 
Discrepancies were explained by historical, 
rather than current, incidences of ARF for 
example, or by guidelines being adopted from 
neighbouring countries with no adaptation for 
local circumstances. Guidelines may be bypassed 
altogether in countries where antibiotics can 
be purchased without a prescription, such as 
in Southeast Asia, and are unavailable in some 
regions, such as parts of Africa. The absence of 
guidance in Nigeria, for example, means most 
people presenting with sore throat are prescribed 
antibiotics as a matter of course.
All of these factors result in a significant volume 
of antibiotics being inappropriately prescribed 
and taken. “We’re in a situation where we must 
reduce unnecessary antibiotic use. It is critical 
to make sure that we have clear ideas and 
structures around the processes of care, and 
that’s particularly so for sore throats,” emphasised 
Dr Duerden.
Rather than promoting the use of antibiotics, 
sore throat guidelines should ensure people 
are recommended symptom relief, Dr Duerden 
explained, adding that the review found 
extremely limited advice in this regard. Just 20 
of the 36 guidelines recommended symptom 
relief such as paracetamol or NSAID, and only 
four of these mentioned topical treatments such 
as lozenges, gargles, or sprays, which evidence 
has suggested can treat symptoms much more 
effectively than antibiotics. “The most effective 
way of treating sore throat in nearly all parts of 
the world is providing symptom relief. Antibiotics 
have a very small part to play in terms of 
affecting the outcome of the infection,” 
highlighted Dr Duerden. 
Global approaches to the treatment of sore 
throat represent an international threat to 
antimicrobial stewardship, yet Dr Duerden fears 
the issue is not taken seriously. “Sore throats 
have been treated this way for 30 or 40 years 
and people don’t think it’s particularly important. 
They don’t see it as being part of the problem,” 
he said.
DEVELOPING THE GUIDELINES OF THE 
FUTURE
AMR is an issue receiving international 
oversight from bodies such as the World 
Health Organization (WHO). Focussing on 
the appropriate treatment of sore throat, 
Dr Duerden suggested, could represent a 
significant opportunity to make a difference. To 
this end, the GRIP has been encouraging 
countries to re-evaluate their guidelines.
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“If complications of GAS are a particular 
problem in your area, you will want to reduce 
infection and transmission. For most parts of 
the world, complications from sore throat are 
astonishingly rare and really what we’re talking 
about is reducing symptoms,” said Dr Duerden. 
“One possibility is developing or emulating 
high-quality guidelines which cover the essentials 
but are configured to local needs.” 
Guidelines should include a clear description 
of the disease, the diagnosis pathway, and 
necessary tests, as well as instructions on using 
symptom scores, which may indicate a more 
severe infection, he noted. Throat swab cultures 
are the gold standard for diagnosis of GAS and 
some countries advocate near-patient ‘rapid 
antigen’ testing. Where antibiotics are indicated, 
the guideline should explain the reasons, and 
set out the medication class and duration of 
treatment. “We also need to make sure people 
know the ‘red flags’, or the things likely to 
indicate severe infection, such as impaired 
swallowing, and when people should return if 
their symptoms persist,” said Dr Duerden.
Critically, guidelines should advise on symptom 
relief, including paracetamol, NSAID, and 
topical treatments, such as lozenges, sprays, or 
gargles. Not only are these much more effective 
than antibiotics, they do not contribute to 
AMR, Dr Duerden explained. 
Patient education is another consideration. 
Past experience often leads people with sore 
throat to ask their healthcare professional for 
antibiotics. Dr Duerden remarked: “We can 
educate around how sore throats are generally 
self-limiting, that you don’t need to see a doctor, 
and that you can go to your pharmacist and take 
simple, symptomatic treatment.”
THE COVID-19 OPPORTUNITY 
The emergence of severe acute respiratory 
syndrome coronavirus-2 (SARS-CoV-2) could 
represent an opportunity to correct guideline 
omissions, avoid antibiotic overuse, and 
ensure people have access to evidence-based 
symptomatic treatment, said Dr Duerden. “I 
think COVID-19 is going to change things,” he 
said. “Obviously, sore throat is a symptom of 
COVID-19. In the future, it’s possible that when we 
see people with sore throat, we may need to do 
swabs or tests for coronavirus, and we need to 
think about how that gets built into guidelines.”
“It’s early days and we’re not entirely sure 
how COVID-19 will pan out, but we need to be 
thinking about how we incorporate it into 
assessment for sore throat,” he concluded. 
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Loose ENDs: Electronic Nicotine Delivery Systems 
and the FDA’s Recent Enforcement Policy
INTRODUCTION
Electronic nicotine delivery systems (ENDS), 
including electronic cigarettes (e-cigarettes), 
have been commercially available since the early 
2000s. Since then, their use has increased both 
among adults and adolescents.1 E-cigarettes 
consist of an electric heater that aerosolises a 
liquid (e-liquid), which usually contains nicotine 
dissolved in a liquid vehicle (propylene glycol 
[PG] and vegetable glycerin [VG]) and chemical 
flavours.2 These flavours served to mask the 
bitter taste of nicotine, and they also facilitate 
the initiation and uptake of e-cigarettes by 
attracting youth and young adults.3 In the USA 
alone, there are over 1,200 different vendors and 
over 8,000 flavors.4 E-cigarettes have undergone 
a series of design evolutions and are currently 
sold both as tank-based devices (e.g., ‘mods’, 
so called because of their customisability) and 
as cartridge-based (JUUL-type) devices, with 
cartridge-based e-cigarette products currently 
being the most popular form of e-cigarette in 
the USA.5,6 These products are especially popular 
among young adults and adolescents,7 and may 
facilitate nicotine addiction and dependence.8
The long-term impact of vaping on the 
cardiovascular system, and the cancer risk, remain 
to be determined. However, increasing evidence 
shows that exposure to e-cigarette vapor in 
human models affects pulmonary and vascular 
functions,9,10 although the impact of individual 
flavours to these effects remain to be fully 
determined. More recently, e-cigarette or vaping 
product use associated lung injury (EVALI) has 
been described, which was particularly prevalent 
in youth, and has further raised concern over 
e-cigarette safety.11 In many cases, EVALI was 
most likely caused by the inclusion of vitamin 
E acetate, which was present to solubilise 
tetrahydrocannabinol,12 although not all EVALI 
patients used tetrahydrocannabinol, suggesting 
that other, as-yet-unknown, e-cigarette 
components may have been responsible.11 The 
EVALI outbreak of 2019 reconfirms the need 
for appropriate e-liquid regulation. As a case 
in point, the European Union’s (EU) Tobacco 
Product Directive banned both the use of 
refillable cartridges and the inclusion of vitamins 
in e-liquids,13 and to date, EVALI has essentially 
been absent from the EU,14 suggesting that 
appropriate e-cigarette legislation can influence 
health outcomes. 
The Family Smoking Prevention and Tobacco 
Control Act of 2009 banned the use of all natural 
and artificial flavour compounds (except for 
menthol) in combustible cigarettes and any of 
their component parts to eliminate flavoured 
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tobacco products that held special appeal in the 
youth market. However, this ruling did not apply 
to other tobacco products, such as ‘little cigars’, 
and also did not apply to e-cigarettes. In 2020, 
the U.S. Food and Drug Administration (FDA) 
finalised their enforcement policy on flavoured 
cartridge-based e-cigarette products, including 
fruit and mint flavors.15 In this commentary, the 
authors discuss the potential impact of flavours on 
human health and addiction, and the implications 
on regulation.   
TYPES OF FLAVOURS
Flavour is most commonly sensed by taste 
receptors in the mouth and the five flavours bitter, 
salty, sour, sweet, and umami (savoury), can be 
sensed. These receptors are typically either 
G-protein coupled receptors (e.g., taste receptor 
TAS1R2, sweet) or ion channels (e.g., the epithelial 
Na+ channel, salty).16,17 Flavour, and activation 
of taste receptors, is an important part of the 
smoking/vaping experience. For example, the 
inclusion of sweet flavours is reinforcing and has 
been shown to potentiate the effect of nicotine 
on the brain.18 
E-liquids contain many different flavours, 
including aldehydes (vanillin, benzaldehyde, 
cinnamaldehyde, damascenone), benzyl alcohol, 
terpenes (linalool, limonene, farnesol), pyrazines, 
menthol, and sweet flavours including ethyl 
maltol. These flavours are mixed to produce the 
thousands of commercially available e-liquids. 
Many of these flavours have also been used in 
the food and perfumes/cosmetics industries. 
However, their safety in the lung, at levels inhaled 
by e-cigarette users, is uncertain because the 
majority of toxicology studies for these flavours 
were carried out following oral ingestion only.19 
For example, high doses of inhaled diacetyl (2,3 
butanedione, used for  buttery flavour in popcorn) 
can lead to severe lung disease, in the form of 
bronchiolitis obliterans (aka ‘popcorn lung’).20 
Despite the danger, diacetyl has been detected in 
some e-liquids.21,22  
Flavoured e-liquids and individual flavours have 
been shown to induce toxicity and/or exert 
biological effects, which has been reviewed 
elsewhere.23 The number of flavours used in 
an e-liquid varies from product to product; 
previously, the authors identified 100 different 
flavours in 148 e-liquids, and found that vanillin 
was the most common flavour.22 Interestingly, the 
number of flavours contained within an e-liquid 
directly correlated with degree of toxicity.22 
Flavour concentrations in most e-liquids have not 
yet been determined; however, both vanillin and 
cinnamaldehyde were typically in the mmol/L 
range, and in some cases, cinnamaldehyde levels 
exceeded 1 mol/L.22,24 Flavourings such as vanillin 
and cinnamaldehyde are aldehydes that have the 
potential to form adducts with proteins and DNA. 
This adduct binding can alter protein function 
and possibly cause DNA mutations as DNA 
adduct levels have been considered to serve as 
biomarkers for carcinogen exposure.23,25,26 
ROLE OF FLAVOURS IN UPTAKE/
APPEAL TO YOUTH
Most people who start using nicotine do so as a 
teenager.27,28  For cigarettes, the use of flavours 
to mask the unpleasant taste (bitter) and 
irritation of the combusted cigarette has been 
well described.29-31  Moreover, menthol directly 
activates transient receptor potential channels 
in pulmonary neurons to suppress cough and 
irritation, thus making it easier to overcome the 
initially unpleasant effects of tobacco smoke 
inhalation.32 The 2019 National Youth Tobacco 
Survey (NYTS) found that over 5 million middle 
and high school students in the USA (10.5% 
and 27.5%, respectively) were e-cigarette users, 
defined as having used e-cigarettes within the last 
30 days,33 the majority of whom used cartridge-
based products. In addition to masking the 
unpleasant sensations of nicotine, e-cigarettes 
can be made in appealing ‘candy’, ‘dessert’, and 
‘fruit’ flavours, among several others, which also 
aids with marketing and appeal to teenagers.34-36 
UPDATE ON RECENT LEGISLATION 
Having a broad range of commercially-available 
flavours is a common marketing practice used 
by e-liquid vendors.37 The FDA has taken steps 
to regulate e-cigarette sales in order to prevent 
sales to youth. First, they deemed e-cigarettes to 
be tobacco products and included them in the 
2009’s Family Smoking Prevention and Tobacco 
Control Act.38 They subsequently issued an 
“Advanced Notice of Proposed Rulemaking” that 
gives importance to the regulation of flavours in 
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tobacco products.39 This year, the FDA finalised 
their rules on flavours and have banned flavoured, 
cartridge-based e-cigarettes.40 Given that JUUL-
type cartridges have the largest market share, 
this is certainly a step in the right direction. 
More specifically, the FDA has banned: a) any 
flavoured, cartridge-based ENDS product (other 
than a tobacco- or menthol-flavoured ENDS 
product); b) all other ENDS products for which 
the manufacturer has failed to take (or is failing 
to take) adequate measures to prevent minors’ 
access; and c) any ENDS product that is targeted 
to minors or likely to promote use of ENDS 
by minors.40 
This legislation is certainly a step in the right 
direction. For example, JUUL previously sold 
eight different flavours, including Crème brûlée, 
mint, fruit medley, and mango, with mint, mango, 
and fruit medley being the most popular amongst 
school-age vapers.41 However, now they only sell 
‘Classic Tobacco’, ‘Virginia Tobacco’, and ‘Menthol’, 
which will likely limit appeal to youth, as intended 
by the FDA. Unfortunately, this legislation has 
some loopholes. For example, while sales of 
e-cigarette cartridges containing flavoured 
e-liquids have been banned, individual containers 
of flavoured e-liquids, including those with 
fruit, candy, and other enigmatic names are still 
commercially available via a number of websites. 
Moreover, it is now possible to purchase off-
market, empty/refillable cartridges for cartridges-
type devices. Therefore, at the moment it is 
relatively easy to circumvent the flavour ban by 
purchasing flavoured e-liquids, and putting these 
into either second- or third-generation e-cigarette 
devices which are refillable, or by using refillable 
cartridges for JUUL-type e-cigarettes. One might 
argue that these attractively-named, flavoured 
e-liquids are targeted at minors, in which case, 
the FDA needs to enforce the sale of flavoured 
non-cartridge e-liquids in order to fully enforce 
the flavour ban for cartridge-based e-cigarettes.  
Another important omission from the FDA’s rule 
is the continued sale of menthol. As mentioned 
above, menthol directly stimulates neuronal 
transient receptor potential channels to suppress 
cough after smoke  inhalation and is arguably 
the most biologically active of the available 
flavours.32 There is strong evidence that menthol 
initiates smoking, and menthol is popular among 
young smokers. Indeed, cigarette and e-cigarette 
company marketing strategies have been based 
around this information. Thus, given its impact 
on smoking initiation, it is hard to explain why 
menthol continues to be available despite the 
flavour ban. The tobacco industry continues to 
lobby for the promotion of their products and 
USA states with more active tobacco lobbies 
are less likely to legislate for tobacco control.42 
However, the degree to which lobbying has 
influenced the continued availability of menthol 
remains to be determined. 
CONCLUSIONS 
In conclusion, the FDA’s recent ban on flavoured 
e-cigarette cartridges is an important milestone in 
the regulation of this relatively new product. Given 
that it took many individuals, several decades, 
and innumerable lawsuits before conventional 
tobacco was regulated, by comparison the FDA 
has moved at “light speed” with their deeming 
rules and their flavour ban. However, loose ends 
need to be addressed, including the availability 
of e-liquid flavours in other forms, the availability 
of refillable cartridges, and the lack of regulation 
surrounding menthol. 
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Worsening of asthma during pregnancy is of major concern due 
to the potential impacts on the mother and fetus. Therefore, the 
Editor’s Pick for this issue is the article is by Chen et al., which delineates 
the current pharmacological and non-pharmacological interventions that 
can be utilised in patients with uncontrolled asthma during pregnancy.
Improving Antenatal Asthma Management:  
A Complex Journey
Abstract
Asthma is a highly prevalent comorbidity during pregnancy, which can worsen as gestation progresses 
and is associated with several adverse perinatal outcomes. The adverse outcomes associated with 
maternal asthma are preventable with appropriate asthma management in pregnancy. However, the 
prevalence of adverse outcomes has not changed significantly over the last 20 years, even though 
knowledge and treatments for managing the disease in pregnancy has improved significantly. This 
is of concern now in the current climate with the coronavirus disease (COVID-19) pandemic and its 
potential impact on pregnant individuals with asthma. This article will discuss the treatments available 
for the management of asthma in pregnancy, the barriers for the translation of current knowledge into 
obstetric practice, and the importance of asthma education and self-management skills.
INTRODUCTION 
Worldwide, asthma is one of the most prevalent 
chronic conditions to potentially have adverse 
effects in pregnancy and subsequent perinatal 
outcomes. It affects up to 16% of females of 
reproductive age, resulting in asthma being 
one of the most common morbidities to 
affect pregnancy.1 Limited progress has been 
made towards optimising maternal asthma 
management, particularly in relation to improving 
adverse outcomes associated with uncontrolled 
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asthma during pregnancy. With rapid global 
impacts such as the coronavirus disease (COVID-19) 
pandemic, this emphasises the need to reassess 
current strategies and evidence to facilitate 
more productive approaches. Therefore, this 
commentary serves to highlight the consequences 
of uncontrolled asthma during pregnancy and 
provide insight into existing implications impeding 
effective management. Additionally, it also aims 
to evaluate the current literature to understand 
knowledge gaps and promote future areas of 
research towards enhancing asthma management 
during pregnancy. 
CONSEQUENCES OF UNCONTROLLED 
MATERNAL ASTHMA 
Pregnant individuals with asthma often 
experience unpredictable changes in their 
asthma symptoms, with 50% experiencing a 
loss of asthma control and 20% experiencing 
moderate to severe exacerbations.2 The reasons 
for these changes are largely unknown, but can be 
attributed to the complexity and heterogeneity 
of the disease itself.3,4 Patients with asthma are 
likely to undergo mechanical, immunological, 
hormonal, and metabolic changes during 
pregnancy, ultimately experiencing varying 
degrees of dyspnoea and changes in pulmonary 
function.2,4-8 However, the evidence quantifying 
the extent and significance of such influences 
are frequently inconsistent and inconclusive.2,4 
More importantly, uncontrolled maternal asthma 
and subsequent exacerbations are significant 
risk factors for adverse maternal and perinatal 
outcomes.9 This includes an increased risk 
for pre-eclampsia, gestational hypertension, 
gestational diabetes, caesarean, preterm birth, 
neonatal hypoxia, and perinatal mortality.9-12 
New findings have also acknowledged that 
adverse effects related to uncontrolled maternal 
asthma extend past birth. A study conducted 
by Abdullah et al.12 was the first to longitudinally 
investigate the long-term intergenerational impact 
of maternal asthma exacerbations. Children 
younger than 5 years of age had a 23% increased 
risk of developing early childhood asthma and 
a 12% higher chance of developing pneumonia 
if their mother had experienced asthma 
exacerbations during their gestation. These 
findings support the outcomes of smaller cross-
sectional studies,13,14 which identified childhood 
bronchiolitis and allergic rhinitis as a potential 
long-term development risk.  Additionally, a 
nationwide Swedish cohort study15 found that the 
risk of developing childhood allergic rhinitis was 
higher in children born preterm or via caesarean 
delivery, which are known adverse outcomes of 
uncontrolled maternal asthma.9 These findings 
suggest that maternal asthma in pregnancy may 
confer an inherited genetic risk for childhood 
asthma and allergies, while its lack of control may 
confer an epigenetic risk for both the fetus and 
the child.12,15 Given these alarming outcomes, there 
is a need to re-evaluate and optimise evidence-
based asthma management strategies during 
pregnancy to reduce adverse perinatal outcomes 
and early childhood diseases.
CURRENT ASTHMA  
MANAGEMENT STRATEGIES 
According to international and national 
guidelines,16,17 current maternal asthma therapy 
is the same as for non-pregnant people with 
asthma, with goals to optimise symptom 
control, preserve respiratory function, and 
provide medication with minimal adverse side 
effects. Another objective in pregnancy is to 
prevent maternal hypoxic episodes to maintain 
fetal oxygenation.16,17 This is achieved through 
vigilant monitoring and clinical symptom 
assessment, self-management education that 
includes reviewing inhaler technique, medication 
adherence, and symptom management and 
application of pharmacotherapies advised 
by health professionals via a multidisciplinary 
approach.16,17 Counselling for smoking cessation is 
also recommended as part of asthma education 
and management because it is a common 
problem in pregnant females with asthma18,19 
that contributes to severe exacerbations during 
pregnancy20 and preterm delivery.19 Clinical 
assessment of symptoms, including wheeze, 
shortness of breath, cough, and chest tightness, 
are typically measured using spirometry.16,17 
Guidelines also recommend a stepwise approach 
for pharmacological intervention, adjusted based 
on clinical assessment.16,17  This primarily includes 
intermittent use of short-acting β-agonists as 
reliever medication with an appropriate dose 
of inhaled corticosteroids (ICS), combined with 
or without a long-acting β-agonist or other 
alternative treatments.16,17 Active management 
Creative Commons Attribution-Non Commercial 4.0 November 2020  •  RESPIRATORY 99
during pregnancy is also recommended, with 
regular monthly reviews, supply of a written 
asthma plan, and additional management of 
comorbid conditions.16,17 Asthma exacerbations 
are serious events in pregnancy due to the risk 
of a hypoxic insult to the fetus and have been 
recommended to be managed aggressively with 
oral glucocorticoids as soon as possible.16,17    
Recommendations for asthma management 
during labour and delivery advise asthma 
medications should be continued during labour.21 
Asthma symptoms can occur in 10% of females 
during labour22 and intravenous hydrocortisone 
during labour for those with severe asthma 
is recommended to avoid the risk of an 
exacerbation during labour and/or adrenal 
insufficiency. Most patients (73%) return to 
prepregnancy asthma symptoms within 3 
months postpartum and can be titrated back 
to prepregnancy asthma medications.22 Overall, 
there is a need for improved guidelines for asthma 
management during pregnancy, birth, and the 
postpartum period, and this matter has been 
raised in several recent publications.23,24 
LIFESTYLE MODIFICATION AND RISK 
FACTOR REDUCTION
There are a number of lifestyle factors and 
comorbidities that are known to affect asthma 
control and increase exacerbation risk in 
pregnancy, including smoking, dietary behaviour, 
rhinitis, gastric reflux, and mental health illnesses 
or disorders that could be modified with 
appropriate interventions to reduce the risk of a 
loss of asthma control or exacerbations during 
pregnancy. Cigarette use by pregnant individuals 
with asthma is a major health concern, affecting 
up to 30% of females.18 From the authors’ 
prospective cohort studies of pregnant 
individuals with asthma, 29% of smokers ceased 
smoking during early pregnancy through 
usual antenatal care support mechanisms.25 In 
contrast, among those who received additional 
support through a nurse-led antenatal asthma 
management programme, 54% stopped 
smoking in early pregnancy, suggesting that 
lifestyle factors can be modified with an 
appropriate intervention.25
Another potentially modifiable behaviour in 
pregnancy is nutritional intake. In a socially 
disadvantaged population of pregnant females 
with asthma consuming a diet high in fat, sugar, 
and takeaway meals, there was an increased 
likelihood of uncontrolled asthma during 
pregnancy, whereas a diet high in protein, fruit, 
or vegetables was associated with controlled 
asthma.26 Nutritional advice should be 
considered for individuals with asthma who are 
obese as there was an increased prevalence of 
asthma exacerbations among pregnant females 
who were overweight (51%) or obese (48%) 
compared with those with a healthy weight 
(25%).8 However, pregnancy-related weight gain 
appeared to have no impact on exacerbation 
risk.8 These findings provide important evidence 
that lifestyle modification is a consideration for 
the antenatal management of maternal asthma, 
but it remains to be determined whether they 
represent a key determinant for asthma control 
in pregnancy. 
Comorbidities known to exacerbate asthma, 
including rhinitis, gastric reflux, and mental 
health illnesses and disorders, could be managed 
clinically with maternal antenatal asthma 
management. Rhinitis is the most common 
comorbidity, occurring in 65% of females with 
asthma during pregnancy, with 20% of females 
experiencing pregnancy rhinitis.27 The presence 
of rhinitis was shown to be associated with poorer 
asthma control and lung function.27 A history of 
depression or anxiety in patients with asthma 
during pregnancy increased the risk of uncontrolled 
asthma during pregnancy.28-30 Furthermore, 
anxiety was an independent risk factor for 
poor asthma control and exacerbations.29,30 A 
number of studies have also reported that gastric 
reflux exacerbates asthma in those who are not 
pregnant.31 A prospective study reported that 
80% of pregnant indiviuals experience some 
gastric reflux during pregnancy, with it being 
more severe in those with asthma;32 therefore, it 
is possible asthma control in pregnancy may be 
influenced by the presence or absence of gastric 
reflux. These studies highlighted that lifestyle 
factors and comorbidities could be examined 
holistically with antenatal asthma management 
to develop preventive strategies for asthma 
control in pregnancy and ultimately improve 
pregnancy-related outcomes. 
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EFFECTIVENESS OF 
PHARMACOLOGICAL AND NON-
PHARMACOLOGICAL INTERVENTIONS
Pharmacological Treatment 
Pharmacological therapy is the current mainstay 
treatment for effective asthma control in 
pregnancy.10,33,34 Uncontrolled maternal asthma 
poses a greater risk to the health of the 
mother and her baby than medication use.33,34 
Table 1 summarises asthma medication safety 
data with respect to reported doses and 
adverse events. 7,35-38
The safety of ICS has been extensively 
investigated in pregnancy and there is growing 
evidence supporting ICS/long-acting β-agonists 
combinations.10,33,34 This strengthens the 
argument and recommendation, by guidelines, 
that females entering pregnancy should 
continue medication/s they were taking 
prior to conception, if the treatment remains 
clinically appropriate. Other commonly used 
asthma medications with pregnancy safety 
data include systemic steroids, leukotriene 
receptor antagonists, omalizumab, and, 
rarely, theophylline.10,33,34
The cumulation of pharmacological safety data 
in pregnancy is progressive; however, may be 
limited by studies that have small sample sizes, 
insufficient control for cofounders, and missing 
data.39 Thus, more research is required to 
improve evidence-based safety data of asthma 
pharmacological treatment during pregnancy.39 
Furthermore, asthma pharmacotherapy adjusted 
in response to lung function and symptom 
assessment does not always reflect airway 
inflammation, the target of ICS treatment.40 This 
suggests that decisions in therapy based on 
clinical assessment alone may be inappropriate, 
with growing awareness of the heterogeneity of 
asthma and its differing phenotypes.40 Therefore, 
the correct identification of phenotypic asthma 
unique to the individual proposes the potential for 
individualising asthma treatment.41 Additionally, 
as mentioned before, the perceptions concerning 
the relative safety of medication use in pregnancy 
is a continuous impediment in optimising 
maternal asthma management.34
Fraction of Exhaled Nitric  
Oxide-Guided Diagnosis and  
Asthma Management
The pursuit for novel, individualising-type 
treatments is unsurprising, particularly as 
biomarker-guided therapies, such as the use of 
the noninvasive measure of fraction of exhaled 
nitric oxide (FeNO), have already shown to 
improve asthma control in those who are not 
pregnant.42,43 In particular, as FeNO can be used 
to identify eosinophilic airway inflammation, it 
helps guide ICS dose titrations, thereby limiting 
ICS exposure and exacerbation rates.42,43 In 
pregnancy, the efficacy of FeNO-based therapy 
has been established in one randomised 
controlled trial (RCT) study conducted by 
Powell et al.44 The study involved 220 non-
smoking females and reported that one-half of 
the exacerbations were reduced in the FeNO 
participants in comparison to the control group. It 
also reported that there was increased retention of 
asthma control in the FeNO participants, thereby 
allowing progressive ICS dose reductions, as well 
as minimised oral corticosteroid and short-acting 
β-agonist use. 
Long-term benefits of FeNO treatment in 
pregnancy have also been investigated, with 
reports of reduced wheeze and childhood 
asthma prevalence in children of mothers who 
received FeNO treatment during pregnancy.45,46 
Additionally, a qualitative study by Mclaughlin 
et al.42 determined that clinicians found 
FeNO-guided treatment implementation to 
be feasible within hospital-based antenatal 
care settings if resources and education are 
appropriately provided. 
Despite these positive outcomes, limitations have 
been identified in this approach by Grzeskowiak 
and Clifton,43 including its uncertain applicability 
in primary clinical care, accessibility, and cost-
effectiveness. However, continuing studies such 
as The Breathing for Life Trial40 will not only 
address these limitations to better comprehend 
the feasibility of FeNO-guided antenatal therapy, 
but will also include smokers within the pregnant 
females with asthma cohort. This allows the 
generalisability of this approach to be better 
understood, particularly because there is a high 
proportion of pregnant individuals with asthma 
who smoke (>20%).19,43 
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Table 1: Summary of the efficacy of asthma medications used in observational trials to maintain or strengthen 
asthma control in women with asthma.7,35-38
Medications and usual dose Use Associated risks, safety data, and other information on use
Short-acting inhaled β-agonists
Salbutamol  
100–200 µg when required
Rescue/reliever therapy 
Salbutamol has more reassuring 
human data in pregnancy than 
terbutaline and is preferred  
in pregnancy.
Terbutaline  
500–1,500 µg when required
Long-acting inhaled β-agonists
Salmeterol 
25–50 µg twice daily
Rescue/reliever therapy; typically 
used as add-on therapy when asthma 
cannot be adequately controlled 
with inhaled corticosteroids alone, 
but should not be used without 
preventative/controller medication
Limited experience but reassuring data 
available for salmeterol or formoterol.
Relationship with perinatal outcomes 
is conflicting but can assume that the 
pharmacologic and toxicologic profile 
is similar to short-acting  
inhaled β-agonists.
Formoterol 
6–12 µg twice daily
Vilanterol 
25 µg once daily
Inhaled corticosteroids
Beclometasone dipropionate 
Low: 100–200 µg/day
Medium: 250–400 µg/day
High: >400 µg/day
Preferred preventative/controller 
medication; inhibits the number of and 
activity of inflammatory cells in airway
Reassuring human data available, 
but beclometasone, budesonide, or 
fluticasone propionate are preferred 
due to greater experience.
No association with oral clefts, 
congenital malformations, caesarean 
delivery, or other offspring disease risk 
when used during pregnancy. 
Limited teratogenic risk data. 
Budesonide 
Low: 200–400 µg/day
Medium: 500–800 µg/day
High: >800 µg/day
Ciclesonide 
Low: 80–160 µg/day
Medium: 240–320 µg/day
High: >320 µg/day
Fluticasone propionate 
Low: 100–200 µg/day
Medium: 250–500 µg/day
High: >500 µg/day
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Adapted from Grzeskowiak et al.10
Medications and usual dose Use Associated risks, safety data, and other information on use
Systemic corticosteroids
Prednisolone 
Exacerbation: 40–50 mg once daily for 
5–10 days
Maintenance: Variable dose according 
to response
Preventative medication and mainstay 
treatment of asthma exacerbations; 
used if asthma cannot be controlled 
with other preferred medications
Use of systemic corticosteroids 
associated with increased risk of oral 
cleft, especially if used in first trimester 
of pregnancy.
Also associated with increased risk 
of adverse pregnancy outcomes 
(e.g., pre-eclampsia, preterm birth, 
small-for-gestational age), but likely 
confounded by maternal asthma 
severity.
Leukotriene receptor antagonist
Montelukast 
10 mg once daily
Inhaled corticosteroid alternative
Limited experience.
Reassuring human data available 
as no risk for major congenital 
malformations has yet been found.
Zafirlukast 
20 mg twice daily
Other treatments
Omalizumab
Subcutaneous 75–375 mg every 2–4 
weeks; dose according to weight and 
serum total IgE level
Anti-IgE monoclonal antibody; add-
on therapy or inhaled corticosteroid 
alternative for allergic asthma
Limited experience but reassuring 
human data.
No significant increased risk of major 
congenital malformations, small-
for-gestational age, or prematurity 
was found for women taking it 8 
weeks prior to conception or during 
pregnancy compared to pregnant 
asthmatics not taking it.
Carries risk of anaphylaxis, so should 
not be started during pregnancy.
Theophylline 
300–600 mg/day; dose according to 
theophylline level or use ideal weight 
to calculate dose for obese patients
Alternative therapy or alternative 
adjunctive long-acting bronchodilator 
therapy; rarely used in pregnancy.
Reassuring human data available 
but limited role in practice due 
to monitoring requirements and 
associated risk of toxicity (need to 
ensure serum levels remain between 5 
and 12 µg/mL). 
Serum concentration can be increased 
with alcohol and concurrent use of 
formoterol.
Table 1 continued.
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It is also important to understand that FeNO 
cannot be applied as a stand-alone approach, nor 
does it replace the need for appropriate asthma 
self-management education.42
Asthma Self-Management Education: 
Optimal Models of Care
Antenatal asthma self-management education 
plays a key role in improving maternal asthma 
control and asthma-related outcomes in 
pregnancy. Many studies have established the 
benefits of asthma self-management education. 
A review by Williamson et al.47 reported 
antenatal asthma self-management education 
implemented via two interventions, one 
nurse-led and the other pharmacist-led, showed 
significant improvements in asthma self-
management and control. Patients had improved 
medication knowledge and inhaler technique, 
with more than 80% of the cohort retaining 
the skills they learnt for at least 6 months 
postpartum. This indicates that implementation 
of asthma self-management education could 
potentially reduce the perceived medication-
related risks mothers might have.
The RCT conducted by Lim et al.48 showed 
asthma self-management involving pharmacist-
guided regular monitoring and education could 
improve maternal asthma outcomes. The study 
monitored asthma control in 60 pregnant 
females with asthma at less than 20 weeks’ 
gestation via an Asthma Control Questionnaire 
(ACQ), where scores <1.5 indicated adequately 
controlled asthma. Patients who received 
guidance from the multidisciplinary intervention 
had significant reductions in their ACQ score, with 
adequately controlled asthma after 6 months 
compared to 69% of patients who received usual 
care. As this RCT was conducted at antenatal 
clinics in major maternity hospitals, this study also 
showed that the multidisciplinary intervention 
could easily be integrated into antenatal settings. 
A recent RCT conducted by Zairina et al.49 
assessed the efficacy of a telehealth-based 
intervention in providing 72 pregnant patients 
asthma self-management education. The 
intervention group were supported by a 
smartphone application for advice on managing 
deteriorating asthma symptoms and allowed 
symptom monitoring via a handheld respiratory 
device. The study reported that they had superior 
asthma control and asthma-related quality of 
life at 6 months post intervention compared to 
usual care. This unique method alleviated the 
need to see health professionals in person, while 
also streamlined the process of communication 
between patient and health professionals as data 
were provided electronically. Across all these 
studies, appropriate implementation of asthma 
education, particularly via a multidisciplinary 
approach, had positive influences in improving 
maternal asthma control. However, more studies 
are required to see if these interventions actually 
lead to improved perinatal outcomes.50
OTHER LIMITATIONS  
AND RECOMMENDATIONS  
FOR IMPROVEMENT
A lack of uniformity and gaps for specific 
treatment recommendations exist within current 
maternal asthma guidelines. A systematic 
appraisal by McLaughlin et al.23 identified that only 
respiratory guidelines included recommendations 
for managing maternal asthma, but antenatal 
guidelines did not. The specific recommendations 
are also unclear in certain categories; for instance, 
the need for regular asthma review in pregnancy 
is not well addressed in guidelines, but should 
be essential given the unforeseen physiological 
changes that can occur during pregnancy.23 This 
also raises the concern that there are limited 
data available to determine which periods of 
pregnancy are critical for improving maternal 
asthma control to minimise the probability of 
an adverse outcome. Moreover, while guidelines 
have become increasingly more accessible to 
health professionals, the prevalence of poor 
outcomes for mothers with asthma and their 
neonates remain unchanged, indicating that 
there has been a lack of implementation of 
these guidelines.31 Additionally, a review by 
Grzeskowiak et al.10 found  the evaluation of 
asthma exacerbations are not well defined, 
particularly as it often relies on the patient’s own 
self-awareness and understanding of symptoms. 
This is unreliable, particularly as asthma 
exacerbations by self-help seeking behaviours 
generally leads to unnecessary emergency 
department presentations or unscheduled 
doctor visits.10 These limitations and current gaps 
in knowledge in maternal asthma guidelines 
are future areas of research to improve current 
guidelines and limit short- and long-term risks of 
maternal asthma on mother and fetus. 
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BARRIERS PREVENTING  
EFFECTIVE MANAGEMENT 
A discordance exists between current antenatal 
asthma management guidelines and clinical 
practice, which restricts health advances in 
optimising asthma management in pregnant 
females.26 A contributing factor is that maternal 
asthma management appears to be reactive 
rather than proactive.26,51 While current maternal 
asthma guidelines recommend a written asthma 
action plan, longitudinal and prospective 
studies showed only 10–20% of females had a 
written asthma action plan throughout their 
pregnancy. 26,35,51 These findings indicate that the 
majority of pregnant females self-manage their 
asthma, which may be problematic if they are 
unaware of how to appropriately respond to the 
changes in their asthma pathology.51 
Another barrier limiting effective maternal 
asthma control is nonadherent medication use. 
For instance, a major reason for medication 
discontinuation relates to the perceived fear 
or lack of need to use asthma medications, 
particularly ICS.50 Fear-related suboptimal 
use during pregnancy has been reported in 
multiple countries, reflecting the global scale 
of this problem.35,52-55 Individuals were found to 
be unaware that their asthma symptoms could 
worsen during the course of their pregnancy, 
or considered medication use to be a greater 
concern than the potential risks associated with 
uncontrolled maternal asthma.35,52-55 Other reasons 
also included inadequate support and guidance 
from health professionals and their desire to seek 
alternative therapies.56
Physician reluctance to prescribe and lack of 
confidence to endorse asthma medication use 
is another barrier towards effective maternal 
asthma control.26 In a cross-sectional survey 
by Lim et al.,57 >25% of pregnant patients with 
asthma were instructed by their family physician 
to cease and reduce asthma medication use 
despite having well-controlled asthma, while a 
French study by Beau et al.58 showed guidelines 
were not followed by all physicians. In particular, 
one-half of pregnant patients with asthma were 
not prescribed asthma medication on a regular 
basis and medications prescribed differed to 
those used during preconception, which does not 
reflect guideline recommendations to continue 
the same preconception asthma medication/s 
during pregnancy.58
Clearly, based on the evidence, it can be inferred 
that asthma management largely differs 
depending on the healthcare specialist and views 
of the patient, highlighting the discrepancy 
between clinical practice and current maternal 
asthma guidelines. This emphasises the 
importance of asthma education for the 
patients and multidisciplinary teams managing 
their asthma. It also reinforces the idea that 
multifaceted approaches should work 
synergistically for optimal management of 
asthma during pregnancy.50 A more current 
and pressing issue for pregnant individuals with 
asthma is the current outbreak of coronavirus 
disease (COVID-19) infection across the world 
and how it can be treated and managed in this 
vulnerable population.
MATERNAL ASTHMA MANAGEMENT 
AND COVID-19
In December 2019, an outbreak of pneumonia 
with unknown origins was identified in Wuhan, 
China. This was found to be caused by a 
novel coronavirus,59 now named severe acute 
respiratory syndrome coronavirus 2 (SARS-
CoV-2) by the World Health Organization 
(WHO).60 This virus causes COVID-19, a disease 
characterised by a severe respiratory illness 
similar to severe acute respiratory syndrome 
(SARS).61 The impact of the virus on pregnant 
females with asthma and their offspring is 
currently unknown, but we do know that the 
pregnant population has been at high risk of 
adverse outcomes in previous epidemics, with 
significantly higher rates of death during the 
1918–1919 Spanish flu pandemic, 1957–1958 
Asian flu pandemic,36 2002 SARS epidemic, and 
2012 Middle East respiratory syndrome (MERS) 
epidemic. Case fatality rates for SARS and 
MERS were as high as 15% and 27%, respectively, 
for pregnant females, although this is based 
on only a small number of reported patients 
with disease.37 
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To date, preliminary reports from China indicated 
that pregnancy does not aggravate the course 
of symptoms of COVID-1938 and, unlike SARS 
and MERS, there have been few maternal deaths 
associated with COVID-19 infection in pregnancy.62 
A systematic review of pregnancy outcomes 
from COVID-19 indicated that preterm birth and 
perinatal death were the most common outcomes 
in pregnancies complicated by the virus, with 
limited evidence of vertical transmission of the 
virus to the fetus.63 In the USA, 15% of COVID-19 
infections in pregnancy were severe and occurred 
in females who had comorbidities that included 
obesity and asthma.64 Spanish data identified 
that 12.5% of pregnant patients with COVID-19 
pneumonia have asthma.65 One maternal death 
reported in the UK occurred in a 29-year-old 
Pakistani female who had multiple comorbidities, 
including asthma.66 Brazilian data reporting 
COVID-19 maternal deaths associated with a 
comorbidity identified that 45% of deaths were 
pregnant females with asthma.67 Personalised 
predictive modelling for mortality, ventilation, 
and need for  intensive care unit admission 
developed from Mexican data reported that 
pregnancy and asthma were predictors of these 
outcomes.68 These data suggest that severe 
COVID-19 infections arise in pregnant females 
with multiple comorbidities, including asthma, 
and that these females are at greater risk 
of intensive care unit admission and death. 
Furthermore, a prospective study examining viral 
infections in pregnant patients reported that 
those with asthma had a higher susceptibility 
to infection and more severe infections than 
those without asthma during pregnancy,69 which 
suggests pregnant females with asthma are an 
at-risk population for COVID-19 infection. Centers 
for Disease Control and Protection (CDC) 
guidelines indicate people with asthma may be 
at greater risk of more severe disease if infected 
with COVID-19, and there are data emerging that 
supports this information. 
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Figure 1: Variables that influence asthma control during pregnancy.  
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Treatment recommendations for people with 
asthma and COVID-19 infection remain the 
same as noninfected people with asthma, 
but to avoid nebuliser treatments due to 
aerosolisation of the virus and potential risk 
of transmission to others.70 
CONCLUSION 
Maternal asthma is a substantial burden for 
both the mother and the health system. With 
the current paucity of the ability of evidence-
based strategies to improve adverse outcomes, 
it is important to understand that uncontrolled 
maternal asthma and subsequent exacerbations 
in antenatal settings can contribute to 
increased risks of adverse pregnancy outcomes 
(Figure 1). More research evaluating the 
relationship between COVID-19 and its effect on 
the state of asthma control during pregnancy 
should be considered to determine if the 
development of treatment strategies is required. 
Ultimately, there is a need for evidence-based 
clinical practice guidelines that translate current 
research findings to clinical practice and optimise 
asthma control within antenatal settings to 
potentially improve health outcomes for the 
mother and baby.
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Spatiotemporal Cellular Networks Maintain Immune 
Homeostasis in the Lung
Abstract
A dynamic and intricately connected tissue-resident immune cell network continuously monitors 
the lungs, which are incessantly subjected to external environmental insults. The lungs are protected 
by the respiratory epithelium, which not only serves as a physical barrier through mucociliary 
mechanisms, but also a reactive one that can release cytokines, chemokines, and other defence 
proteins in response to danger signals. In the maintenance of pulmonary homeostasis in health, the 
lung-resident immune cell network instructs tolerance to innocuous particulates and can rapidly 
and efficiently drive immunity and memory to pathogenic antigens. This review examines the 
spatiotemporal dynamics that underlie the exquisite network of highly specialised immune cells and 
their mediators in the support of pulmonary tissue homeostasis and effective lung immunity in health. 
In particular, this review examines the specialised immune cells that reside in distinct populations 
within the diverse compartments of the lung, and the molecular signals that retain and recruit lung-
resident immune cells, to further our understanding of how these can be targeted therapeutically to 
return inflamed or diseased lungs to homeostasis. 
INTRODUCTION
Lung homeostasis is maintained by an immune cell 
network of tissue-resident cells that constantly 
monitor the respiratory tract, which is exposed 
to inhaled matter containing aeroallergens and 
airborne pathogens that can cause infection, and 
noxious agents including dust, smoke, and other 
environmental pollutants known to induce lung 
tissue injury. Channelling air into the respiratory 
system are the conducting airways, comprised 
of a single layer of ciliated epithelium tissue 
interspersed with mucus-producing goblet cells 
that protects against particulates and infectious 
agents that adhere to the mucus, and through the 
actions of the cilia are cleared from the airways. 
This respiratory epithelial cell surface therefore 
represents a large and exquisitely delicate surface 
undergoing continuous challenge by immunogenic 
antigens. Maintenance of pulmonary immune 
Authors: Jessica G. Borger 
Central Clinical School, Monash University, Alfred Research Alliance,  
Melbourne, Australia
*Correspondence to jessica.borger@monash.edu 
Disclosure: The author has declared no conflicts of interest.
Acknowledgements: The author thanks Layla Southcombe for the invitation to write a review for EMJ 
Respiratory, and thanks Dr Lakshanie Wickramasinghe for her critical reading of  
this manuscript.
Received: 03.07.20
Accepted: 05.09.20
Keywords: γδ-T cell, dendritic cell (DC), homeostasis, innate lymphoid cells (ILC), lung, 
macrophage, mucosal, T cell, regulatory T cell (Treg), Th1, Th2, Th17.
Citation: EMJ Respir. 2020;8[1]:108-119.
Creative Commons Attribution-Non Commercial 4.0 November 2020  •  RESPIRATORY 109
homeostasis, required to dynamically support 
efficient gas exchange between the epithelial 
cell surfaces and the vascular bed, is provided at 
this interface by constant immune surveillance 
differentiating between self and the environment, 
instructing tolerance mechanisms to innocuous 
inhaled particles, and through mounting rapid 
responses to pathogenic challenge. 
Maintenance of immune homeostasis and 
the triggering of pathogenesis requires a 
sophisticated understanding of the dynamic 
interplay between the network of tissue-resident 
immune cells within the microanatomical 
organisation of the lung. This review will discuss 
the spatiotemporal cellular dynamics of the 
innate and adaptive immune cell networks during 
homeostasis, focussing on the participation of 
the individual lung-resident immune cell types 
and their intricate interplay to maintain the 
pulmonary microenvironment. How these 
immune cells then participate in wound healing 
and tissue repair, become dysregulated and 
contribute to chronic inflammation, and 
the treatment of subsequent respiratory 
complications will not be discussed in this 
review, but reference to topical studies on 
advancements in these fields will be highlighted.
SPATIOTEMPORAL ORGANISATION  
OF THE PULMONARY IMMUNE  
CELL NETWORK
The lung is populated by heterogenous tissue-
resident innate and adaptive immune cells that 
function together to maintain tissue homeostasis 
and protect from recurrent pathogenic 
challenges. Dysregulation of the immune 
response can cause acute respiratory distress 
syndrome1 and asthma,2 or drive chronic 
inflammatory diseases3 including chronic 
obstructive pulmonary disease (COPD),4 
bronchopulmonary dysplasia,5 pulmonary 
fibrosis,6 and lung cancer.7 To appreciate the 
maintenance of homeostasis and development of 
immune responses within the lung, it is critically 
important to consider spatiotemporally how and 
where immune cells interact and function.
In the steady state, macrophages, the 
predominant innate leukocyte population, and 
dendritic cells (DC) continually sample and 
phagocytose the majority of inhaled innocuous 
and pathogenic particulate material that enters 
the airways, to protect local tissues from damage 
by suppressing induction of the adaptive immune 
response.8 Cluster of differentiation (CD)4+ and 
CD8+ T cells are the prevalent adaptive immune 
cells that generate specific effector and memory 
responses to innocuous bacterial, viral, and fungal 
antigens.9 Pathogenic antigen not cleared from 
the conducting airways within mucous secretions 
from goblet cells or digested by macrophages is 
sampled through the airway epithelium by DC 
and instead transported to the lung-draining 
lymph nodes for processing into the major 
histocompatibility complex Class I or II pathways 
for generation of a specific adaptive T-cell effector 
response (Figure 1).
Distinct leukocyte networks extend throughout 
the entirety of the lung, reflecting contrasting 
and variable levels of airborne antigen exposure 
experienced throughout the pulmonary 
system, which facilitate highly specific and 
directed immune responses to maintain tissue 
homeostasis. The lung is segregated into numerous 
anatomically distinct cellular compartments, 
including the conducting airway mucosa, the 
lung parenchyma, the draining lymph nodes, 
bronchoalveolar space, bronchus-associated 
lymphoid tissue (BALT), the intravascular cell 
pool, and periarterial space.10 
Conducting Airway Mucosa
The conducting airway mucosa is composed 
of ciliated epithelial cells and mucus-secreting 
goblet cells that remove inhaled particulate 
through mucociliary clearance mechanisms. The 
bronchial epithelium contains a unique leukocyte 
network, enriched in DC, predominantly myeloid 
DC, as well as plasmacytoid DC (pDC) and 
pulmonary alveolar macrophages (AM). Lung-
resident airway mucosal DC are reported to 
be strategically positioned with highly motile 
projections extended between epithelial cells to 
support direct antigen sampling from the airway 
luminal surface.11-14 Interestingly, many of these 
studies are inferred from static imaging and flow 
cytometry studies11,15,16 with recent work utilising 
elegant slice imaging, suggesting the conducting 
airways are rarely sites of transepithelial DC 
projections,17 challenging current dogma and 
indicating antigenic sampling occurs upon escape 
of particulate from mucociliary actions and its 
exposure within the lung parenchyma.
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Intraepithelial lymphocytes (IEL), specialised 
lymphocytes that do not require antigen priming 
for their effector functions, are also found in 
relatively high numbers in the mucosal linings in 
the lung as well as gastrointestinal tract, where 
they are components of the gut-associated 
lymphoid tissue. Both CD8 and CD4+ 
intraepithelial T cells are found intraepithelially 
and in the lamina propria, and express an 
effector cell phenotype (CD45RO+). Indeed, in 
allergic inflammation and bronchial infections, 
intraepithelial lymphocytes participate in 
crosstalk with the bronchial epithelium in the 
regulation of inflammatory processes18 and 
present with many functions.19 The lamina propria 
also homes antibody-producing plasma cells 
(IgA+) and some B cells which may contribute 
to local antigen presentation, as demonstrated in 
the lymph nodes that drain the lungs.20
Lung Parenchyma
The lung parenchyma includes the respiratory 
bronchi, which branch into bronchioles and 
terminal bronchioles, which extend into alveolar 
Figure 1: Lung-resident immune cell network.
Immune homeostasis is maintained in the numerous distinct compartments of the lung by specific populations of 
lung-resident immune cells beyond initial mucociliary clearance of inhaled innocuous and pathogenic antigens. 
Within the airways lung-resident AM and DC from the rapidly responding innate immune system phagocytose 
airborne antigen for clearance or processing and presentation respectively to T cells in the lung-draining lymph 
nodes. These innate cells, along with ILC and innate-like γδ-T cells provide a rapid first-line of defence to inhaled 
antigenic particulates. Antigens escaping mucociliary or phagocytic clearance are sampled by DC through the 
surface lung epithelium of the bronchial mucosa or alveoli of the conducting airways. Activated DC migrate to 
the lung-draining lymph nodes through the lymphatics which are recognised by TN which become activated and 
differentiate into TEFF including Treg and Th17 or generate memory. Antigen-specific activate T cells migrate through 
the lymphatics and pulmonary capillaries into the lung parenchyma and site of infection. B cells will also generate IgE 
antibody response through the differentiation and activation of plasma B cells.
AM: alveolar macrophages; DC: dendritic cells; IM: interstitial macrophages; ILC: innate lymphoid cells; TEFF: effector T 
cells; TMEM: memory T cells; TN: naïve T cells; Treg: regulatory T cells. 
This figure was produced using images modified from Servier Medical Art (Servier, https://smart.servier.com/, licensed 
under a Creative Commons Attribution 3.0 Unported Licence).
Ɣ𝝳𝝳
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ducts and alveolar sacs. The pulmonary 
circulation, a dynamic network of capillaries that 
are in close contact with the alveolar space in the 
interstitium that separates the alveoli, localises a 
unique immune response within the parenchyma.
The alveolar space, and not the airways, appears 
to be the main site of particulate ingestion and 
movement to the airways. Intravital imaging has 
demonstrated that AM are the major phagocytes 
in the alveolar space and become immobile 
and phagocytic following antigen encounter, 
digesting all antigenic material that evades 
mucosal clearance. Lung-resident DC project 
dendrites into the alveoli to support antigen 
uptake, differentiating innocuous insults from 
dangerous ones, and trafficking to the airways 
to release antigen into the interstitium.17 Having 
an abundant number of AM residing in the 
terminal alveoli suggests that particulate will 
be transported upward by DC to the branching 
airways to the lung-draining lymph nodes 
resulting in local or systemic activation of T cells.21 
Thus, DC uptake and presentation only appears 
to account for a fraction of antigen uptake at 
steady state, which is enhanced during immune 
responses.17 This appears to be driven not by a 
change in the ability of DC to gain access to the 
alveoli, but by a rapid influx of monocyte-derived 
DC into the alveoli during antigenic challenge.
Another less commonly considered tissue-
resident immune cell, the neutrophil, resides 
throughout the pulmonary vasculature of the 
parenchyma at steady state, sequestered at high 
numbers in both narrow and wide capillaries. 
In response to inflammatory challenge in 
models of lung injury, lung-resident neutrophils 
dramatically increase within the pulmonary 
capillaries, cluster, and extravasate rapidly.17,22-24 
Recent imaging has suggested that neutrophils 
may actually be sequestered following a leading 
monocyte population that transmigrates into the 
interstitium immediately after lung injury.22 This 
suggests that in homeostasis, the lungs are 
primed to rapidly respond to insults due to 
the abundant number of neutrophils trapped 
throughout the microvasculature that are primed 
to enter the lung and immediately degranulate. 
Lung-Draining Lymph Nodes
Lung-draining lymph nodes are an essential 
component of the pulmonary immune cell 
network, a critical site for the development of 
adaptive immunity in infection and allergy,25 
and the primary site for the induction of 
immunological memory. Migratory DC and AM, 
although participating in alternate transport 
pathways of antigen presentation, both migrate 
from the lung to the lung-draining lymph nodes 
to actively transfer antigen and activate effector 
T-cells responses.26 Whether the lung-draining 
lymph nodes serve to functionally integrate with 
the overall immune system and exactly how this 
cross-communication is regulated is yet to be 
fully understood.
Intravascular Leukocyte Pool
The intravascular leukocyte pool is contained 
within the endothelium of capillaries and 
venules of the lung. Although the intravascular 
leukocyte pool is critical for the range of immune 
reactions in the lung, it remains unclear whether 
intravascular leukocytes are a prerequisite for 
efficient immune reactions in the lung25,27,28 and 
how their numbers and migration into the lung 
parenchyma is regulated.10
Bronchus-Associated Lymphoid Tissue
Although only present during early childhood in 
healthy individuals, BALT is a potential inductive 
site contained with the greater airway mucosa.29 
BALT, comprising discrete lymphoid-cell 
aggregates underlying a specialised epithelium, 
is part of the integrated mucosal immune system, 
facilitating the migration of lymphocytes to other 
mucosal sites.30 BALT can reappear in conditions 
of inflammation such as smoking.31 Inducible 
BALT from mice that lack other organised 
lymphoid tissue can generate protective 
immunity against pathogens, such as influenza 
virus,32 which suggests in early life that BALT may 
play a role in maintaining local immunological 
homeostasis when central lymphoid structures in 
the respiratory tract are functionally immature.
Periarterial Space
Periarterial space is located around the 
pulmonary arteries surrounded by lymphatic 
vessels and blood capillaries. The periarterial 
space was recently demonstrated to be involved 
in pulmonary host defense,33 yet whether innate 
or adaptive immunity is dominant within the 
periarterial space and the mechanisms driving 
immune cell infiltrate from the alveoli to the 
periarterial space is yet to be understood. 
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CELLULAR DYNAMICS OF THE IMMUNE 
NETWORK IN THE LUNG
A dynamic dual phagocytic system involving AM 
and neutrophils is continually removing inhaled 
particulates, but activation and recruitment of 
adaptive immune cells to the site of infection 
is critical for elimination of innocuous micro-
organisms from the alveolar space. Immune 
cell recruitment to the lungs is ‘unique’ in that 
it has two separate circulatory systems: the 
bronchial arteries from the systemic circulation 
that nourishes the bronchial wall and the low-
pressure pulmonary system that circulates 
through the lung parenchyma.34 The mucosal 
immune responses of the central airways are also 
integrated with those of distinct mucosal tissues 
through mucosal-associated lymphoid tissue. 
Lymphocytes in the lung have distinct imprinting 
of tissue-homing properties. Unlike naïve T cells 
that express adhesion molecules and chemokine 
receptors that restrict their migration to lymphoid 
tissue,35 activated memory T cells downregulate 
these lymphoid-tissue-homing receptors and 
upregulate tissue-specific adhesion molecules 
and chemokine receptors that target their 
migration to non-lymphoid tissues.36
The regulation of T-cell migration in the lung is yet 
to be fully understood but it has been shown in 
viral infection that memory T cells mainly traffic 
and recirculate through the pulmonary 
capillaries and selectively accumulate in the lung 
parenchyma.37 During homeostasis, endothelial 
cells in the pulmonary vasculature express 
intercellular adhesion molecule 1 (ICAM-1) and 
P-selectin. Lymphocyte function-associated 
antigen 1(LFA-1)–ICAM 1  interactions have been 
demonstrated as the requisite interaction to 
retain and support egress of effector CD8+ T 
cell from the pulmonary vasculature.38 Further 
interactions with P-selectin, through P-selecting 
glycoprotein ligand 1 (PSGL-1) expression by 
CD8 T cells, further mediates the recruitment 
and retention of T cells in the alveoli and lung 
parenchyma. In addition, chemokine interactions, 
such as C-C chemokine receptor type 5 (CCR5)
and chemokine ligand 5 (CCL5), was shown 
during viral challenge to recruit memory T cells 
to the parenchyma and also appear to play 
a role in tissue-specific lung homing.37 Taken 
together with integrin mechanics, this suggests 
that specific combinations of integrin expression 
and chemokine gradients are an important 
mechanism for retention of T cells in the airways 
during homeostasis and pathogenesis.
To summarise the role of chemokine receptors 
expressed on immune cells in homeostasis in 
the lung is difficult, and largely inferred from 
studies on their role in the pathogenesis of lung 
diseases including COPD,39,40 asthma and allergic 
airway diseases,41-43 pulmonary fibrosis,44,45 and 
pulmonary infections.46,47 To determine the role 
of chemokine receptors, mice with a particular 
gene knockout, blocking antibodies, and specific 
inhibitors of chemokine receptors have been 
studied in different lung disease models which 
are comprehensively discussed in a review by 
Tomankova et al.48
TISSUE-RESIDENT IMMUNE CELLS 
CONTRIBUTING TO PULMONARY 
HOMEOSTASIS
Alveolar and Interstitial Macrophages
Alveolar and interstitial macrophages maintain 
pulmonary immune homeostasis via their 
intimate interactions with other lung-resident 
cells, specifically pulmonary epithelial cells. 
Expression of a broad range of surface receptors 
enables them to sense the environment and 
signal to local stromal cells in order to maintain 
immune homeostasis, but also to sense change 
within the inhaled environment. Macrophages 
sense change within the inhaled environment 
that can be activating (toll-like receptors [TLR] 
2, 4, 6; IL-1 receptor; IFN-γ receptor; and TNF 
receptor) or suppressive (CD200 receptor, 
signal-regulatory protein α, mannose receptor, 
triggering receptor expressed on myeloid cells 2, 
IL-10 receptor, transforming growth factor [TGF]
β receptor).49 It is clear that close interaction 
and communication between airway epithelial 
cells and airway macrophages is vital for 
maintenance of immune homeostasis within the 
respiratory tract.
At least two distinct macrophage populations 
exist in the lung at homoeostasis, termed AM 
and interstitial macrophages (IM) that are 
characterised by their distinct locations and 
unique functions (Figure 1).50 Located in the 
airway lumen, AM are characterised by high 
expression of CD206, CD11c, and SiglecF+, but 
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lack CD11b, which is expressed by other tissue 
resident macrophages.51 IM conversely lack 
CD206 and SiglecF, are CD11b bright, express 
only low levels of CD11c, and reside in the lung 
parenchyma.51 IM release cytokines associated 
with the adaptive immune response, such as IL-10, 
which exerts a regulatory role in the lung, whereas 
immunosuppressive highly phagocytic AM play 
a central role in maintaining immunological 
homoeostasis.52 Indeed, in steady state, AM are 
largely quiescent, downregulating the phagocytic 
receptor Macrophage 1 antigen, and secrete 
nitric oxide, prostaglandin endoperoxide 2, and 
immunoregulatory cytokines IL-10 and TGFβ to 
prevent uncontrolled inflammation within the 
respiratory tract.
The renewal of AM populations in the steady 
state largely occurs by local precursor-cell 
proliferation, but during inflammation renewal 
occurs via incoming monocytes and is regulated 
through the C chemokine receptor type 2 (CCR2) 
and chemokine ligand 2 (CCL2) axis.53 Of note is 
the functional phenotype of recently recruited 
monocytes contrasts significantly with that of 
lung-resident AM. Monocytes recruited to the 
alveolar space during inflammation display 
a proinflammatory phenotype with elevate 
levels of steady-state TNFα mRNA; increased 
neutrophil chemoattractants macrophage 
inflammatory protein 2 (MIP2), keratinocyte 
chemoattractant, and IFNγ-induced protein 10 
(CXCL10); TLR4 upregulation; and the expression 
of various lysosomal cysteine proteases 
involved in extracellular matrix degradation and 
tissue remodelling processes.54  Specifically, 
monocytes can function as efficient antigen-
presenting cells (APC) before their maturation 
into immunosuppressive AM, which occurs 
over a period of days.55 Interestingly, these 
‘converted’ AM, which become increasingly 
similar to lung-resident AM, can persist for over 
1 year after lung injury and cause profibrotic 
changes.56 The recruited monocyte population 
is heterogeneous, including immature DC, 
which will also enhance T-cell responsiveness 
through exposure to granulocyte-macrophage 
colony-stimulating factor.57 
Lung-Resident Dendritic Cells
In the steady state, lung-resident DC are critically 
involved in antigen uptake and processing 
in the lung but lack the capacity for efficient 
antigen presentation until they migrate to the 
lung-draining lymph nodes.58 However, during 
inflammation, alveolar myeloid DC (AMDC) can 
become potent APC.59 AMDC present with a 
phenotypic profile of high expression of major 
histocompatibility complex Class II and CD205, 
together with low expression of CD8, CD40, 
CD80, and CD86, similar to systemic DC. Other 
distinct subpopulations of lung DC have also 
been identified60,61 within the airway mucosa but 
the main focus during inflammation is attributed 
to the AMDC pulmonary network. AMDC have a 
high turnover rate in the steady state, constantly 
transporting antigens from the mucosa to the 
lung-draining lymph nodes.62 
During lung homeostasis, resident conventional 
DC (cDC) reside in the lung as two 
phenotypically and functionally distinct subsets: 
CD11b+CD103- (cDC2) and CD11b-CD103+ 
(cDC1).63,64 cDC1 are located in the epithelial 
layer, extend their dendrites between epithelial 
cells to capture antigens in the airway lumen, 
and migrate to the lung-draining lymph nodes to 
cross-present to CD8+ T cells during respiratory 
viral infection.65 cDC2 are located in the lamina 
propria and unable to directly penetrate the 
airway lumen and migrate to the lung-draining 
lymph nodes in a later stage of infection, shown 
to coincide with the peak of viral load in the 
lung tissue.65 
pDC in the lungs play an immunoregulatory role 
by influencing regulatory T (Treg) cells66 and have 
recently been implicated in tolerance induction 
to inhaled antigen.67,68 Furthermore, the high 
capacity of pDC to produce IFNα in response 
to microbial stimuli suggests this subset of DC 
may play a critical role in the lung in antiviral 
immunity.69-73 However, it is unlikely that pDC 
migrate out of lung tissues, but instead enter 
the lung-draining lymph node from the blood to 
respond and participate in local inflammation. 
Tissue-Resident Memory Cells
The majority of lung T cells are non-circulating 
tissue-resident memory T cells (TRM), which persist 
in stable frequencies for decades of human life. 
Lung TRM were first identified as CD4+ T cells that 
were retained specifically in the lung in parabiosis 
studies, occupying specific airway niches.74,75 
Displaying a unique transcription profile76,77 
and resident in specific mucosal, barrier, and 
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lymphoid tissues, TRM were distinguished as 
a distinct subset of effector memory T cells 
residing within the epithelium (Figure 1). TRM are 
sufficient to generate local inflammation, even in 
the absence of T memory cells from secondary 
lymphoid organs.78 Present in the healthy lung, 
TRM cells express CD69 and CD103 to promote 
tissue retention, as well as a diverse T-cell receptor 
repertoire.79,80 Recent studies reveal an important 
role for lung TRM in rapid protective immune 
response to maintain tissue homeostasis upon 
exposure to a diverse range of inhaled antigenic 
material, and are also important in surveillance 
for tumours and persistent viruses. Mouse studies 
have revealed the central role of TRM in multiple 
aspects of lung immunity including following 
influenza or respiratory syncytial virus infection81-83 
and in response to allergen exposure,84,85 
indicating high therapeutic potential. 
Regulatory T Cells
Treg appear to be present from birth with 
their inducible phenotype influenced by local 
microbiota from early life.86 Lung-resident Treg 
are central for the maintenance of immune 
tolerance to airborne antigen87 and in the control 
of peripheral T-cell responses.88 Crosstalk between 
AM and T  cells is considered a mechanism 
through which inducible Treg cells are generated 
and allergic responses are dampened.89 Treg cells 
have been shown as critical for lung homeostasis 
with adoptive transfer of inducible Treg cells 
inhibiting allergic inflammation and hyperreactivity 
via production of IL-10.90 Treg cells were also 
shown to attenuate airway hyperresponsiveness 
through recruitment to the airway mucosa 
following the first wave of inflammation triggered 
by allergen inhalation, demonstrating a critical role 
of Treg cells in homeostasis to maintain healthy 
pulmonary function.34
T Helper 17 Cells
T helper (Th)17 cells provide critical immuno-
regulation in the lung through the production 
of IL-17, IL-22, and IL-23. Although the role for 
Th17 cells in lung immune homeostasis remains 
poorly understood, Th17-derived IL-17 plays 
a critical response in early inflammation and 
pathogen clearance in the lung by mobilising 
neutrophils. Th17 cells are induced through the 
production of IL-6, IL-21, and TGFβ in mice and 
IL-6 and IL-1β in humans. Interestingly, Th17 and 
Treg cell differentiation in the lung appears to 
be mutually exclusive with TGFβ inducing Th17 
and Treg cells, although IL-6 inhibits Treg-cell 
differentiation enabling the Th17 population.91,92 It 
has been proposed that the reversal of Treg cell 
suppressive function that is induced by TLR 
activation may be a reflection of an increase 
in Th17 cell differentiation (involving IL-6 and 
TGFβ) rather than a decrease in the ability for 
suppression,91 suggesting a role for Th17 cells in 
re-establishing homeostasis. 
Innate Lymphoid Cells
Innate lymphoid cells (ILC) constitute several 
phenotypically distinct groups of innate 
lymphocytes that lack the usual lineage markers 
that define conventional cells, notably antigen-
specific receptors thus ILC do not mediate 
antigen-specific responses.93 ILC numbers are 
largely tissue-resident, enhanced at barrier 
surfaces, and thought to be vital for maintenance 
of tissue homeostasis, repair, and regulation 
of immunity (reviewed in Borger et al.94).95 
Like effector T cells, ILC have been classified 
according to the transcription factors that they 
express and the effector cytokines that they 
secrete ILC1 (T-bet), ILC2 (Gata3), ILC3 (Rorγt)96 
and can rapidly response to changes in the local 
tissue microenvironment. 
ILC2 are the main population of ILC within the 
lung, shown to direct protective immunity during 
helminth infections: development of allergic 
inflammation, tissue repair, and maintaining 
metabolic homeostasis.93,95,97 In an elegant 
series of parabiotic experiments using the ILC2 
found within the lung were demonstrated to be 
of host origin, indicating residency.98 Moreover, 
virtually all of the ILC2 and ILC1 identified were 
situated within the lung parenchyma rather 
than the circulation, with ILC2 being the major 
population. Somewhat surprisingly, even during 
episodes of inflammation such as during helminth 
infection, expansion of ILC2 was largely due 
to local proliferation rather than recruitment.98 
ILC2 accumulation in the lung can be facilitated 
by interaction with both local stromal cells as 
well as haematopoietic cells. Cytokines secreted 
by pulmonary epithelial cells such as IL-33 and 
TGFβ enhance the accumulation of ILC2 cells 
within the lung, particularly after encounter with 
allergen.99,100 Interestingly, the majority of studies 
to date focus on ILC2, however, ILC3 are in fact 
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the most prevalent group in the human lung 
and their rapid secretion of IL-17A and IL-22 has 
led to their investigation in inflammatory and 
infectious diseases.101 Interestingly, although the 
importance of ILC3 as a source of granulocyte-
macrophage colony-stimulating factor, an 
important cytokine in pulmonary host defence, in 
the lung is unknown, ILC3 in the gut are known to 
orchestrate inflammation.
γδ-T Cells
γδ-T cells constitute 8–20% of resident pulmonary 
lymphocytes, where they respond to danger 
signals and facilitate orchestration of immune 
responses.102 The abundance of γδ-T cells 
maintains lung tissue homeostasis. The lung is a 
major site for homing of γδ-T cells during in the 
perinatal period, with Vγ6+ γδ-T cells the major 
γδ-T cell population from birth until 8–10 weeks 
of age, whereas Vγ4+ γδ-T cells predominate from 
that age on.103 In adult mice, γδ-T cells are divided 
into subsets expressing Vγ4+ (45%), Vγ1+ (15%), 
Vγ6+ (20%), and Vγ7+ (rare).104,105 These γδ-T cells 
are present in all regions of the lung, except for 
the airway mucosa. Interestingly, Vγ4+ and Vγ1+ 
populations have a more parenchyma-biased 
distribution.105 Evidence of lymphoid precursors 
present in the lungs indicates that these cells 
might undergo differentiation and selection in the 
lung environment. 
The γδ-T cells residing in the lung are potent 
producers of IL-17 whereas γδ-T cells expressing 
a different T-cell receptor in the skin, gut, liver, 
spleen, uterus, and peripheral blood can produce 
IL-17 or IFN-γ.106 IL-17 producing cells, such as ILC3, 
γδ-T cells, natural killer T cells, mucosal associated 
invariant T cells, and ILC3, as well as adaptive 
Th17 cells, play distinct roles in host defence 
against diverse pathogens.107 The abundance of 
γδ-T cells in the lung supports tissue homeostasis, 
through potentially a similar IL-17/IL-22 axis as 
ILC3, although γδ-T cells have also been shown to 
play critical roles in bacterial clearance and the 
prevention of inflammation and lung fibrosis.108
In the lung, although little is known of the role of 
γδ-T cells in maintaining pulmonary homeostasis, 
γδ-T cells rapidly respond to pathogens as critical 
effector cells in innate host responses.109 This 
now introduces the question of how γδ-T cells, 
along with other tissue-resident unconventional 
T cells (mucosal associated invariant T cells, 
natural killer T cells) functionally integrate with 
ILC to enhance the innate-like immune response 
(reviewed in Borger et al.110). Whether or not 
these innate-like lymphocytes coregulate one 
another or the adaptive T-cell arm, or function 
independently remains to be answered. Their 
enhanced sensitivity to the changing lung tissue 
microenvironment and rapid innate ability to 
respond to diverse antigens, in participation with 
the almost immediate ability of macrophages 
and neutrophils to phagocytose and degranulate 
and the highly specific response of the adaptive 
arm and generation of memory, demonstrates a 
highly complex spatiotemporal network exists 
in the lung immune system to maintain tissue 
homeostasis and protect from lung injury.
Together the cells of the innate and adaptive 
immune system provide diverse effector and 
regulatory mechanisms that maintain pulmonary 
homeostasis during the persistent challenges of 
aeroallergens, airborne pathogens, and noxious 
agents along the respiratory tract (Figure 2). The 
dysregulation of the exquisite balance between 
effector and regulatory immune processes is 
an important disease mechanism contributing 
to chronic lung disease such as COPD and 
asthma;111,112 in viral, fungal, helminthic, and other 
pathogenic infections;113 and in the development 
of lung cancer.114 COPD, for example, is a 
pathologically complex disease with patients 
presenting with inflamed airways containing 
macrophages, neutrophils, DC, and CD8 T 
cells. The influx of these inflammatory effector 
cells and the activation of tissue-resident 
cells including ILC and γδ-T cells drive airway 
remodelling and parenchymal destruction 
through the secretion of inflammatory mediators 
such as reactive oxygen species; chemokines 
including IL-8, proinflammatory cytokine TNFα, 
IL-1β, IL-6, and IL-17; and proteases including 
matrix metalloproteinase and neutrophil 
elastase. Cigarette smoke, an established risk 
factor for COPD, has been shown to have a 
suppressive effect on innate immune cells within 
the respiratory tract and cause defects in the 
generation of adaptive immunity in the lung.115,116 
In this respect, although the immune cells that 
maintain tissue homeostasis and pulmonary 
function are still abundantly present, they are 
functionally deficient or abnormal. 
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Therefore, it could be surmised that in chronic 
lung disease, and other lung pathologies, 
the immune sentinels responsible for 
pulmonary immune homeostasis have been 
detrimentally reprogrammed.
CONCLUDING REMARKS
Numerous immune cell populations contribute 
to the maintenance of pulmonary immune 
homeostasis, and in many cases exhibit 
phenotypic and functional features that 
appear specifically adapted to the unique 
local lung microenvironments. The immune 
cell network provides efficient surveillance in 
the lung, discriminating between innocuous 
and potentially pathogenic antigens due to 
the unique combination and spatiotemporal 
localisation of immune cells residing in the 
microanatomically distinct lung compartments. 
To fully appreciate the maintenance of lung 
homeostasis, a greater understanding of the 
Figure 2: Effector and regulatory mechanisms that maintain pulmonary homeostasis.
Immune homeostasis in the lung requires an exquisite balance between effector cytokine and soluble factors 
with regulatory cytokines and humoral responses. The immediate innate response made of ‘sensor cells’ including 
granulocytes such as neutrophils and eosinophils, AM, IM, and DC, continually sample and respond to inhaled 
antigens to clear localised infections. This first and immediate line of immune defence secrete various factors such 
as IFN to clear pathogens, and other proinflammatory cytokines including IL-1, IL-6, and TGFβ. Tissue-resident 
innate-like lymphocytes, including ILC, γδ-T cells, and TRM cells, bridge the innate and adaptive immune systems, 
secreting proinflammatory mediators and signals to recruit and activate effector cells from the adaptive immune 
system. Together these cytokines and soluble mediators serve to promote pathogen clearance, tissue repair and the 
maintenance of pulmonary immune homeostasis.
AM: alveolar macrophages; DC: dendritic cells; GM-CSF: granulocyte-macrophage colony-stimulating factor; 
Gran: granulocytes; IM: interstitial macrophages; MIF: macrophage migration inhibitory factor; MMP: matrix 
metallopeptidase; NE: neutrophil elastase; NOS: nitric oxide synthase; PGE2: prostaglandin E2; ROS: reactive oxygen 
species; TEFF: effector T cells; TGFβ: transforming growth factor β; Th17: T helper 17; Treg: regulatory T cells; TRM: 
tissue-resident memory T cells; TSLP: thymic stromal lymphoprotein. 
This figure was produced using images modified from Servier Medical Art (Servier, https://smart.servier.com/, licensed 
under a Creative Commons Attribution 3.0 Unported Licence).
Ɣ𝝳𝝳
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Risk Factors for Severe  
Coronavirus Disease (COVID-19)
Abstract
Background: During the recent coronavirus disease (COVID-19) pandemic there have been 
several studies implicating an association between obesity, COVID-19 severity, and mortality. 
This retrospective study aims to investigate the association between obesity, other risk factors, 
and COVID-19 mortality of patients admitted over a 6-week period to the respiratory units at the 
authors’ hospitals.
Methods: This is a retrospective study of 71 patients who were admitted into a respiratory unit 
over a 6-week period where the data were analysed for correlation between various risk factors, 
COVID-19 severity, and mortality. The statistical analysis was performed using excel statistics and 
SPSS (IBM, Armonk, New York, USA) statistical software. The significance was considered at p<0.05. 
The multivariate analysis, Z-test, Cox regression, Pearson correlation, and Kaplan–Meier analysis 
were used.
Results: The mean age of the patients was 65.8 years (range: 35.0–93.0 years) standard deviation 
(13.21) and the male to female ratio was 2.73 (52:19, respectively). The most frequent comorbidities 
were obesity (42/71; 59%), hypertension (36/71; 50%), diabetes (22/71; 31%), heart disease (13/71; 
18%), respiratory disease (9/71; 13%), and cancer (8/71; 11%). The mean body weight was 83.7 kg (60.4–
147.7 kg) and the mean BMI was 32.2 (22.0–53.0 kg/m2). Smoking was reported in 8 (11%) of the 
patients. There were 20 (83%) mortalities among patients >70 years old (p<0.0001), 20 (83%) deaths 
among male patients (p<0.0001), 14 (58%) deaths among patients with a BMI >25 kg/m2 (p=0.001), 17 
(70%) deaths reported for patients with hypertension (p=0.008), 6 (25%) mortalities for patients with 
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INTRODUCTION
Obesity is suggested as a risk factor for severe 
acute respiratory syndrome coronavirus-2 
(SARS-CoV-2) infection,1,2 though this has not 
been confirmed in randomised trials. In the 
outbreaks of the influenza virus H1N1 and SARS, 
obesity was reported in 23% of patients and was 
a predictor and risk factor for severe disease and 
poor outcomes.3-5 This affinity is based on several 
underlying factors, mostly related to a defective 
immune system, antigen presentations, cellular 
and humoral responses, cytokines activation, 
interleukins interactions, immune system 
regulation, and adipose tissue inflammation.6-10 
According to the Intensive Care Units National 
Audit and Research Centre (ICNARC), once 
the infection is established in patients who 
are obese, it leads to severe outcomes in the 
majority.11 The ICNARC data has shown that 
>73% of newly diagnosed cases of coronavirus 
disease (COVID-19) had a BMI >25 kg/m2, 74% of 
patients needed advanced respiratory support, 
and nearly 50% died in an intensive care unit. 
The health systems in Western countries with high 
rates of obesity, including the UK, have experienced 
challenges whilst managing patients with 
COVID-19. Despite the huge resources and well-
developed health infrastructures, the progression 
to organ failure and death in a significant number 
of patients, unfortunately, has been confirmed.12,13 
The primary endpoint of this article was to 
investigate obesity as a risk factor for mortality in 
COVID-19 patients. The secondary endpoints were 
to assess age, sex, diabetes, cancer, hypertension, 
smoking, and respiratory and cardiovascular 
diseases as risk factors for COVID-19 mortality.
METHODS
Study Design
This was a retrospective study of 71 consecutive 
patients with COVID-19 who were admitted and 
treated at a respiratory unit (RU) at the authors’ 
hospitals. The data was initially retrospectively 
collected but subsequently populated 
prospectively during the hospital stay and then 
analysed. All patients showed severe symptoms 
of COVID-19 and tested positive for SARS-
CoV-2 on a reverse transcriptase–PCR assay 
after a nasopharyngeal swab. All 71 patients (age 
range: 35–93 years) were admitted to the RU 
with hypoxaemia.    
Setting
In the university hospitals, the RU was 
managed and supervised by a consultant 
respiratory physician. Patients were admitted 
to the intensive therapy unit (ITU) if they failed 
respiratory management. 
Data Collection 
The data were collected by the respiratory 
and ITU teams over a 6-week period. Initially 
retrospectively, then prospectively, the data 
were collected as the patient’s clinical condition 
developed. The data were collected from case 
notes and clinical electronic systems; they were 
saved on Microsoft Excel files with a secured, 
encrypted password that could only be accessed 
by the research team. The anonymous data 
were then passed over to another research team 
to analyse.
Variables
The variables included age, sex, BMI, smoking, 
respiratory and cardiovascular disease, 
hypertension, diabetes, and cancer. The mortality 
was calculated for each of these risk factors. The 
data source was the daily patient records from 
the RU and ITU.
Bias
This is a retrospective study of a cohort of 
patients; there was no selection bias as all 
patients were included over the 6-week study 
cardiovascular disease (p=0.001), 14 (30%) deaths among patients who were mechanically ventilated 
(p=0.00028), and 5 (20%) mortalities among patients with cancer (p=0.003).
Conclusions: Obesity, cancer, mechanical ventilation, male sex, intensive care unit admission, 
cardiovascular disease, and hypertension are significant risk factors for mortality in patients 
with COVID-19.
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period. The clinical decisions were governed by 
clinical guidelines and supervised by experienced 
consultant physicians.
Quantitative Variables
The most important demographic features, 
comorbidities, and mortality rates were reported. 
The data were added to the Microsoft Excel file 
as they emerged, which was frequently both 
during admission and during progression of 
the disease. 
Statistical Analysis 
Microsoft Excel statistics and XLSTAT (Addinsoft, 
Paris, France) statistical software was used. The 
mean was used to compensate for missing data 
related to smoking and BMI. The rest of the data 
for all patients were available and there was no 
loss to follow-up. The significance was considered 
at p<0.05. Z-test, multivariate analysis, logistic 
regression, and correlation tests were used. Cox 
regression analysis was used to assess the survival 
and calculate the proportional hazard ratios. A 
Kaplan–Meier survival graph was produced to 
show the survival pattern (Figure 1). 
RESULTS
All of the patients’ data were included at all stages 
of the study. The mean age of the patients was 
65.8 years (range: 35–93 years) and the male to 
female ratio was 2.73 (52:19). The most frequent 
comorbidities were diabetes (22/71; 31%), heart 
disease (13/71; 18%), hypertension (36/71; 50%), 
respiratory disease (9/71; 12.7%), and cancer 
(8/71; 11%).
The mean body weight was 83.7 kg (60.4–147.7 kg) 
and the mean BMI was 32.2 (standard deviation 
[SD]: 6.8; range: 22.0–52.0 kg/m2). Seventeen 
patients (24%) were managed at Level 2 of care, 
while 54 were managed at Level 3 of care. The 
mean number of days needed by the patients to 
achieve >40% fraction of inspired oxygen (FiO2) 
was 1.09 days (SD: 1.23). The mean O2 after 12 
hours of starting continuous positive airway 
pressure (CPAP) was 10.35 L/min (SD: 4.38); the 
partial pressure of oxygen before CPAP (SpO2 
pre-CPAP) was 93.60% (SD: 0.04); the FiO2 (last 
pre-CPAP) was 69.80% (SD: 0.13); the SPO2/FiO2 
ratio pre-CPAP was 1.40 (SD: 0.37); the mean 
respiratory rate pre-CPAP was 24.68 breaths per 
minute (SD: 4.97); the mean days on CPAP was 
3.71 (SD: 2.23); and the mean maximum positive 
end-expiratory pressure (PEEP) was 12.78 cmH2O 
(SD: 2.27).
Of the 71 patients, 25 (35%) were discharged, 
while 46 (65%) were intubated and managed at 
Level 3 of care. 
Figure 1: Kaplan–Meier survival graph.
COVID-19: coronavirus disease.
 
Survival
0    5     10     15     20       25        30
1.0
0.8
0.6
0.4
0.2
0.0
Su
rv
iv
al
 p
ro
b
ab
ili
ty
Time
COVID-19
Creative Commons Attribution-Non Commercial 4.0 November 2020  •  RESPIRATORY 123
Twenty-eight patients (39%) were mechanically 
ventilated. Ten patients (14%) died in the RU and 
the total mortality up to the date of writing this 
report was 24 (34%). At present, 16 patients (23%) 
are still in hospital. The mean length of stay was 
10.3 days (SD: 4.9), the mean C-reactive protein 
level on admission was 147.30 mg/L (SD: 99.93), 
the peak C-reactive protein was 264.42 mg/L (SD: 
113.99), and the D-Dimer mean was 9,742 ng/mL 
(range: 224–80,000 ng/mL; SD: 22515) (Table 1). 
The incidence of obesity in this cohort of patients 
was 59%. The length of hospital stay ranged from 
5 to 19 days (SD: 4.9), excluding the 16 patients 
still in hospital at the time of writing.
BW: body weight; COPD: chronic obstructive pulmonary disease; CVD: cardiovascular disease; HDU: high 
dependency unit; ITU: intensive therapy unit.
Table 1: Characteristic features and mortality.
Number (%) Standard 
deviation
Respiratory HDU outcome p value
Died/ITU  
n (%)
Discharged/alive 
n (%)
Mean age (years)
>70
<70
65.8
33 (46)
38 (54)
13.2
20 (83)
4 (17)
13 (39)
34 (89)
<0.0001
Male 52 (73) - 20 (83) 32 (61) <0.0001
Female 19 (27) - 4 (17) 15 (79) 0.17
Mean BW (kg) 83.65 22.1 - - -
BMI >25
BMI <25
Mean BMI
56 (79)
15 (21)
32.2
-
-
6.8
14 (58)
6 (26)
42 (75)
9 (60)
0.001
Diabetes 22 (31) - 6 (25) 16 (72) 0.217
COPD 9 (13) - 5 (20) 4 (44) 0.140
Smoking 21 (13) - 9 (37) 12 (57) 0.352
Cancer 8 (11) - 5 (20) 3 (38) 0.003
CVD 13 (18) - 6 (25) 7 (54) 0.001
Hypertension 36 (50) - 17 (70) 16 (44) 0.008
Level 2 of care 17 (24) - 10 (14) 7 (10) 0.448
Level 3 of care 54 (76) - 14 (19) 40 (56) 0.006
Mechanical 
ventilation
46 (65) - 14 (30) 32 (70) 0.00028
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Multivariate analysis showed a significant 
association between all the aforementioned risk 
factors (except chronic obstructive pulmonary 
disease [COPD] and diabetes; p=0.140 and 
p=0.217, respectively) and COVID-19 mortality 
(p=0.000172). There were 20 (83%) mortalities 
among patients >70 years old (p<0.0001) and 20 
(83%) deaths among male patients (p<0.0001). 
There were 14 (58%) deaths among patients with 
a BMI >25 kg/m2 (p=0.001), 17 (70%) deaths 
among patients with hypertension (p=0.008), 
6 (25%) mortalities among patients with 
cardiovascular disease (p=0.001), 9 (37%) deaths 
among those who smoked (p<0.00001), and 5 
(20%) mortalities among patients with cancer 
(p=0.003). On multi-regression analysis, BMI 
(p<0.0001), cancer (p=0.003), and smoking 
(p<0.0001) significantly predicted mortality 
(Table 1). Cox regression analysis showed an 
increased proportional hazard ratio for age, heart 
disease, hypertension, cancer, obesity, sex, and 
the need for mechanical ventilation (Table 2).
DISCUSSION
The most striking findings of this study are that 
obesity is pivotal in severe COVID-19 progression 
and mortality (p=0.043). Obesity is a complex 
disease with several factors increasing the 
likelihood of severe disease and mortality 
in cases of COVID-19, among them being a 
local prevalence of obesity; the associated 
comorbidities of obesity such as diabetes, 
cardiovascular, stroke, respiratory disease, 
and defective innate and adaptive immune 
responses; and the exposure of the patients 
to the virus because of their frequent hospital 
visits and need for medical support.14-16 It is not 
surprising that a significant number of severe 
COVID-19 cases led to mortality in highly prevalent 
areas for obesity such as the USA17 and the UK.11
A recent meta-analysis showed that obesity, age, 
critical illness, the need for advanced respiratory 
support, and severe comorbidities are risk factors 
for mortality in patients with COVID-19.18 Obesity 
is thought to be a major risk factor for COVID-19 
mortality because of the impaired immune 
response, cellular failure to control the infection, 
and the effect of adipose tissue mass, to which the 
virus affinity is higher than to the lung tissues.19,20 
The overexpression of inflammatory adipokines 
from visceral fat depots can affect the immune 
response, impair the chemotaxis, and alter the 
macrophage differentiation.21 Other publications 
had confirmed the association between obesity 
and mortality and leading organisations such 
as the British Obesity and Metabolic Surgery 
Society (BOMSS) have called for increasing 
bariatric surgery capacity to protect patients 
with obesity and reduce the definitive risks if they 
go on to develop COVID-19.22
The mean age of the participants was of 65.8 
years, and several studies on COVID-19 have 
confirmed that elderly people are likely to 
experience the severe form of the infection.23,24 
Other important features strongly associated 
with COVID-19 mortality are male sex, heart 
disease, respiratory disease, and cancer. Previous 
studies have also shown the vulnerability of 
hypertensive patients for severe infection.25 
It is known that the virus attaches itself to cells 
via the angiotensin-converting enzyme-2 (ACE2) 
receptors for purposes of entry, replication, 
and subsequent shedding.26 ACE2 are a usual 
target in the management of hypertension as 
their receptors are abundant in the lung, heart, 
kidney, and gastrointestinal tract. Administering 
ACE2 inhibitors blocks the receptors and 
reduces angiotensin-1. Angiotensin II receptor 
blockers are able to reduce inflammation and 
could diminish the potential for the development 
of either acute respiratory distress syndrome, 
myocarditis, or acute kidney injury, which is 
known to occur in patients with COVID-19.27 
Several studies have reported hypertension 
as an indicator of severity without adjusting 
the confounding factors. The accurate 
association is not known and larger studies 
are needed to address this controversy.28,29 
 
Smoking is frequently reported in cases of 
COVID-19, and it is a risk for severity, ITU 
admission, and mortality;30 this is because 
smoking increases the levels of goblet cells and 
ACE2 receptors. Theoretically speaking, higher 
levels of smoking leads to additional ACE2 
receptors which gives more opportunity for the 
SARS-CoV-2 to attach to cells.31 If the viral load 
is high, then the expected outcome is a severe 
disease and possible mortality. 
It is, however, not clear whether ex-smokers will 
be at as high a risk as current smokers, and more 
studies are needed to elucidate this. 
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Again, confounding factors that need 
adjustment must be observed before jumping 
to the conclusion of significance as deemed by 
statistical tests. 
Additionally, cardiovascular disease is a predictor 
for COVID-19 severity, ITU admission, and 
mortality. This again is linked to ACE2 receptors 
and progression to myocarditis, heart failure, 
and death.32
Patients with COPD are also at significant risk 
of poor COVID-19 disease progression and 
mortality. Many other studies have shown 
similar outcomes in patients with COPD and 
COVID-19,24,33,34 where significant number of 
patients were admitted to the ITU or had to 
undergo CPAP ventilation.35,36
Patients with cancer are especially vulnerable to 
infection and severe outcomes because of poor 
general health, immunosuppression, and the 
type of cancer and anticancer treatment regimen 
they are following.37,38 Cancer was significantly 
associated with mortality in the patients in this 
study (p=0.003). 
In this study, diabetes was a predicter of mortality 
in linear regression; however, it did not reach 
statistical significance in multivariate analysis 
(p=0.491). Several reports on patients with 
diabetes have shown a strong association between 
vulnerability, severe disease progression, and 
mortality when presenting with COVID-19.23,39-41 
This is likely because of immunosuppression, 
defective metabolic systems, and associated 
morbidities of chronic complications of 
diabetes such as cardiovascular, renal, and 
cerebrovascular disease.
As this study is relatively small, caution should 
be taken when considering the generalisability 
of the results. It is, however, one of several 
studies to provide evidence on obesity as a risk 
factor for COVID-19 mortality.
Limitations 
Firstly, this is a cohort of consecutive 
patients who were admitted to the RU for 
respiratory support and possible escalation to 
the ITU. It is a relatively small study; however, the 
sample representation was adequately powered 
for statistical analysis. Secondly, a significant 
number of patients are still in hospital and are 
therefore not available for mortality analysis.
Table 2: Cox regression analysis variables.
95% CI for Exp(B)
B SE Wald DF Sig. Exp(B) Lower Upper
Age 0.064 0.030 4.626 1 0.031 1.066 1.006 1.130
Smoking -0.503 0.574 0.768 1 0.381 0.605 0.196 1.863
Diabetes -0.113 0.585 0.037 1 0.847 0.893 0.284 2.812
Heart disease 0.554 0.594 0.867 1 0.352 1.740 0.543 5.578
Hypertension 1.215 0.562 4.677 1 0.031 3.369 1.121 10.131
Respiratory 
disease
-0.472 0.955 0.245 1 0.621 0.623 0.096 4.050
Cancer 1.261 0.743 2.882 1 0.090 3.529 0.823 15.136
BMI 0.072 0.765 0.009 1 0.925 1.074 0.240 4.817
Sex 0.382 0.625 0.373 1 0.541 1.465 0.430 4.988
Mechanical 
ventilation
0.418 0.546 0.585 1 0.445 1.518 0.521 4.428
B: exponential; CI: confidence interval; DF: Dickley–Fuller test; SE: standard error; sig: significance test; Wald:  
Wald test.
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CONCLUSIONS
This is one of several clinical studies to confirm 
obesity as a risk factor for COVID-19 mortality. 
Cancer, smoking, cardiovascular disease, and 
hypertension are also additional risk factors 
for mortality. 
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Effects of Noninvasive Versus Invasive  
Mechanical Ventilation on Sleep in the  
Intensive Care Unit – A Pilot Study
Abstract
Rationale: Use of noninvasive ventilation (NIV) has increased in intensive care units, but sleep during 
NIV has received little attention. The authors surmised that due to frequent air leaks and mask 
discomfort, patients receiving NIV would manifest poorer sleep quality than those receiving invasive 
mechanical ventilation (INV). 
Methods: A prospective observational study on patients receiving NIV or INV for respiratory failure in 
a medical intensive care unit or coronary care unit. Patients were monitored by polysomnography for 
24 hours with simultaneous collection of data on ventilator and environmental parameters. 
Results: Eight subjects in each group were studied. Mean total sleep time was 7.29 +1.78 hours 
(range: 0.57–13.82) in the NIV versus 11.74 +0.65 hours (8.95–15.19) in the INV group (p=0.034). Sleep 
efficiency was lower in NIV than INV group (30.4% versus 53.3%, respectively; p=0.013). The NIV 
group had lighter sleep than the INV group (mean % of Stage 1: 36.9% versus 17.2% of total sleep time, 
respectively; p=0.000), whereas no significant differences were found for other stages. Median total 
arousal and awakening indexes were higher in the NIV group (16.8/hour versus 4.4/hour and 5.3/hour 
versus 2.1/hour, respectively; p=0.005), as well as spontaneous arousals and awakenings (p=0.006 
and p=0.005, respectively). Sedation was provided mostly by intermittent bolus in the NIV group 
whereas often by infusion in the INV group. 
Conclusion: Compared to INV, NIV in critically ill patients was associated with poorer quality and 
quantity of sleep. Future studies should determine whether adjustments in ventilator settings, mask 
type or fit, or use of sedation/analgaesia can improve sleep in patients receiving NIV. 
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INTRODUCTION
Disruption of sleep is remarkably common in 
critically ill patients.1-3 Abnormalities of sleep 
in this population include sleep deprivation, 
sleep fragmentation, and alterations in sleep 
architecture and circadian rhythm. These 
abnormalities may lead to undesirable 
consequences, such as delirium, delayed weaning 
in intensive care units (ICU), or late noninvasive 
ventilation (NIV) failures.4-6 Mechanical ventilation 
is one of the important factors associated with 
sleep disturbances in the ICU.3,7,8
NIV has been increasingly used in ICU.9-11 Although 
recognition of the importance of poor sleep in 
mechanical ventilation patients is increasing, only 
a few studies have investigated the effect of NIV 
on sleep in patients with acute respiratory failure 
(ARF).5,12 Earlier studies focussed on patients 
with chronic respiratory failure.13,14 Air leaking was 
associated with frequent arousals during lighter 
stages of sleep and decreased sleep efficiency 
and durations of slow-wave sleep (SWS) and 
rapid eye movement (REM) sleep.13,14 Sleep studies 
on hypercapnic ARF patients receiving NIV in the 
ICU showed similar sleep architecture changes.5,12 
The authors hypothesised that because of 
frequent air leaks and mask discomfort, patients 
receiving NIV would manifest poorer sleep 
quality than those receiving invasive mechanical 
ventilation (INV). Therefore, they aimed to define 
and compare sleep characteristics in critically ill 
patients receiving NIV and INV during a 24-hour 
monitoring period.  
METHODS
Patients
This prospective, observational, pilot study was 
conducted in critically ill adult patients undergoing 
INV or NIV for ARF in the medical ICU unit or 
coronary care unit (CCU) at Tufts Medical Center, 
Boston, Massachusetts, USA. The Institutional 
Review Board of Tufts Medical Center approved 
the study (Tufts ID #8053).15 Written informed 
consent was obtained from all participants or 
their families. 
All adult patients receiving NIV or INV for ARF 
in the medical ICU or CCU and anticipated to 
be continuing NIV for >8 hours/24 hours or INV 
for 24 hours were eligible and screened on the 
days when the primary researcher (Dr Ugurlu) 
was available. All patients were in private rooms 
that could be isolated from the nursing station 
through a sliding glass door. 
Exclusion criteria are listed as presence of 
premorbid diseases that could interfere with 
application or interpretation of sleep monitoring 
(including central nervous system disorders, 
dementia, known sleep disorders); previous home 
treatment with bilevel positive airway pressure 
(BiPAP) or continuous positive airway pressure; 
depressed sensorium (Riker score: <2); presence 
of head trauma, psychiatric illness, anoxic brain 
injury, drug overdose, or uncontrolled seizure 
disorder; severe haemodynamic instability; 
recalcitrant hypoxaemia (inability to sustain 
oxygen saturation  >88%); and tracheostomy.
All patient care decisions (supportive care 
and mechanical ventilation) were made by the 
ICU team and not by any investigator during 
the study. Respiratory therapists, nurses, and/
or critical care physicians periodically checked 
patients to ensure that the subjects were adapted 
to the NIV use (proper mask fit, synchrony with 
ventilation, etc).
Polysomnography and Scoring 
Continuous 24-hour standard polysomnography 
(PSG) utilising portable noninvasive PSG 
monitoring equipment (Grass Comet, West 
Warwick, Rhode Island, USA)  was conducted 
with simultaneous monitoring of noise. The staff 
attending the study fixed displacing leads.
Sleep studies were continuously attended 
and scored manually according to standard 
criteria16,17 by a registered PSG technologist 
and then reviewed in total by a sleep specialist 
blinded to mode of ventilation (Dr D’Ambrosio). 
Circadian sleep distribution was evaluated by 
separating the total recording time into a daytime 
segment (6 AM–10 PM) and a nocturnal segment 
(10 PM–6 AM).  
Sleep efficiency was defined as the ratio of 
time asleep to total recording time. Total sleep 
time (TST) was defined as the sum of total time 
spent in any sleep stage during total recording 
time. The percentage of time spent in each sleep 
stage during TST was calculated. The sleep 
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fragmentation index was defined as the number 
of arousals and awakenings per hour of sleep. 
Arousals and awakenings caused by noise, patient 
care activities, patient–ventilator asynchronies 
(including auto-triggering, ineffective triggering, 
and double triggering, based on inductance 
plethysmography and airway pressure 
measurements), or mask leak (based on leak 
and airway pressure monitoring) were defined as 
those occurring within 3 seconds of termination 
of these events. The rest of the arousals or 
awakenings were defined as spontaneous.
Environmental Monitoring
Environmental noise was continuously monitored 
by a sound level meter (Extech Instruments, 
Nashua, New Hampshire, USA) secured to the 
head of the bed, and simultaneously recorded 
on the PSG. The ceiling fluorescent light turned 
on throughout the daytime and turned off at 
night, except during nursing care. The bedside 
environment was monitored by the staff, who 
recorded the time and duration of all activities 
(including interactions between the patients 
and the visitors or critical care team member, 
nursing care, and procedures) on the patient’s 
bedside diary. 
Data Collection
Data included demographics, date and time 
of hospital and ICU/CCU admission, admitting 
diagnosis, causal diagnosis, and reason for 
mechanical ventilation. Further data included type 
of mechanical ventilation, settings, sedation level, 
medications, last arterial blood gas measurement, 
and last chest X-ray findings. Acute physiology 
and chronic health evaluation II (APACHE II) 
score was calculated on the day of the sleep 
study using the most abnormal values during the 
24-hour PSG period. Additionally, the investigator 
attending the sleep study recorded all pertinent 
events and times in a bedside log.  
Statistical Analysis 
This study was performed as a pilot and no 
previous study has compared sleep patterns 
during NIV and INV in critically ill patients. 
Accordingly, no power analysis was proposed. 
Statistical analysis was performed using SPSS 
statistical software (SPSS 17.0, Chicago, Illinois, 
USA). Continuous variables were expressed as 
median (interquartile range) or mean±standard 
error of mean with minimum and maximum 
values, based on the distribution of data. Variables 
were compared using chi-squared test or Mann–
Whitney U test. A two-tailed p value <0.05 was 
considered statistically significant.
RESULTS
Patient Demographics
Out of 383 patients with ARF anticipated to 
continue using NIV or INV for >24 hours, 346 
patients were excluded (central nervous system 
disorder/injury: 170; depressed sensorium: 51; 
tracheostomised: 33; previous home continuous 
positive airway pressure/BiPAP: 26; known 
sleep disorder: 22 [not using NIV at home]; 
severe haemodynamic instability: 17; unstable 
status: 17; legal issues: five [e.g., prisoner, no 
relatives]; diffuse skin lesions: three; recalcitrant 
hypoxaemia: two). Furthermore, 17 patients 
refused enrolment. Overall, 20 patients were 
enrolled to the study; however, a total of four 
patients were excluded after enrolment because 
of early extubation (<24 hours) in the INV group 
(three patients) or early intubation (<24 h) in the 
NIV group (one patient). 
The study population characteristics are provided 
in Table 1. Chronic obstructive pulmonary disease 
and heart diseases (including coronary arterial 
disease, rhythm disorders, and congestive heart 
failure) were the predominant comorbidities in 
both the NIV and INV groups (Table 1). Although 
there was no statistically significant difference in 
the comparison of causal diagnoses, there tended 
to be more acute-on-chronic respiratory failure 
in the NIV group and more de novo respiratory 
failure in the INV group.  
Characteristics of Mechanical 
Ventilation at Initiation of the Study
All patients in the NIV group were on BiPAP 
delivered through dedicated ventilators. Mean 
inspiratory and expiratory positive airway 
pressures were 11±0.7 (8–15) and 5.1±0.1 (5–6) 
cmH2O, respectively. All INV patients were on 
volume-limited assist-control ventilation with a 
mean tidal volume of 507.9±24.6 (350–550) mL 
(7.1±0.3 mL/kg per ideal body weight), similar to 
NIV patients (441.3±24.4 [316–512] mL [7.8±0.7 
mL/kg per ideal body weight]). 
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Mean fraction of inspired oxygen and mean 
set respiratory rate in the NIV and INV groups 
were 52.5±7.5 versus 40±3.3% (p=0.14) and 
10.5±1.1 versus 13.3±0.8 beats per minute 
(p=0.06), respectively.  
Sleep Architecture of Patients
Compared to INV patients, NIV patients slept less 
and had lower sleep efficiency (Table 2). 
Noninvasive ventilation 
group
(n=8)
Invasive mechanical 
ventilation group
(n=8)
p value
Age (years) 72.6±3.1 (54–85) 64.1±4.6 (38–78) NS
Male (n [%]) 3 (37.5) 8 (100) 0.013
BMI (kg/m2) 25.7±6.37 (16.2–36.0) 26.8±8.22 (16.9–44.3) NS
Location (MICU/CCU) 5/3 5/3 NS
Causes of ARF (n)  NS 
Acute pulmonary oedema 2 1
ARDS 0 2
Cardiopulmonary arrest 0 1
COPD exacerbation 1 0
Haemoptysis 0 1
Lung cancer 0 1
Neuromuscular disease 1 0
Pneumonia 1 1
Pulmonary emboli 1 0
Restrictive lung disease* 2 0
Sepsis 0 1
At the initiation of study: 
duration of MV† (day)
1 (1.00–3.25) 4 (1.00-5.00) NS
Apache II score 20.4±2.3 (13–28) 13.4±1.9 (6–21) 0.039
Vitals NS
Heart rate (bpm) 83.6±6.1 (58–105) 83.5±3.5 (68–97)
Respiratory rate (bpm) 22.1±2.4 (10–32) 20.1±1.5 (13–25)
Systolic blood pressure 
(mmHg)
106.5±5.3 (90–129) 114.8±6.3 (90–140)
Diastolic blood pressure 
(mmHg)
55.6±5.2 (38–81) 56.9±3.2 (42–66)
Arterial blood gases
   pH 7.25±0.03 (7.26±7.48) 7.44±0.01 (7.36–7.49) 0.022
   PaCO2 49.4±5.6 (34–68) 42.4±1.1 (38–48) NS
   PaO2/FiO2† 290 (220–410) 180 (160–240) NS
*Restrictive lung disease was due to pleural effusion.
†Values are given in median (IQR). The rest of the values were given as mean±SEM (min–max). 
ARDS: acute respiratory distress syndrome; ARF: acute respiratory failure; bpm: beats per minute; CCU: coronary care 
unit; COPD: chronic obstructive pulmonary disease; FiO2: fraction of inspired oxygen; IQR: interquartile range; max: 
maximum; MICU: medical intensive care unit; min: minimum; MV: mechanical ventilation; NS: not significant (p>0.05); 
PaCO2: partial pressure of carbon dioxide; PaO2:  partial pressure of oxygen; SEM: standard error of the mean.
Table 1: Characteristics of the patients (N=16).
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Sleep efficiency was significantly lower during 
the daytime in the NIV group, but not during the 
night. The NIV group also had an increased mean 
percentage of Stage 1 sleep than the INV group 
and a reduced percent of SWS. When one patient 
with non-REM sleep that was inconsistent with 
normal due to the absence of typical Stage N2 
sleep figures was excluded,5 the significance for 
the difference of SWS was lost (p=0.07). REM 
sleep was virtually absent in both groups. 
Sleep of NIV compared to INV patients was also 
more fragmented, with increased frequency of 
arousals and awakenings (Table 2). Although 
arousals as a result of ventilator asynchrony 
tended to be more frequent in NIV patients, the 
difference was not statistically significant. Only 
two NIV patients had respiratory event related 
arousals (7.4 and 8.4/hour) during spontaneous 
breathing and none during NIV use. Therefore, 
median number of arousals related to respiratory 
Noninvasive ventilation 
group
Invasive mechanical 
ventilation group
p value
TST (hours) 7.3±1.8 (0.6–13.8) 11.7±0.7 (9.0 –15.2) 0.034
Day/night (% of TST) 57/43 60/40 NS
Sleep efficiency (%)
  Total 30.4±7.5 (2.4–57.6) 53.3±3.1 (37.5–64.0) 0.013
  Daytime (6 AM–10 PM) 23.5±6.4 (3.7–51.6) 50.1±2.8 (34.9–57.4) <0.001
  Night-time (10 PM–6 AM) 44.2±10.3 (0.0–74) 58.9±5.0 (36.0–77.3) NS
 Stage 1 (% of TST) 36.9±3.3 (23.7–53.0) 17.2±2.8 (3.3–26.9) <0.001
 Stage 2 (% of TST) 57.1±3.1 (46.2–70.6) 64.8±6.2 (26.4–86.8) NS
 SWS* (% of TST) 1.4 (IQR 0.0–4.5) 9.5 (IQR 5.5–17.3) 0.04
 REM* (% of TST) 0.6 (IQR 0.0–2.9) 0.0 (IQR 0.0–1.1) NS
Total fragmentation  
index/hour
22.4 (IQR 14.0–39.5) 6.3 (IQR 5.2–11.4) 0.003
Arousal index*/hour 16.8 (IQR 9.1–31.8) 4.4 (IQR 3.7–8.5) 0.005
Spontaneous arousal index* 14.1 (IQR 7.4–17.9) 3.2 (IQR 2.2–4.2) 0.006
Ventilator asynchrony-air leak 
associated arousal index*
2.2 (IQR 0.1–10.9) 0.1 (IQR 0.0–1.5) NS
Noise associated arousal 
index*
0.7 (IQR 0.1–1.1) 0.4 (IQR 0.2–0.5) NS
Patient care associated 
arousal index*
0.5 (IQR 0.0–1.2) 0.6 (IQR 0.3–1.2) NS
Awakening index*/hour 5.3 (IQR 4.9–6.8) 2.1 (IQR 1.7–3.0) 0.005
Spontaneous awakening 
index*
2.6 (IQR 2.0–4.9) 1.0 (IQR 0.6–1.4) 0.005
Ventilator asynchrony-air leak 
associated awakening index*
1.4 (IQR 0.0–1.7) 0.2 (IQR 0.1–0.2) NS
Noise associated awakening 
index*
0.4 (IQR 0.1–0.7) 0.3 (IQR 0.1–0.3) NS
Patient care associated 
awakening index
0.5±0.2 (0.0–1.7) 0.8±0.1 (0.3–1.4) NS
Table 2: Comparison of sleep characteristics between patients treated with noninvasive ventilation and invasive 
mechanical ventilation.
*Values are given in median (IQR). Rest of the values are given as mean±SEM (min-max). 
IQR: interquartile range; max: maximum; min: minimum; NS: not significant (p>0.05); REM: rapid eye movement; SEM: 
standard error of the mean; SWS: slow-wave sleep; TST: total sleep time. 
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events was negligible (0 in both groups; p>0.05). 
Sleep architecture and circadian rhythm varied 
greatly between patients (Figure 1).
Vital Signs and Duration of Noninvasive 
Ventilation Use
Vital signs (including heart rate, respiratory rate, 
diastolic blood pressure, and oxygen saturation) 
recorded hourly during the study were similar in 
both groups except for systolic blood pressure, 
which was lower in the NIV group than the INV 
group (median systolic blood pressure of 107 
[100–112] versus 123 [112–125]; p=0.04). 
NIV was applied continuously in two patients and 
intermittently in six patients. For those six patients, 
NIV was applied 70% of the total recording time 
with a mean sleep efficiency of 39%, and it was 
removed 30% of the time (with application of O2 
via nasal cannulae) with a mean sleep efficiency 
of 7.8% (p=0.045). 
Use of Sedation and Analgesia
NIV patients received more intermittent sedation 
and less sedation overall than INV patients 
(p=0.001). Two of the NIV patients received 
no sedation; the other NIV patients received 
morphine (two patients), diphenhydramine, 
(two), lorazepam (one), quetiapine (one), 
and hydromorphone (one), all intermittently. 
The sedative agents used by the INV group 
were fentanyl (seven patients), propofol 
(three), midazolam (five), hydromorphone 
(two), quetiapine (one), and lorazepam (one). 
Two INV patients received only continuous 
sedation protocols, whereas six of them 
received not only continuous sedation, but also 
intermittent boluses. 
Long-Term Outcomes
Three of the NIV patients were intubated and 
eventually died (1–5 days and 4–11 days after 
the termination of the study, respectively), and 
two of the INV patients died (10 days after the 
termination of the study). The mean TST of the 
NIV patients requiring intubation was longer than 
other NIV patients, but this was not statistically 
significant (9.2±4.0 [1.2–13.8] versus 6.2±1.8 [0.6–
10.7] hours, respectively; p>0.05), whereas the 
mean APACHE II score was higher on the day of 
the study (26.0±2.0 [22–28] versus 17.3±1.8 [13–
22], respectively; p=0.02). Mean hospital and ICU 
lengths of stay were similar between the NIV and 
INV groups (18±1.1 [10–23] versus 19.8±3.1 [7–35] 
days, and 14.0±2.2 [5–21] versus 14.9±3.2 [5–34] 
days, respectively; p>0.05). 
DISCUSSION
This first pilot study comparing sleep architecture 
in patients receiving NIV and INV for management 
of ARF in the ICU found that NIV patients 1) were 
sicker based on higher APACHE II scores and 
lower pH; 2) slept less and lighter in 24 hour; 3) 
had more fragmented sleep; and 4) received less 
sedation. Fragmentation of sleep was mainly 
due to spontaneous arousals and awakenings. 
Although arousals due to ventilator asynchronies 
(including asynchronies due to air leakages) 
were more common during NIV than INV use the 
difference was not significant. Noise and patient 
care contributed little to the sleep fragmentation. 
Lengths of stay and mortality outcomes were 
similar between groups although the number of 
patients was small. 
Sleep abnormalities in critically ill patients have 
been repeatedly reported over the past three 
decades.5,12,18-32 Most of the studies performed in 
intubated patients reported normal or near normal 
duration of sleep (6–8 hours/24 hours),18-20,28,32 
although some studies revealed a decreased 
TST,20,22,23,31 and others showed longer durations 
of sleep.21,24,30 In this study, patients on NIV had 
shorter TST with lower sleep efficiency than 
patients receiving INV. The TST of NIV patients 
from this study were similar to those reported for 
NIV patients previously,5,12 whereas INV patients 
would have been considered ‘long sleepers’ as 
described by others.21,24,30 The shorter TST of 
NIV compared to INV patients could be related 
to many factors including the higher severity of 
illness of this study’s NIV population and more 
frequent and continuous use of sedatives in 
the INV patients. Furthermore, the NIV patients 
had received less ventilatory assistance than 
the INV patients (median 1st day versus 4th day) 
before enrolment and could have been less well 
acclimated. Furthermore, patients on both types 
of ventilation varied greatly in sleep duration, 
ranging from 0.6 to 15.2 hours over 24 hours. This 
corresponds with prior studies18,19,32 and probably 
reflects the great variability between patients 
in acuity of illness, use of and responsiveness to 
medications, and many other possible factors.7 
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Figure 1: 24-hour hypnograms of six patients.
A, B, C in noninvasive ventilation group and D, E, F in invasive mechanical ventilation group (X axis is the timeline). 
The circadian rhythm was partly conserved in some patients (B and F) but lost in others (A and D). Total sleep time 
was severely decreased in two of the noninvasive ventilation patients who slept <2 hours (C). One of the patients on 
invasive mechanical ventilation had an abnormal sleep pattern with increased slow-wave sleep (E). 
EPAP: expiratory positive airway pressure; IPAP: inspiratory positive airway pressure; REM: rapid eye movement.
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Previous ICU studies have shown disruption of 
the circadian pattern with increased napping so 
that daytime sleep reached up to an average of 
60% of TST in a 24-hour cycle.18-20 Similarly, the 
patients of this study in both groups slept around 
60% of the TST during the daytime. 
Patients on mechanical ventilation in ICU generally 
have diminished sleep quality, characterised 
by an increase in the proportion of time spent 
in ‘light’ stages of sleep and a decrease in the 
proportion or even absence of slow wave or REM 
sleep.19,23,24,31,32 Consistent with these observations, 
patients of this study, especially the ones on 
NIV, also manifested a greater than normal 
proportion of time spent in lighter stages 
of sleep. REM sleep was observed only in 
four NIV and two INV patients with a range 
Arousal
Arousal
Arousal
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of 1.2 to 11.5% of TST. Still, sleep efficiency was 
better preserved during application of NIV 
compared to breaks off NIV, consistent with 
prior observations, but this might be related to 
increased patient activities during breaks.12
Two prior PSG studies have evaluated sleep in 
hypercapnic patients receiving NIV in an ICU 
for 17 hours.5,12 Median TST was 5.8 hours with 
68–74% of sleep occurring during at night. REM 
sleep deprivation (7–11% of TST) and severe sleep 
fragmentation (24–33/hour) were noted. Based 
on the assumption that patients were awake 
between 8 AM and 3 PM (because of nursing 
activities and diagnostic testing), the authors 
surmised that circadian rhythm and the 
proportion of SWS (22%) were better preserved 
with NIV compared to earlier studies on patients 
receiving INV.18-20 The latter findings conflict 
with findings from this study. Here, sleep was 
directly compared during NIV and INV in 
contemporaneous patients in the same ICU 
rather than earlier studies and monitored for the 
entire 24 hours rather than 17 hours. Furthermore, 
patients had greater acuity of illness, more 
acidaemia (pH: 7.25 versus 7.32), an earlier period 
of observation during ventilator assistance and 
greater use of sedative/analgesic medications, 
which may account for some of the differences.
The study authors encountered more sleep 
fragmentation, attributable mainly to an increased 
number of arousals and awakenings, in NIV group 
compared to INV group. Common contributors 
to disrupted sleep include factors associated 
with the ICU environment, critical illness, 
medications, and mechanical ventilation.1,3,8 
The higher level of sleep disruptions with more 
frequent spontaneous arousals and awakenings 
during NIV compared to INV could have been 
related to the higher severity of critical illness 
in NIV patients, less frequent use of continuous 
sedation, or other unmeasured factors. On the 
other hand, it should be mentioned that the 
arousal index for both groups still seems to be 
within normal limits33 and the sleep fragmentation 
index for the NIV group to be less than the prior 
studies (22/hour versus 33/hour),5,12 which could 
be attributed to differences in severity of the 
disease, ventilator, or sedative management as 
mentioned above. 
Patients on mechanical ventilation usually receive 
intermittent or continuous sedation to control 
agitation and to improve patient–ventilator 
interactions. Even though benzodiazepines and 
propofol at night can increase TST or decrease 
sleep fragmentation,21,34,35 they can lead to 
significant disturbances of sleep architecture, 
with suppression of SWS and REM sleep.4,7,36 
While two of the NIV patients were not receiving 
any sedatives or analgesics, the rest were 
receiving less sedation on a more intermittent 
basis than INV patients. This difference could 
have contributed to the decreased quantity 
and quality of sleep in the NIV compared to the 
INV patients. 
The presented study has a number of strengths 
including the complete and continuously 
observed PSG recordings for 24 hours, the 
prospective design, and the careful analysis 
including recording of noise and disruptions 
by caregivers. It also has important limitations 
including the small sample size that precludes 
the ability to draw inferences about the effects 
of disrupted sleep on clinical outcomes such as 
lengths of stay or mortality. Furthermore, patients 
were not randomised; therefore, selection 
bias was likely to create inevitable differences 
between the NIV and INV groups. Additionally, 
the authors were unable to control confounding 
variables such as use of medications and 
sedation level, severity of illness, fluctuations in 
patient illness, presence of undiagnosed sleep 
apnoea, activities of medical personnel, and 
clinical testing. On the other hand, the study 
was performed as a pilot to attract attention 
to this topic. The study was labour intensive, 
difficult to enrol (only 5% of screened patients), 
and technically challenging to administer in an 
ICU given interference with delivery of clinical 
care was prohibited. Furthermore, use of the 
Rechtsschaffen and Kales16 sleep scoring manual 
has not been well validated in critically ill patients 
and is confounded by poor inter-observer 
reliability, except for REM sleep.37
CONCLUSION
The study demonstrated that compared to INV, 
critically ill patients using NIV for ARF had lower 
quantity and quality of sleep. These data are the 
first to suggest that sleep time and quality are 
compromised to a greater extent with NIV than 
INV. On the other hand, keeping the patient on 
NIV can protect against other adverse events 
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already described in literature related to INV. 
Therefore, future studies should determine 
whether adjustments in ventilator settings, mask 
type or fit, sedation/analgesia use, or other 
interventions can improve sleep in NIV patients. 
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Cryobiopsy In Flexi-Rigid Pleuroscopy in a Region 
with Low Mesothelioma Prevalence
Abstract
Background: The use of conventional flexible forceps during flex-rigid pleuroscopy can be 
challenging when sampling hard and thickened pleura. Pleuroscopic cryobiopsy is an emerging 
field, with various early studies demonstrating good yield and minimal complications.
Objectives: To review the authors’ early experience of pleuroscopic cryobiopsy in their centre and 
highlight its utility in the diagnosis of mesothelioma.
Method: Six cases of undiagnosed pleural effusion that underwent pleuroscopic cryobiopsy via 
flexi-rigid pleuroscopy between July 2017 and June 2019 were retrospectively analysed. 
Results: The cohort had a median age of 59 years, consisting of two females and four males with 
a median age of 57 years. Mean (aggregate) tissue sample diameter was 9.2±1.9 mm. Cryobiopsy 
established a definitive diagnosis in all six cases: one case of malignant mesothelioma, one 
pleural tuberculosis, two small cell carcinomas, and two adenocarcinomas. Immunohistochemical 
staining was performed in all five of the malignant samples (100%). There were no major 
complications reported. 
Conclusions: Based on the case series, pleuroscopic cryobiopsy is a feasible adjunct to conventional 
forceps biopsy, a safe procedure in the authors’ setting, gives high diagnostic yield, and enables 
differentiation between the different causes of exudative pleural effusion. A large, prospective study 
is required to validate this retrospective series.  
INTRODUCTION
Following diagnostic thoracocentesis and closed 
pleural biopsy, 25% of pleural effusions remain 
undiagnosed,1 requiring either pleuroscopy 
or video-assisted thoracic surgery (VATS). 
While VATS is considered the gold standard, 
pleuroscopy is a less invasive, simpler, and cost-
effective alternative with a favourable diagnostic 
yield.2 Furthermore, VATS is not always available, 
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and is sometimes contraindicated, especially 
in patients with high surgical risk or advanced 
metastatic malignancy.2
Rigid pleuroscopy demonstrates higher yields 
of 97.8% versus 73.3% for flexi-rigid pleuroscopy 
due to larger sample sizes, superiority in sampling 
fibrous pleura in suspected mesothelioma, and 
its effectiveness in adhesiolysis.3 On the other 
hand, advantages for flexi-rigid pleuroscopy 
include less pain and easier maneuverability.4,5 
Efforts to increase yield of flexi-rigid pleuroscopy 
has led to the use of cryobiopsy, a technique 
previously validated for endobronchial and 
transbronchial biopsies.6 Cryobiopsy through 
flexi-rigid pleuroscopy is an emerging technique 
which carries the promise of both larger sample 
size with preserved tissue architecture, while 
maintaining ease of manoeuvrability with a 
flexible pleuroscope. 
In the Southeast Asia region, the incidence of 
mesothelioma is lower compared with European 
or Oceanian countries. Many benign pleural 
diseases mimic similar histopathological changes 
in mesothelioma;7 therefore, proper acquisition 
of tissue is important in Malaysia to ensure a 
diagnosis of mesothelioma is not missed. 
MATERIALS AND METHODS
Six patients with malignancy-suspicious pleural 
effusion who underwent pleuroscopic cryobiopsy 
at the authors’ unit between July 2017 and June 
2019 were analysed. In that period, a total of 244 
patients underwent pleuroscopic biopsy: 14 via 
rigid pleuroscope, 224 via flexi-rigid pleuroscope 
using conventional forceps, and six via flexi-rigid 
pleuroscope using cryobiopsy. Written informed 
consent was obtained from all patients. Pleural 
fluid analysis was performed via ultrasound-
guided diagnostic thoracocentesis prior to 
the procedure. Baseline blood investigations 
including coagulation profile were taken for each 
patient and ensured normal prior commencing 
the procedure. 
Transthoracic ultrasound was performed on each 
patient to identify the safe entry site with the 
patient in lateral position with the abnormal side 
upwards. The procedure was performed under 
conscious sedation with intravenous midazolam 
and pethidine. Under aseptic technique, the entry 
site was infiltrated with local anaesthesia (2% 
lidocaine). Flexible electrocautery equipment 
were prepared for any potential bleeding 
complications. 
A 1.5 cm incision was then made on the skin and 
blunt dissection was performed until the pleura 
was breached. A 11 mm metallic trocar was then 
inserted into the pleural cavity for pneumothorax 
induction. Pleuroscopy was performed using a 
flexi-rigid scope (LTF-160, Olympus, Tokyo, Japan) 
passed through the trocar. All pleural fluid was 
aspirated until clear to allow clear examination of 
the pleural cavity. Pleural fluid was sent for further 
analysis if initial diagnostic thoracocentesis data 
was inadequate.
After cautious examination of the pleural cavity, 
cryobiopsies were obtained at visibly abnormal 
areas using a 950 mm cryoprobe of either 1.9 or 
2.4 mm diameter passed through the working 
channel of the pleuroscope in conjunction with 
the ERBECRYO®2 system (Erbe Medizintechnik, 
Tübingen, Germany). Carbon dioxide was used 
as cryogen. The tip of the cryoprobe was applied 
to the target biopsy sites and activated for a 
minimum time of 3 sec under direct vision, and 
pleural specimens were removed by extracting 
the cryoprobe and flexi-rigid scope together 
through the trocar. The specimen was thawed 
in normal saline, placed into formalin solution, 
and immediately sent to the laboratory for 
histopathological analysis. Meanwhile, the 
pleuroscope was reinserted into the pleural cavity 
to assess for any bleeding or complication. The 
biopsy procedure was repeated for a minimum 
of three times, given that no complications 
occurred. The decision to employ cryobiopsy 
was at the discretion of the endoscopist when 
specimen from forceps biopsy was deemed 
inadequate during intraprocedure. 
CASE SERIES
Case 1
Case 1 was a 64-year-old indigenous Malaysian 
female who did not smoke and had no underlying 
medical illness. She presented with 1 week of 
progressively worsening shortness of breath 
on a background of 1 month of persistent non-
productive cough and loss of appetite. When 
asked, she did not report any fever or night 
sweats. Clinically, she was not tachypnoeic but 
had finger clubbing and reduced air entry over 
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the left lower zone of the chest. Her vitals were 
unremarkable with a temperature of 36.6 oC 
and oxygen saturation of 97% under room air. 
Chest radiograph showed blunting of the left 
costophrenic angle and ultrasound of the thorax 
confirmed a left non-loculated pleural effusion. 
Her total white cell count was 6.7x109 cells/L. 
Pleural fluid parameters were exudative (pH = 
7.355; pleural fluid:serum protein ratio = 50/72 
g/L; pleural fluid:serum lactate dehydrogenase 
[LDH] ratio = 1554/426 U/L; fluid glucose = 
4.8 mmol/L); pleural fluid cytology showed no 
malignant cells. Pleuroscopy revealed multiple 
pleural and diaphragmatic nodules; cryobiopsy 
was performed with no major complication. 
Talc pleurodesis was applied prior to removal 
of the chest drain. Histopathological and 
immunohistochemical examination confirmed 
epidermal growth factor receptor-positive lung 
adenocarcinoma, and she was referred to the 
oncology team for commencement of tyrosine-
kinase inhibitor therapy.
Case 2
Case 2 was a 59-year-old Malay male with a 
50-pack per year smoking history, underlying 
hypertension, and dyslipidaemia, who presented 
with 1 week of right lateral chest pain and 
shortness of breath on a background of chronic 
dry cough of 2 months, accompanied by loss of 
weight and appetite. He did not have a history of 
fever. On clinical examination, he was tachypnoeic 
with a respiratory rate of 24 breaths per minute 
and oxygen saturation of 92% under room air. 
He had no finger clubbing; chest examination 
demonstrated reduced air entry over the right 
lower and middle zones. His temperature was 
36.5 oC and his total white cell count was 
7.7x109 cells/L. Chest radiograph showed a 
right homogenous opacity with meniscus sign 
obliterating the right heart border. Ultrasound 
thorax confirmed a non-loculated right pleural 
effusion. Pleural fluid parameters were exudative 
(pH = 7.531; pleural fluid:serum protein ratio 
= 42/72 g/L; pleural fluid:serum LDH ratio = 
722/894 U/L; pleural fluid glucose = 5.3 mmol/L); 
pleural fluid cytology showed no malignant cells. 
Pleuroscopy showed multiple visceral and parietal 
pleural nodules; cryobiopsy was performed 
with no major complication. Talc pleurodesis 
was applied prior to removal of the chest drain. 
Histopathological and immunohistochemical 
examination confirmed small cell carcinoma of 
the lung, and he was referred to the oncology 
team for further management.
Case 3
Case 3 was a 60-year-old indigenous Malaysian 
female who did not smoke and had a history of 
right breast carcinoma in 1999, for which she 
had a right mastectomy and subsequently had 
been in stable remission. In December 2017, she 
presented with 2 weeks of shortness of breath 
and right lateral chest discomfort for 3 days, but, 
when asked, did not report any fever, cough, 
night sweats, or overt loss of weight. On clinical 
examination, she had a respiratory rate of 23 
breaths per minute, temperature of 36.2 oC, and 
oxygen saturation of 90% under room air, with 
chest examination demonstrating reduced air 
entry over the entire right thorax. Her total white 
cell count was 8.3x109 cells/L. Chest radiograph 
revealed a ‘white-out’ appearance of the right 
lung. Ultrasound thorax confirmed a very large 
non-loculated right pleural effusion. Pleural 
fluid parameters were protein-discordant 
exudative (pH = 7.497; pleural fluid:serum protein 
ratio = 34/74 g/L; pleural fluid:serum LDH ratio 
= 472/400 U/L; pleural fluid glucose = 3.6 
mmol/L); pleural fluid cytology was inconclusive, 
showing malignant cells. Pleuroscopy showed 
multiple diaphragmatic nodules; cryobiopsy 
was performed with no major complication. 
Talc pleurodesis was administered prior to 
chest tube removal. Histopathological and 
immunohistochemical examination confirmed 
metastatic adenocarcinoma secondary to her 
primary breast malignancy. She underwent 
palliative treatment under the oncology team. As 
of 18 months after the cryobiopsy, surveillance CT 
did not show further progression of disease.
Case 4
Case 4 was a 67-year-old Malay male who did 
not smoke but did have underlying Type 2 
diabetes mellitus and was on insulin treatment. 
He presented in January 2019 with complaints 
of fever, shortness of breath, and loss of appetite 
for 2 weeks, associated with right lateral chest 
discomfort. He did not report any chronic cough 
or haemoptysis. On clinical examination, he 
had a respiratory rate of 22 breaths per minute, 
temperature of 37.1 oC, and oxygen saturation 
of 95% under room air, with chest examination 
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showing reduced air entry over the right lower 
zone. His total white cell was 6.8x109 cells/L. 
Chest radiograph showed a right homogenous 
opacity with meniscus sign partially obliterating 
the right heart border. Ultrasound thorax revealed 
a non-loculated pleural effusion. Pleural fluid 
parameters were exudative (pH = 7.466; pleural 
fluid:serum protein ratio = 59/78 g/L; pleural 
fluid:serum LDH ratio = 330/612 U/L; pleural fluid 
glucose = 10.38 mmol/L); pleural fluid cytology 
showed predominantly lymphocytic effusion. 
Sputum examination for acid-fast bacilli was 
negative. Pleural fluid and sputum culture for 
tuberculosis were negative. Pleuroscopy revealed 
multiple parietal pleural nodules, several of 
which were tangentially oriented; cryobiopsy 
was performed with no major complication. No 
talc pleurodesis was given in view of suspected 
tuberculous infection. Histopathological and 
immunohistochemical examination confirmed 
caseating granulomas; the patient was started 
on tuberculosis treatment, after which clinical 
improvement in terms of weight gain, symptom 
resolution, and radiological improvement as 
evidenced by eventual resolution of the effusion 
on chest radiographs were demonstrated.
Case 5
Case 5 was a 58-year-old Malay male who 
smoked but had no underlying medical illness. He 
presented in June 2019 with a 3-month history of 
chronic cough and loss of weight and appetite. He 
did not report fever and haemoptysis. Clinically, 
he had a respiratory rate of 24 breaths per minute, 
temperature of 37.0 oC, and oxygen saturation of 
93% under room air. He was clinically clubbed, 
and chest examination revealed reduced air 
entry over the left lower and mid zone. Chest 
radiograph showed a left homogenous opacity 
with meniscus sign and obliteration of the left 
heart border. Ultrasound of the thorax showed 
a non-loculated left pleural effusion. His total 
white cell count was 9.9x109 cells/L. Pleural fluid 
parameters were exudative (pH = 7.394; pleural 
fluid:serum protein ratio = 45/77 g/L; pleural 
fluid LDH = 207 U/L; pleural fluid glucose = 
6.8 mmol/L); pleural fluid cytology showed no 
malignant cells. Pleuroscopy revealed multiple 
pleural and diaphragmatic nodules; cryobiopsy 
was performed with no major complication. 
Talc pleurodesis was applied prior to removal 
of the chest drain. Histopathological and 
immunohistochemical examination confirmed 
small cell carcinoma of the lung. He was referred 
to the oncology team for further care.
Case 6
Case 6 was a 71-year-old indigenous Malaysian 
male who smoked and had a history of asbestos 
exposure. He presented in June 2019 with a 
2-month history of progressive shortness of 
breath and dry cough, associated with loss of 
weight. He did not report fever or haemoptysis. 
Clinically, he had a respiratory rate of 23 
breaths per minute, temperature of 36.8 oC, and 
oxygen saturation of 91% under room air. Chest 
examination revealed reduced air entry over 
the right lower and midzone. Chest radiograph 
revealed a right homogenous opacity with 
meniscus sign and obliteration of the right 
heart border. Ultrasound of the thorax showed 
a non-loculated right pleural effusion. His total 
white cell count was 7.9x109 cells/L. Pleural 
fluid parameters were exudative (pH = 7.258; 
pleural fluid:serum protein ratio = 42/73 g/L; 
pleural fluid:serum LDH ratio = 954/321 U/L; 
pleural fluid glucose = 5.1 mmol/L); pleural fluid 
cytology was inconclusive, showing atypical 
cells. Pleuroscopy showed scattered small hard 
nodules; cryobiopsy was performed with no major 
complication. Talc pleurodesis was applied prior 
to removal of the chest drain. Histopathological 
and immunohistochemical examination 
confirmed malignant mesothelioma, and the 
patient was referred to the oncology team for 
further management.
RESULTS
Baseline Demographic Data
A total of six patients of either indigenous 
Malaysian or Malay descent underwent 
pleuroscopic cryobiopsy (Table 1). Two were 
female and four were male, with a median age of 
59 years (interquartile range: 56–67).
Characteristic of Pleural Effusion
Two (33.3%) of the effusions were left-sided, 
while four (66.7%) were right-sided. All effusions 
had a simple appearance on ultrasound. 
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Three (50.0%) patients had effusions occupying 
one-half of the hemithorax, two patients (33.3%) 
had effusions occupying less than one-half of 
the hemithorax, and one (16.7%) had a massive 
white-out effusion. Pleural fluid pH was elevated 
in Cases 2, 3, and 4. Five of the effusions were 
exudative, one was protein-discordant (Case 
3). Median pleural fluid protein was 43.5 g/dL 
while median LDH was 597 IU/L. Pleural fluid 
cultures were negative in all samples. Cytology 
was inconclusive in all six specimens, with only 
one sample showing malignant cells (Case 3) and 
another showing atypical cells (Case 6).
Pleuroscopic Characteristic 
All six cases (100%) had a nodular pleuroscopic 
appearance. A 1.9 mm probe was used in three 
cases (50%), while a 2.4mm probe was used in 
the other three cases (50%). 
Patient
1 2 3 4 5 6
Age (years) 61 56 57 67 56 69
Gender Female Male Female Male Male Male
Effusion 
laterality Left Right Right Right Left Right
Ultrasound 
appearance Simple Simple Simple Simple Simple Simple
Pleural fluid 
protein (g/dL) 50 42 34 59 45 42
Serum protein 72 72 74 78 77 73
Pleural fluid 
LDH 1554 722 472 330 207 954
Serum LDH 426 894 472 612 N/A 321
Pleural fluid 
pH 7.355 7.531 7.497 7.466 7.394 7.258
Pleural fluid 
glucose 4.8 5.3 3.6 10.38 6.8 5.09
Pleural fluid 
cytology Not available
No malignant 
cells Malignant cells
Lymphocytic 
effusion
No malignant 
cells Atypical cells
Procedure 
time (min) 35 20 20 30 20 35
Appearance Nodules Nodules Nodules Nodules Nodules Nodules
Probe size 
(mm) 2.4 1.9 2.4 1.9 2.4 1.9
Complication None None None None None None
HPE Lung adenocarcinoma
Small cell 
carcinoma
Lung 
adenocarcinoma
Caseating 
granuloma, 
negative ZN 
stain
Small cell 
carcinoma Mesothelioma
IHC feasible? Yes Yes Yes No Yes Yes
HPE: histopathological examination; IHC: immunohistochemistry; LDH: lactate dehydrogenase; ZN: Ziehl–Neelsen.
Table 1: Characteristics of pleuroscopic cryobiopsy patients. 
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Median activation time and the number of exact 
activations were not recorded in the patients. 
The mean aggregate sample size was 9.2±1.9 
mm (Table 2).4,8-12 A definite histopathological 
diagnosis was obtained in all six cases. Five 
(83.3%) patients had confirmed malignancy (one 
adenocarcinoma lung, one adenocarcinoma 
breast, two small cell carcinomas, and one 
mesothelioma) and one (16.7%) patient was 
diagnosed with pleural tuberculosis. The five 
(83.3%) malignant samples were adequate for 
immunohistochemical staining. None of the six 
patients encountered major complications. The 
median procedural time was 25 minutes (range: 
20–35 minutes).
DISCUSSION
Cryobiopsy is a technique that employs the 
use of a blunt probe cooled by nitrous oxide or 
carbon dioxide, which draws moisture out of 
surrounding tissue and freezes with it by creating 
a bond (Joule–Thomson effect).13 In pleuroscopic 
biopsy, cryobiopsy was historically performed 
with a rigid probe via a second trocar, under 
direct rigid pleuroscopy examination.13 Recent 
technological advancements have led to the 
flexible cryoprobe which can be inserted through 
the working channel of flexible endoscopes. The 
use of cryobiopsy in bronchoscopy has been 
validated in multiple studies for endobronchial 
biopsies and transbronchial biopsies with 
minimal additional bleeding risk.6 Meanwhile, 
studies on cryobiopsy via flexi-rigid pleuroscopy 
have only recently burgeoned in the past decade, 
with studies citing comparable sample sizes 
and yield, preserved biopsy sample architecture 
allowing for immunohistochemical studies, and 
similar safety profile compared to conventional 
forceps biopsy via flexi-rigid pleuroscope.4,5,8-12,14,15 
To the authors’ best knowledge, this is the first 
case series of pleuroscopic cryobiopsy in the 
Southeast Asia region.
Pleural fluid biochemical characteristics 
are poor differentiators of tuberculous  and 
malignant  pleural  effusions,16 as demonstrated 
in this case series. The higher pH values in 
Cases 2, 3, and 4 were likely due to exposure to 
air during collection via the suction port of the 
scope, causing artificial elevation of pH.17 Pleural 
fluid cytology carries overall sensitivity of 67.2% 
in malignant pleural effusion of all types; of 
these, the sensitivity was 87.9% for 
adenocarcinomas but dropped to 45.5% in 
malignant mesothelioma.18 In this series, none of 
the pleural fluid cytology results were conclusive; 
IHC: Immunohistochemistry; IQR: interquartile range; N/A: not available.
Table 2: Comparison to previous studies of pleuroscopic cryobiopsy.
Studies Rozman et al.,8 2013
Thomas et al.,9 
2015
Maturu et 
al.,10 2015
Chen et 
al.,4 2018
Tousheed et 
al.,11 2018
Dhooria et 
al.,12 2019
Present 
series
Number of 
subjects 15 22 6 92 87 50 6
Quality of sample
Probe size 2.4 mm 2.4 mm 1.9 mm 1.9 mm 2.4 mm 2.4 mm 1.9/2.4 mm
Size (mm) N/A Median: 10 IQR: 7.0–15.8
Mean: 
9.2±1.84
Mean: 
9.4±4.9
Mean: 
13.2±6.7
Median: 
7.0 
Mean: 
9.2±1.9
Diagnostic 
yield (%) 15/15 (100) 20/22 (91) 6/6 (100) 91/92 (99) 86/87 (99) 39/50 (78) 6/6 (100)
IHC stain 
done (%) 13/13 (100%) N/A N/A 91/92 (99) 29/29 (100) N/A 5/5 (100)
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only Cases 3 and 6 had abnormal fluid cytology 
showing malignant and atypical cells, respectively, 
which were later confirmed via cryobiopsy as 
adenocarcinoma and mesothelioma (Table 1). 
While the diagnostic accuracy of cytology in 
malignant mesothelioma has been shown to 
increase with the availability of an experienced 
cytopathologist in a region of high prevalence 
for mesothelioma,18 this may not be applicable 
in the Southeast Asia region. This highlights the 
unreliability of pleural fluid cytology and the need 
for a definitive biopsy to clinch the diagnosis. 
While sensitivity and specificity of flexi-rigid 
pleuroscopy using conventional forceps in 
undiagnosed exudative pleural effusion is high,5 
increased false-negative results are seen in 
cases of thickened pleura.19,20 Some factors that 
contribute to this include inadequate depth 
of biopsy sample20 and the lack of mechanical 
power of the conventional forceps and a small 
cup size.4,5
Cryobiopsy poses a potential solution to this 
problem, having been shown to be non-inferior to 
conventional forceps in the diagnosis of malignant 
mesothelioma.21 The crucial advantage lies in 
that it can acquire significantly greater depths of 
tissue than conventional forceps;4,9,10,12 one study 
reported extrapleural fat in 65.2% of cryobiopsy 
samples as opposed to 40.8% in conventional 
forceps biopsy.12 This was demonstrated 
in Case 6 (Table 1), whereby the patient’s 
diagnosis of malignant mesothelioma was 
confidently obtained due to the demonstration 
of extrapleural fat, which is essential to visualise 
invasion of abnormal mesothelial cells in 
mesothelioma (Figure 1). In Southeast Asia, 
reported rates of non-specific pleuritis range 
from 12.0%22 to 21.6%.23 
Figure 1: Cryobiopsy sample for Case 6 was conclusive for malignant mesothelioma. 
A) Extrapleural adipose tissue is well demonstrated and there are no artefacts. There is marked increase of atypical 
mesothelial cells proliferation superficially, with infiltration into the underlying adipose tissue, which is indicative of 
malignancy (x40) H&E stain. B) The tumour cells are arranged in sheets (x200) H&E stain. C) Tumour cells are seen 
infiltrating into extrapleural adipose tissue (x200) H&E stain. D) Tumour cells infiltrating in between adipose cells 
(x400) H&E stain. E) The tumour cells show round vesicular nuclei with prominent nucleoli. Tubular formation is also 
noted. F) Immunohistochemical staining was positive for calretinin (d: ×200)
H&E: haemotoxylin and eosin.
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Although long-term follow-up on these 
cases did not frequently reveal a diagnosis 
of mesothelioma,20 it is prudent to consider 
the possibility that the low prevalence of 
mesothelioma in Southeast Asia may be partly 
contributed by shallow biopsies leading to 
inconclusive or alternative diagnoses. Further 
research could look into the value of cryobiopsy 
in non-specific pleuritis.
Moreover, certain varieties of mesothelioma 
such as desmoplastic mesothelioma make 
conventional biopsy extremely difficult 
because they are often smooth and non-
nodular macroscopically. In such cases, one 
author has proposed a combination of incisions 
via electrocautery technique followed by 
cryobiopsy.21 Another author has suggested 
creating a break in the pleura with forceps 
prior to cryobiopsy,9 but this has to be weighed 
against the risk of bleeding. The present authors 
have yet to implement these combined methods 
in their pleuroscopic setting; further studies are 
needed to validate them.
The second advantage of the cryoprobe is its 
ability to biopsy samples from lesions positioned 
tangentially to the instrument.4,10 As opposed to 
conventional forceps, which only allow forward 
sampling, cryoprobe can obtain tissue in a 360o 
manner laterally.24 Similarly, in the experience 
with Case 4, nodules that were tangentially 
oriented despite having the pleuroscope at 
maximal angulation were much easier to sample 
with cryoprobe than conventional forceps. 
Third, in terms of technical difficulty, there is no 
significant difference in operator-rated difficulty 
when comparing cryobiopsy to conventional 
forceps technique;12 this is promising and may 
encourage more pulmonologists to adopt it in 
the future, although studies on its learning curve 
are lacking. The authors’ limited experience 
with pleuroscopic cryobiopsy was not a major 
deterrent to obtaining accurate diagnosis, as 
evidenced by good sample sizes comparable 
to other larger studies, and successful 
histopathological diagnosis in all six of their 
patients (Table 2).
The most dreaded complication of cryobiopsy 
is always major bleeding, which was not 
encountered in these six cases (Table 1). Early 
studies have not described any significant risks 
of major bleeding, but various authors have 
advocated gentle withdrawing of the probe as 
essential to prevent severe haemorrhage.4,8-11 
Furthermore, one author opined that in cases 
when the probe was already attached to the 
tissue but could not be gently removed, the 
probe should be allowed to unfreeze and resume 
with a shorter period of freezing.8 Freezing 
time of the cryoprobe should be variable, to be 
adjusted throughout the procedure, as to not 
take tissue samples deeper than the muscle layer 
to reduce the risk of bleeding or nerve injury.21 
One of the limitations of the authors’ study 
is that biopsy was only performed on visibly 
abnormal areas for at least three passes. Expert 
recommendations advocate at least five biopsies 
carried out over abnormal and normal pleura to 
ensure adequate tissue quality and quantity.25,26 
However, these recommendations were made 
in regard to conventional forceps rather than 
cryobiopsy. In Case 6, three cryobiopsies were 
performed, comparable to prior studies which 
performed a range of one to four cryobiopsies 
per patient.4,8-11,14,16 The optimal number of 
cryobiopsies needed to balance yield and the 
risk of bleeding remains uncertain, this is a 
potential area for future research. 
Another limitation of this study was that pleural 
biopsy for tuberculosis culture was not routinely 
sent. The gold standard of diagnosing pleural 
tuberculosis is the isolation of Mycobacterium 
tuberculosis in either pleural fluid or pleural 
tissue by culture, or demonstration of caseating 
granulomas in histology.27 Tuberculosis culture 
is important for drug sensitivity testing, but 
has a sensitivity of only 68.7% as opposed to 
100.0% in pleuroscopy.28 Furthermore, there 
is often a delay in waiting for culture results. In 
tuberculous endemic regions at the hand of an 
experienced investigator, tuberculous pleurisy 
usually presents with characteristic inflammatory 
patterns on pleuroscopy, such as caseous, sago-
like nodules, or fibrin deposits and loculations.29 
As demonstrated in Case 4, representative 
appearance on pleuroscopy combined with 
histological finding of granuloma was sufficient 
to clinch the diagnosis of pleural tuberculosis. 
A demonstrated therapeutic response to 
antituberculous medication further reinforced 
the diagnosis of pleural tuberculous in this cohort 
of patients. 
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CONCLUSION
In conclusion, pleuroscopic cryobiopsy was 
feasible with no major complications in the 
six subjects; samples were comparable in 
size to those in previous studies and had 
preserved tissue architecture, allowing for 
histopathological confirmation of diagnosis and 
immunohistochemistry studies. Pleuroscopic 
cryobiopsy may prove useful both in the 
diagnosis of malignant mesothelioma in regions 
of low prevalence or in centres where cytological 
analysis is unreliable or unavailable.
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